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ABSTRACT 
 This study explored the symptom experience of patients receiving epidermal 
growth factor receptor inhibitors (EGFRIs) for breast, colon, head and neck, and colon 
cancer. EGFRIs are targeted therapies used at various points along the treatment 
continuum for these solid tumors, and may be first, second or third-line agents which can 
be used as single agents or in combination with other therapies.  The most common side 
effect of these agents include dermatologic effects, such as rashes, hair, and nail changes, 
but they can also contribute to other side effects such as fatigue, anxiety and diarrhea.  
Most previous work has addressed the dermatologic side effects and has not addressed the 
holistic patient experience. A descriptive, correlational design, guided by the theory of 
unpleasant symptoms, explored the overall symptom experience, including dermatologic 
and other symptoms, in patients receiving these treatments.  The relationship of key 
variables (age, diagnosis, gender, EGFRI therapy, and symptom clusters) to the outcomes 
of quality of life, psychological status, and functional status was also explored.  Co-
occurring symptoms (symptom clusters) were identified by factor analysis procedures.  
Three symptom clusters were identified: a psychological-cognitive cluster; a treatment-
related dermatologic cluster that has not been previously identified as a symptom cluster; 
and, a mucocutaneous and fatigue cluster.  These symptom clusters had differing impacts 
on outcomes, so knowledge of the effects of these symptom clusters can guide nursing 
practice in the care of patients receiving these targeted therapies. 
 xv 
Keywords: Symptom experience, factor analysis, theory of unpleasant symptoms, 
epidermal growth factor receptor inhibitor, quality of life, functional performance, 
psychological status, symptom cluster. 
 
 1 
CHAPTER ONE 
 
INTRODUCTION 
Significance of the Problem 
People living with cancer must cope not only with the threat of serious illness, but 
also with bothersome and disruptive symptoms brought on by rigorous cancer therapies.  
Chemotherapy and radiation therapy are associated with well-known symptoms, such as 
hair loss, nausea and vomiting, and myelosuppression, as well as symptoms resulting 
from organ toxicities, and an array of long-term side effects. The symptom experiences of 
patients receiving these traditional modalities of treatment have been extensively studied 
and are well understood by health care providers. In recent years, however, targeted and 
biologic therapies have outpaced traditional chemotherapy for new drug approvals in 
oncology, and much remains to be discovered about the symptom experience associated 
with these agents.   
The newer targeted therapies exert their therapeutic effects differently than 
cytotoxic chemotherapies. Rather than killing both healthy and cancer cells, targeted 
therapies aim to more precisely alter cellular function. Some focus on cell signaling 
pathways, others induce apoptosis (programmed cell death), some influence the immune 
system, while others deliver radiation or other substances to cancer cells (Targeted 
Cancer Therapies, 2014).  Treatment with targeted therapies, such as the epidermal 
growth factor receptor inhibitors (EGFRIs), may result in a challenging symptom  
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experience that features novel dermatologic symptoms that patients may not expect to be 
associated with cancer treatment.   
The present study explored the symptom experience of patients receiving 
epidermal growth factor receptor inhibitors (EGFRIs), also called anti-EGFR therapies or 
signal transduction inhibitors. Rather than exerting their mechanism of action through the 
cytotoxic effects characteristic of conventional chemotherapy, targeting rapidly dividing 
cells at various points in the cell cycle, EGFRIs work by influencing human epidermal 
growth factor receptor (EGFR) signaling pathways. The human epidermal growth factor 
family comprises four tyrosine kinase receptors, including ErbB1 or HER1 (EGFR), 
ErbB2 (HER 2/neu), ErbB3 or HER3, and ErbB4 or HER4 (Mahipal, Kothari, & Gupta, 
2014), but for this research study, the focus is on EGFRIs.  
EGFRIs are currently indicated for selected patients diagnosed with advanced 
non-small cell lung cancer, breast cancer, colon cancer, pancreatic cancer, head and neck 
cancers, and other solid tumors of epithelial origin where epidermal growth factor 
receptors (EGFR) are overexpressed.   
New Targets for Cancer Therapy 
The unstable genome of the cancer cell has been described as its Achilles’ heel 
(Levitzki & Klein, 2010), highlighting the genome as a susceptible target. Abnormal and 
overactive cell signaling pathways result from chromosomal mutations, mutations of 
oncogenes and tumor suppressor genes, and other epigenetic changes. Most readers will 
be familiar with an early and newsworthy application of a targeted therapy, using the 
drug imatinib (Gleevec®), for a chronic form of leukemia associated with the Bcr-Abl 
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tyrosine kinase oncogene. Patients treated with this agent demonstrate a remarkably 
improved remission rate of greater than 90% (Balagula, Rosen, & Lacouture, 2011), 
offering a glimpse of the potential of targeted therapies in cancer. As molecular profiling 
of tumors continues to be refined, subtype characteristics of tumors will influence the 
type of targeted therapy prescribed, as in the case of EGFRIs. 
Science is just beginning to identify these molecular changes that lead to the 
development of cancer, and as they are discovered, future therapies will target these 
genetic aberrations. One such mutation affects the EGFR protein on the surface of cancer 
cells, contributing to the development of various solid tumors. The EGFR gene encodes a 
type of protein kinase which serves as a receptor for the epidermal growth factors family.  
In normal cells, epidermal growth factor binds to EGFRs and spurs activation of 
signaling pathways, which in turn, help to govern cell growth, proliferation, and 
migration. Activation of overexpressed or mutated EGFRs requires a process of binding, 
dimerization and phosphorylation. When a mutation creates an excess number of 
receptors, the result is pathway dysregulation and subsequent abnormal cell growth, cell 
proliferation, avoidance of apoptosis (programmed cell death), cell migration and 
neovascularization of tumors.   
EGFRs include an extracellular ligand-binding domain, a transmembrane region, 
and an intracellular tyrosine kinase domain.  Both the extracellular and intracellular 
domains of these proteins are treatment targets.  EGFRIs include both monoclonal 
antibodies (MOABs), cetuximab and panitumumab, which are given by infusion, and 
tyrosine kinase inhibitors (TKIs), afatinib, erlotinib, gefitinib, and lapatinib, which are 
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oral agents. MOABs target tyrosine kinase receptors outside of the cell, while TKIs are 
small molecules that target the intracellular domain.    
Lung cancer has a projected incidence in the United States of 224,210 (Siegel, 
Ma, Zou, & Jemal, 2014), and is the most common cause of cancer death globally, 
contributing to more than a million deaths (Network, 2014).  Activated oncogenes such 
as EGFR or other mutations (e.g. ALK) occur to varying degrees in various patient 
populations, but the impact of EGFRI therapy on the patient symptom experience will be 
significant, primarily because of the prevalence of lung cancer. In lung cancer, 
approximately 10-15% of Caucasian, and 40% of Asian non-small cell lung cancer 
patients carry the EGFR mutation (Cooper, Lam, O’Toole, & Minna, 2013), making  
treatment with EGFRIs a first treatment option over chemotherapy. Genetic signposts, 
such as this mutation and others, now influence treatment selection, allowing providers to 
tailor therapy, when possible, for each patient.  
Activating EGFR mutations occur most commonly in patients in lung cancer 
patients with no prior history of smoking, in adenocarcinoma, in females, and in Asians, 
and occur in a small area of the EGFR gene.  Because EGFRIs have a different 
mechanism of action than traditional chemotherapy, their symptom profile is different 
and less familiar to practitioners and patients alike.  The impact of these agents on the 
symptom experience is just beginning to be understood, and this study will add to the 
evidence on this topic.   
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Overview of EGFRI-Related Symptoms 
The on-target effects of EGFRIs result in a high incidence of dermatologic 
toxicities, such as skin, hair and nail changes, because EGFRI is essential for the normal 
physiology of the skin. EGFR is expressed in the basal cell layer of the epidermis, in the 
outer layers of the hair follicles, as well as in the sebaceous epithelium (Lacouture, 2006; 
Lynch et al., 2007; Andreis et al., 2010; Lacouture, Maitland, et al., 2010; Chan & Tan, 
2011; Chanprapaph, Vachiramon, & Rattanakaemakorn, 2014).  Normal epidermal 
growth and development depends upon EGFR signaling, and its absence or disruption, 
such as occurs in a mutation, has been illustrated in an animal model.  Mice lacking 
normal EGFR expression and signaling displayed skin defects like those experienced by 
patients on EGFRIs (Mascia et al., 2013). 
Dermatologic changes resulting from EGFRI therapy include primarily rash and 
xerosis (dry skin), but also erythema, telangiectasia, hyperpigmentation, and nail and hair 
changes. These are the most commonly reported side effects associated with the EGFRIs, 
with an incidence of all grade skin toxicity ranging from 47 to over 90%, depending on 
the specific agent (Ocvirk, Heeger, McCloud, & Hofheinz, 2013). With a protracted 
treatment course, most patients will develop one or more of these dermatologic 
symptoms.  For example, a study of 16 patients treated with the EGFRIs cetuximab, 
panitumumab, or erlotinib for more than six months reported that 100% developed some 
form of cutaneous symptom (Osio et al., 2009); however, more severe Grade 3 or 4 skin 
toxicities occur in only about one of five patients  (Peuvrel et al., 2012 ; Brodell, Hepper, 
Lind, Gru, & Anadkat, 2013).  With the advent of prophylactic skin care protocols, the 
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severity of dry skin, itching and rash can be ameliorated in some patients, but a solid 
evidence base for many treatments is currently lacking. Specific symptoms will be 
addressed more fully in chapter two. 
Other Factors Affecting the Symptom Experience 
The symptom experience of patients receiving EGFRI therapy may also be 
exacerbated by other concurrent treatment modalities, such as chemotherapy and 
radiotherapy (e.g. concurrent cetuximab and radiation in head and neck cancer) (Pryor, 
Burmeister, Burmesiter, Poulsen, & Porceddu, 2011), as well as by other symptoms 
common in the oncology population, such as fatigue or lack of energy.  In addition, many 
patients receiving these therapies may also have advanced disease and may be 
experiencing a greater symptom burden, both physical and psychological, as a result of 
their disease status (Wong et al., 2010).  As a result, the overall symptom experience of 
patients treated with EGFRIs may be much more complex and multifaceted than the 
widely-reported profile depicting primarily dermatologic toxicities.  
Impact on Outcomes 
 Collectively, both a cancer diagnosis and the side effects of treatment 
significantly impact quality of life (Fox & Lyon, 2006, 2007; So et al., 2009; Joshi et al., 
2010; Deshields, Potter, Olsen, Liu, & Dye, 2011; Dodd et al., 2011; Husain, Myers, 
Selby, Thomson, & Chow, 2011; Roiland & Heidrich, 2011), functional status (Dodd, 
Miaskowski, & Paul, 2001; Given, Given, Azzouz, Kozachik, & Stommel, 2001; Chen & 
Tseng, 2006; Miaskowski et al., 2006; Cheng & Lee, 2011; Dodd et al., 2011),  and 
psychological status (Adler & Page, 2008; Breen et al., 2009).  Due to their unique side 
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effect profile, EGFRIs carry a significant symptom burden (Wu, Balagula, Lacouture, & 
Anadkat, 2011), and may exert a negative psychological and physical effect on health-
related quality of life (Joshi et al., 2010; Rosen et al., 2013), and can even lead to 
treatment interruption (Boucher, Olson, & Piperdi, 2011).  All of the TKIs are self-
administered oral medications, so adherence to treatment amidst a difficult symptom 
experience is also a concern (Mancini, McBride, & Kruczynski, 2013; Matthews & 
Caprera, 2014).  A better understanding the overall symptom experience associated with 
EGFRIs will provide actionable knowledge that can proactively address patient 
symptoms so that treatment adherence concerns are minimized.     
Most research addressing symptoms associated with EGFRIs has explored the 
obvious rash and other dermatologic symptoms, while a broader focus on the overall 
symptom experience has been limited (Osio et al., 2009; Andreis et al., 2010; Joshi et al., 
2010; Rosen et al., 2013).   Joshi et al. (2010) found EGFRI-related skin toxicities 
affected emotional well-being, while Wagner and Lacouture (2007) reported physical 
symptoms like pain, itching and stinging had an impact on quality of life.  One study did 
not find a correlation between skin rash and psychological distress, but did find highly 
significant relationships between perceived quality of life and psychological distress and 
social avoidance (Romito et al., 2010).  Despite the fact that there is some evidence that 
quality of life and psychological status are affected by patients receiving EGFRIs, most 
clinical and research literature suggests that patients are most bothered by the esthetic 
complications of the rash (Wu et al., 2011). This misconception suggests that there is a 
need for a greater understanding of the symptom experience so that providers fully 
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appreciate how patients are impacted by EGFRI treatment. As there are only a few 
published studies exploring these relationships, with none in the nursing literature, the 
interplay between EGFRI-related symptoms and the overall symptom experience has not 
been fully explored, so this study is a first step in this direction.  
Purpose of the Study 
EGFRI treatment-related symptoms constitute a significant burden for patients 
undergoing treatment for cancer.  To date, there is a paucity of research on the overall 
symptom experience associated with these therapies, and there is no nursing research that 
addresses this topic. Most research exploring side effects of EGFRIs has been conducted 
in the context of clinical trials, and focuses on dermatologic symptoms, but not on the 
overall symptom experience of the patient receiving these therapies. Along with 
uncomfortable and visible dermatologic symptoms, patients can also experience other 
symptoms such as dry mouth, fatigue, and psychological distress.  
Significance to Nursing 
This study was a descriptive, correlational survey designed to explore the 
symptom experience, including discovery of any co-occurring symptoms (symptom 
clusters), associated with EGFRI therapy.   In addition to describing the full range of 
symptoms associated with EGFRI therapies, this study explored the impact of these 
symptoms on key outcomes. Co-occurring symptoms, or symptom clusters, were 
identified by factor analysis procedures and supported by hierarchical cluster analysis. 
The relationship of key variables (age, diagnosis, gender, EGFRI therapy, and symptom 
clusters) to outcomes was explored.    
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The study of  the symptom experience, including any identified symptom clusters, 
in patients receiving EGFRIs contributes to the nursing literature by:  a) fully describing 
the symptom experience of patients receiving EGFRIs; b) providing data to support the 
co-occurrence of symptoms in patients receiving EGFRIs; c) providing preliminary 
information about the relationship of symptoms or identified symptom clusters and key 
outcomes; and, d) providing preliminary data to help generate hypotheses for 
interventional research to improve symptom control, as well as symptom management 
interventions for symptom clusters. Specific applications to nursing practice, education 
and research are outlined below.  
 Relevance to nursing practice.  The American Cancer Society estimates that 
1,665,540 new cancer cases will be diagnosed, and 585,720 Americans are expected to 
die of cancer, in 2014 (Siegel et al., 2014).  Lung and colorectal cancers are projected to 
be among the most common cancers in men (exceeded only by prostate cancer), and 
breast, lung and colorectal cancers will be the top three cancer diagnoses in women in 
2014.  If even 10% of these newly diagnosed patients with lung, breast, or colon cancer 
were eventually treated with an EGFRI, this would amount to a considerable number of 
patients who could potentially benefit from the new knowledge generated by this study.   
Overall, the number of cancer survivors has more than quadrupled since 1971, 
when 3 million people were identified as survivors.  In 2007, 11.7 million people in the 
United States were described as cancer survivors (Rowland et al., 2011). By 2012, the 
number of U.S. cancer survivors had risen to 13.4 million people in 2012, or just under 
5% of the population, according to a recent report from the Centers for Disease Control 
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(Ekwueme et al., 2014). About 68% of cancer survivors were still alive five or more 
years after their diagnosis (Siegel et al., 2012), and nearly 60% of those individuals were 
older than 65.  Many cancer diagnoses can now be considered to be more like chronic 
diseases which require a series of treatments over time.  An improved understanding of 
the symptom experience of patients receiving EGFRIs may benefit a significant number 
of patients who may be treated with these drugs, whether they are among the newly 
diagnosed with advanced disease, or are receiving EGFRIs later in the treatment 
continuum.   
An essential role of the health care team is to help each patient to manage their 
symptom experience, allaying its impact on important outcomes. Since patients perceive 
their illness and its treatment through their collective symptom experience, optimal 
patient care should address the occurrence of all symptoms in order to tailor symptom 
management strategies (Brown, Cooley, Chernecky, & Sarna, 2011), many of which will 
require multiple interventions.  Describing dermatologic symptoms along with other 
symptoms that co-occur, and exploring their relationship to important outcomes will 
create a better understanding of what patients experience and lead to enhanced patient 
care.  In addition, the majority of oncology patient care has shifted to the outpatient arena 
away from the infusion suite (Neuss et al., 2013), where patients may have less in-person 
contact with oncology nurses. Some EGFRI agents, such as cetuximab and panitumumab, 
are given as infusions, but other agents, such as the TKIs in this study, are taken orally.  
When patients receive oral agents, patient teaching strategies in the practice setting must 
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be highly focused, delivered in new formats, or via new technologies due to limited 
interaction with oncology nurses.  
The EGFRI symptom experience is illustrated by this case example.  A 65 year-
old retired woman taking erlotinib for advanced lung cancer develops an itchy facial rash 
after six weeks of therapy.  The rash causes her anxiety and discomfort, and although she 
has been advised that its presence may be indicative of a therapeutic response, it still 
causes psychological distress.  The rash, as well as her severe dry skin and dry eyes, 
cause her to be irritable. Upon waking, her eyelashes are covered with crusts, causing 
inconvenience and irritation. Everyday tasks like housekeeping are more difficult due to 
changes in her nail beds and sore fingers, and she isn’t sure how her grandchildren will 
react when they come to visit, as she looks different and is unable to prepare their 
favorite foods for them. A holistic plan of care could not only preemptively manage her 
dry skin,  but could help her identify other interventions such as caring for her eyes, 
soaking her nails, and using relaxation techniques or meditation to help her cope with any 
distress symptoms may cause.  
Despite experiencing multiple symptoms, it is possible that patients such as the 
woman described above may prioritize and receive advice only for the most pressing or 
overt (e.g. dermatologic) symptoms during their brief encounter with health care 
providers. But other associated symptoms, such as dry eyes, or feeling sad or nervous, 
could remain untreated.  Evidence suggests that patients may underreport their symptoms 
for a variety of reasons, such as thinking a symptom is too minor to mention, blaming a 
symptom on aging or comorbidity, prior minimization by the provider, failure to receive 
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helpful information upon previous reporting, and lack of time in the patient-provider 
interaction (Royer, Phelan, & Heidrich, 2009).  Further, patients may assign symptom 
priorities “based on the meanings they ascribe to them” (Maguire, Stoddart, Flowers, 
McPhelim, & Kearney, 2014).  For example, about half of all patients who experienced 
fatigue in one study did not report it to their physician, perhaps due to resignation over its 
inevitability, its relative unimportance, or because they perceived a lack of treatment 
options to address it (Stone et al., 2000; Passik et al., 2002), so it is possible that some 
EGFRI-related symptoms could be viewed by patients as unavoidable discomforts.   
Further, clinicians tend to “underestimate the incidence, severity, or distress of symptoms 
experienced by cancer patients” (Xiao, Polomano, & Bruner, 2014). Thorough 
assessment is the first step in addressing all of the EGFRI-related symptoms, and for 
some symptoms, use of a questionnaire may result in an increase in the symptom 
prevalence reported by patients, as patients may feel less encumbered by time restraints, 
and may feel more able to surface symptoms not part of routine clinical assessments 
(Teunissen et al., 2007). 
Treating all symptoms, rather than individual symptoms, could prove beneficial to 
both providers and patients (Chan, Richardson, & Richardson, 2011) by anticipating 
possible problems, preventing symptoms from worsening, reducing the number of 
medications used, decreasing medication side-effects, averting unplanned visits to a 
health care provider, reducing costs, and enhancing patient well-being and satisfaction 
(Walsh & Rybicki, 2006; Berger, Yennu, & Million, 2013). Patients experiencing poor 
symptom management incur unnecessary health care costs for hospitalizations and 
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emergency consultations to manage toxicities and out-of-control symptoms (Fortner, 
Okon, & Portenoy, 2002).  Reduced direct and indirect costs of health care are a potential 
benefit of optimal and novel symptom management, a model which has been explored in 
patients receiving chemotherapy (Given, Bradley, You, Sikorskii, & Given, 2010).  In 
addition, treatments used for one symptom could affect other symptoms (Kapella, Larson, 
Patel, Covey, & Berry, 2006) and offer a “crossover” benefit, as in the examples of 
cognitive-behavioral therapies used for both pain management and amelioration of 
fatigue (Fleishman, 2004). At present, these benefits are largely theoretical, and need to 
be explored in future research, as very few intervention studies have investigated 
treatment protocols for multiple symptoms. 
 Relevance to oncology nursing education. Although oncology nurses have 
always assessed symptoms using a whole person approach, nursing education about 
symptom management traditionally has focused on single, high-incidence symptoms, 
such as fatigue, pain, and nausea and vomiting.  As a result, both nurses and nursing 
students are oriented to the management of those symptoms as they occur individually, a 
situation which contributes to a reductionist approach to patient care.  Studies of the 
symptom experience related to specific treatments create a more realistic picture of what 
patients face, and nursing education content can be based on this new knowledge.   
Symptom clusters can be viewed as correlates of quality of life and other 
outcomes in chronic conditions, and addressing interventions that target them can impact 
outcomes (Motl & McAuley, 2009). Nursing education could emphasize an awareness of 
symptoms that cluster together in various cancer diagnoses or in relation to specific 
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treatments.  In turn, oncology nurses will have a heightened awareness of symptoms 
likely to co-occur, and can proactively teach patients relevant self-care skills, such as 
symptom management strategies that might offer the “crossover” effect as described 
above. Nursing education on symptom assessment and management strategies must 
continually evolve to address the symptom experience associated with new therapies as 
they are introduced.   
 Relevance to oncology nursing research. The Oncology Nursing Society (ONS) 
conducts a research priorities survey and produces a research agenda every few years, 
and for 2013, symptom management: self-management symptom control was rated as the 
fourth highest priority.  Fatigue, pain, nausea, psychological distress, and neuropathy 
were ranked by all respondents as the top five symptoms causing patient distress, and two 
of these (fatigue and psychological distress) have been addressed in the current study 
(Lobiondo-Wood et al., 2014).   
The 2013 ONS research survey also ranked research priorities separately by the 
educational degrees of respondents.  For nurses with advanced degrees, self-management 
interventions to improve symptom control, symptom management interventions and 
management interventions of symptom clusters were ranked as the top three priorities.  
These topics were also ranked in the top 20 for nurses with basic nursing degrees, but at 
lower priorities. The present research provides a foundation for addressing all three of 
these priorities as well as for two of the prioritized symptoms, fatigue and psychological 
distress, in patients receiving EGFRIs (Lobiondo-Wood et al., 2014).  
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Oncology nurses continue to prioritize symptom management as a topic worthy of 
research, with a greater focus on self-management, multiple concurrent symptoms, and 
technology, with each of these elements included in the current work. Nursing research in 
the area of concurrent symptoms or symptom clusters has proliferated over the last 
decade; however, symptom clusters in patients receiving EGFRIs have not been 
systematically studied to date, and the preponderance of research on EGFRIs has focused 
on the dermatologic symptoms.  The present study included a more comprehensive 
assessment of symptoms than in previously published work because 38 possible 
symptoms were included, and data were collected on symptoms beyond skin, hair and 
nail changes, with the intent of discovering the existence of symptom clusters in this 
patient population.  
 Nursing research studies featuring interventions for symptom clusters are limited 
(Xiao, 2010) and have only recently increased, and none related to EGFRI therapy have 
been published at this writing.  A recent review described 24 studies that included 
interventions for patients experiencing symptom clusters, with eighteen focused on early 
cancer and six on advanced disease (Berger et al., 2013),  but none included patients 
receiving EGFRIs. This study is a first step toward the identification of symptom clusters 
in these patients so that interventions can be developed.  
Purpose of the Study 
The current study was designed to describe the symptom experience, including 
any symptom clusters, in patients receiving EGFRIs, and to explore the relationships 
between symptoms, any identified symptom clusters, and key outcome variables of 
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quality of life, performance status, and psychological functioning.  The intent is to 
develop a more comprehensive understanding of the symptom experience of patients 
receiving these therapies, and to provide a foundation for the development of hypotheses 
for interventions aimed at helping these patients to better self-manage their symptoms.  
Specific Study Aims 
 The specific study aims were to:  
1. Describe the symptom experience (symptom frequency and distress) of 
patients receiving EGFRI therapy. 
2. Describe the quality of life, functional performance and psychological status 
of patients receiving EGFRI therapy.   
3. Identify any co-occurring symptoms or symptom clusters in patients receiving 
epidermal growth factor receptor inhibitors. 
4. Explore the relationships between any identified symptom clusters and key 
variables, including gender, age, primary cancer, EGFRI, and the outcome 
variables of quality of life, functional performance and psychological status.   
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CHAPTER TWO 
LITERATURE REVIEW 
Even as cancer care evolves to a paradigm of personalized medicine based on 
molecular profiles and targeted therapies, newer treatments continue to create symptom 
management challenges.  Oncology nurses help patients to navigate their treatment 
course, assisting them to manage the unpleasant symptoms they confront, regardless of 
modality of therapy.  Underpinning this continually evolving clinical practice is nursing 
research, such as the present study, designed to address the gaps in knowledge about how 
patients experience symptoms.   
In this chapter, the theoretical framework used to guide this study will be 
presented.  The concepts of symptoms, the symptom experience, and symptom clusters 
will be briefly reviewed as they relate to this theoretical framework.   The available 
literature on the symptom experience of patients receiving EGFRIs will be summarized, 
and the relationship between EGFRI-related symptoms and key variables, such as age, 
gender, primary diagnosis, and type of agent, as well as performance outcomes of 
interest, including functional status, quality of life and psychological functioning, will be 
presented.  Finally, the current knowledge about EGFRI symptoms and gaps in 
knowledge will be summarized. 
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Conceptual Framework: The Theory of Unpleasant Symptoms 
The revised theory of unpleasant symptoms (Revised Theory of Unpleasant 
Symptoms, Figure 1) is the model selected to guide this research study (Lenz & Pugh, 
2003).  The TOUS has been described by its authors as a middle-range theory (Lenz & 
Pugh, 2008) “designed to integrate knowledge about a variety of symptoms” (p. 159).  As 
Lenz and Pugh (2008) noted, symptom management is a central component of nursing 
clinical practice. The TOUS is valuable as a general tool to address the “multivariate 
assessment of the symptom experience itself and of possible influencing factors, and 
provides a rationale and framework for applying a biopsychosocial 
approach….suggesting that multiple management strategies may need to be applied 
simultaneously” (p. 85). 
The TOUS has served as the theoretical scaffold for a number of discussion 
papers and nursing research studies in oncology (Redeker, Lev, & Ruggiero, 2000; 
Carpenter et al., 2004; Lee, 2005; Fox & Lyon, 2006; Fox, Lyon, & Farace, 2007; Fox & 
Lyon, 2007; Myers, 2009; So et al., 2013; Hsu & Tu, 2014); and in studies of patients 
with Alzheimer’s disease, cardiac disease and heart failure, cirrhosis, domestic violence, 
fatigue, renal failure, stroke, chronic obstructive pulmonary disease, inflammatory bowel 
disease, multiple sclerosis, Parkinson’s disease, and in pregnant, postpartum and 
breastfeeding women  (Hutchinson & Wilson, 1998; McCann & Boore, 2000; Corwin, 
Klein, & Rickelman, 2002; Gift, Stommel, Jablonski, & Given, 2003; Gift, Jablonski, 
Stommel, & Given, 2004; Crane, 2005; Reishtein, 2005; Kapella et al., 2006; Liu, 2006; 
Rychnovsky, 2007; Jurgens et al., 2009; Motl & McAuley, 2009; Song, Moser, & Lennie, 
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2009; Farrell & Savage, 2010; Woods, Kozachik, & Hall, 2010; Robinson et al., 2013; 
Eckhardt, Devon, Piano, Ryan, & Zerwic, 2014). 
Model Components 
The TOUS comprises three major concepts: the symptom or symptoms, 
influencing factors (physiological, psychological, and situational), and performance 
outcomes (Lenz, Suppe, Gift, Pugh, & Milligan, 1995; Lenz, Pugh, Milligan, Gift, & 
Suppe, 1997; Lenz & Pugh, 2003, 2008). In the present study, in an effort to 
operationalize all three major concepts, the symptoms or symptom clusters align with the 
symptom element of the model; the influencing factors are the primary cancer diagnosis, 
EGFRI therapy, gender, and age; and the performance element (cognitive, physical and 
social functioning) includes the outcome measures of quality of life, performance status 
and psychological functioning. For the purpose of this study, all of these elements make 
up the patient’s symptom experience, as represented in Figure 2.  
All three components of the model—symptoms, influencing factors and 
performance outcomes—can affect the symptom experience.  When the original TOUS 
model was published (Lenz et al., 1995), a single symptom was represented in the model 
schematic since the original work was derived from the study of single symptoms.  A 
major revision to the model (Lenz, Pugh, Milligan, Gift, & Suppe, 1997) added the 
concurrent measurement of more than one symptom, including interaction and 
multiplicity between and among multiple symptoms (Myers, 2009). The revised model is 
a more realistic foundation for research on symptoms, particularly in patients with 
advanced cancer when patients are likely to experience multiple concurrent symptoms 
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(Vainio & Auvinen, 1996; Walsh & Rybicki, 2006; Kirkova, Aktas, Walsh, Rybicki, & 
Davis, 2010).      
The TOUS model is not without limitations.  For example, the distinct attributes 
of the three categories of influencing factors are somewhat hazy. The theorists have 
wrestled with how to categorize social support and similar constructs as either situational 
factors or psychological factors. For example, social support and level of education 
would be considered as situational factors, while level of trust and self-efficacy might be 
described as psychologic factors, so the classification seems somewhat arbitrary. Further, 
the distinction between psychologic and physiologic factors is blurry. According to the 
theorists, “Psychologic factors represent one of the more complex and controversial 
components of the model…..As psychobiological research underscores the physiological 
basis for mood, the psychologic and physiologic factors impacting the symptom 
experience become difficult to separate”  (Lenz and Pugh, 2001, pp. 77-78).  
Lenz and Pugh concede that “the complex relationships among the three 
categories of influencing factors and between these factors and the symptom experience 
need much fuller elaboration, and the categories themselves need continuing 
clarification” (p. 87).  Additionally, the theorists recognize the need for additional 
development of the performance or outcomes aspect of the theory, including the addition 
of more inclusive outcomes beyond performance that “that may be important 
consequences of the symptom experience” (p.88).  The “meaning” of the symptom 
experience is also not included in the model (Armstrong, 2003), and might be considered 
a significant omission, although it could be argued that the distress component of  
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symptom measurement and the cognitive element of performance could address symptom 
meaning. However, Lenz and Pugh (2008) state that the concept of meaning is distinct 
from distress.  
Further, by characterizing psychologic constructs as influencing factors, perceived 
symptoms such as anxiety and worry are not addressed by the model. The model has been 
critiqued for an overemphasis on physical symptoms since there is not a clear distinction 
between psychological symptoms and the psychologic influencing factors, so these 
concepts overlap (Xiao, 2010). Although TOUS is not a perfect model (Brant, Beck, & 
Miaskowski, 2009), it fits with the current study by embracing the multiplicity and 
synergy inherent in the symptom experience, and allowing for the incorporation of other 
performance-related constructs as part of the overall symptom experience.  
Symptoms Component of the Model 
The Oxford American Dictionary defines symptom as “a physical or mental 
feature that is regarded as indicating a condition of disease, particularly such a feature 
that is apparent to the patient: a sign of the existence of something, especially of an 
undesirable situation” (Mc Kean, 2005).  Symptom is derived from the, late Middle 
English synthoma, symptom of a disease, from Medieval Latin based on the Greek 
sumptoma, a happening.  Symptoms, defined as “the perceived indicators of change in 
normal function as experienced by patients” (Rhodes & Watson, 1987), and as 
“subjective experiences reflecting changes in a person’s biopsychosocial function, 
sensation, or cognition” (Larson et al., 1994), are the subjective heart of the human illness 
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experience. Symptoms can also include deviations in sensation and appearance (Tse, 
2003).   
The TOUS model accounts not only for the presence of symptoms, but reflects the 
multidimensionality of symptoms by including the dimensions of distress, timing, 
intensity, and quality as part of the model.  The distress dimension captures the 
bothersome nature of the symptom, or its affective impact.  The dimension of quality 
describes the unique characteristics of a symptom, such as burning or stinging.  The 
dimension of intensity refers to the degree, strength, or severity of a symptom.  Finally, 
the dimension of timing refers to the duration and/or frequency of a symptom, and/or its 
temporal relationship to any precipitating factor or situation.  Lenz  and Pugh (2008) note 
that while measuring all of these dimensions would be ideal when conducting symptom 
research, selection of  “one, two, or three characteristics is still valid and informative for 
health care providers in managing symptoms” (p.167), and is the approach used in the 
current study.  
 Symptom clusters. Despite the fact that oncology patients often experience 
multiple symptoms, until recently, much symptom research has focused on single 
symptoms.  Researchers at the University of California at San Francisco (Dodd, Janson, 
et al., 2001; Dodd, Miaskowski, et al., 2001) were the first to discuss the concept of 
symptom clusters in oncology. The definition of symptom clusters used in the current 
study is derived from this early work on symptom clusters and then later refined. 
Symptom clusters are defined as a set of two (Chow, Fan, Hadi & Filipczak, 2007; Kim, 
McGuire, Tulman & Barsevick, 2005) or perhaps three (Dodd, Janson, et al., 2001; 
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Miaskowski, Aouizerat, Dodd, & Cooper, 2007) or more symptoms that occur together 
and appear to be related to each other, such as nausea, vomiting and anorexia, but which 
are not required to share causation (Dodd, Miaskowski & Lee, 2004. p. 77).   
Kim et al. defined a symptom cluster as:   
…2 or more symptoms that are related to each other and that occur together. 
Symptom clusters are composed of stable groups of symptoms, are relatively 
independent of other clusters, and may reveal specific underlying dimensions of 
symptoms.  Relationships among symptoms within a cluster should be stronger 
than relationships among symptoms across different clusters. Symptoms in a 
cluster may or may not share etiology. (p. 278) 
 
Symptom clusters have also been described as a “group of concurrent symptoms 
that may have a synergistic effect as a predictor of patient outcome” (Ferreira et al., 
2008) and morbidity (Fan, Filipczak, & Chow, 2007).  Synergy among symptoms is 
consistent with the definition used for symptom clusters in this study and is supported by 
the theory of unpleasant symptoms.  Although there is agreement that concurrency of 
symptoms is necessary, there is no consensus on temporal aspects of each symptom, or 
how long symptoms must be present to be considered as part of a symptom cluster 
(Dodd, Miaskowski, & Paul, 2001).  In addition, there is no consensus on the interactivity 
and the strength of relationship required between and among symptoms, despite 
suggestions that symptom clusters are characterized as the “degree to which symptoms 
are inextricably interactive, where any single symptom is largely codependent on changes 
in other symptoms” (Tilden, Tolle, Drach & Hickman, 2002, p. 74). 
 Symptom experience. Patients do not experience symptoms as isolated events, 
but rather through the totality of their symptoms.  The term symptom experience 
embraces the multidimensional aspects of having symptoms, including the “individual’s 
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perception of a symptom, evaluation of the meaning of a symptom and response to a 
symptom” (Dodd, Janson, et al., 2001). The concept of the symptom experience was first 
characterized  as an individual’s perception and response to both the occurrence of 
symptoms and the resulting distress  (Watson, Rhodes, & Germino, 1987), and later 
described as the manifestation of symptom occurrence and symptom distress (Rhodes, 
McDaniel, Homan, Johnson, & Madsen, 2000). The symptom (Dodd, Janson, et al., 
2001) or symptoms experience (Armstrong, 2003) is particularly complex and 
multidimensional in oncology patients, who rarely experience single symptoms, 
depending on their treatment and physiologic status.   
Armstrong (2003), in a concept analysis of the symptoms experience, noted that 
while the phrase is commonly used in the oncology literature, the concept has not been 
well-defined. For the purposes of her analysis, Armstrong referred to the “experience of 
multiple symptoms as the ‘symptoms experience’” (p. 601), defined as “the perception of 
the frequency, intensity, distress, and meaning occurring as symptoms are produced and 
expressed” (p. 602), and subsequently developed the Symptoms Experience Model to 
address how patients perceive symptoms.    
The symptom experience component of TOUS is implied, rather than directly 
stated. However, through utilization of valid instrumentation, the symptom experience 
can be adequately measured.  All of the major TOUS concepts, including influencing 
factors (operationalized in this study as age, disease, specific EGFRI, and gender), 
outcomes (operationalized as quality of life, performance, and psychological status) and 
symptoms (e.g. symptom assessment instruments), can be empirically measured with 
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good reliability and validity, and serve as a basis for describing the symptom experience 
in patients receiving EGFRIs.   
 Operationalization of the symptoms component. In the present study, the 
symptoms were measured on the dimensions of timing and distress.  As noted by the 
model developers, measurement of one or more dimensions of each symptom is 
acceptable, so timing and distress were included as they are measured by the symptom 
instrument. Timing of symptoms was addressed through assessment of symptoms over 
the past week, which is the time frame employed by the symptom assessment 
instruments.  Distress was measured by directly asking how much each symptom 
distressed or bothered the respondent.  Intensity was not included in this study, nor was 
quality. Asking participants to evaluate four dimensions of their reported symptoms 
would have proven daunting and may have led to incomplete surveys, so response burden 
was considered when choosing the MSAS-SF over the original version.  
Influencing Factors Component of Model 
In the TOUS model, influencing factors are classified as physiological, 
psychological and situational factors.  Physiologic factors can include disease status and 
severity, such as cancer diagnosis and stage of illness, as well as comorbidities.   
Psychological factors address mood, response to illness, understanding of disease, and 
other mental and emotional aspects. Situational factors may include socioeconomic 
factors, family and social support, and lifestyle behaviors (Gift, 2009).  Application of the 
TOUS model places the patient in the context of family, community and environment, 
and considers how these factors can contribute to the symptom experience, and in turn 
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can affect performance (Lenz & Pugh, 2008). In the TOUS model, these influencing 
factors can also interact, synergize and impact each other.  
Critiques of the model have asserted that there is a lack of clarity with regard to 
influencing factors (or antecedents), symptoms and outcomes (Brant et al., 2009) in that 
they are sometimes overlapping (Hutchinson & Wilson, 1998), with the authors 
responding that the “components of the TOUS …are better conceptualized as fluid and 
possibly interchangeable depending on context” (Lenz & Pugh, 2003, p. 84).  This 
remark is relevant to the present study, as psychological symptoms, such as worrying, 
feeling sad, feeling irritable, and feeling nervous are viewed as symptoms and overall 
psychological status is an element of performance and is measured as an outcome.  
 Operationalization of the influencing factors. As noted above, the influencing 
factors included in the present study are primarily physiologic and include age, gender, 
primary cancer diagnosis, and specific EGFRI, and were included as part of the 
demographic questionnaire.  
Performance Component of the Model 
Performance, including cognitive, physical and social functioning, represents how 
the patient lives with their health issues, and encompasses activities of daily living, social 
interaction, ability to problem solve, ability to concentrate, role performance and quality 
of life (Gift, 2009).  Lenz and Pugh (2008) acknowledge that the performance component 
of the model should be further refined, and specifically note that one of the limitations of 
the model is the omission of quality of life as an element of the performance outcome, 
which has also been  noted  in other critiques of the model (Myers, 2009).   
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 Operationalization of the performance factors.  In this study, outcome 
measures serve as a proxy for performance, and include measures of quality of life, 
performance status, and psychological functioning.   
Review of the Literature on the Symptom Experience  
of Patients Receiving EGFRIs 
 
Because the original conception of this study included the concept of symptom 
clusters, multiple literature searches were conducted to determine the state of the science 
on symptoms, symptom experience, symptom clusters, and EGFRIs, using the following 
databases:  Academic Search Premier; CINAHL Plus; Health Source: Nursing/Academic 
Edition; PsychInfo; MEDLINE via OvidSP; and ProQuest Dissertations.  No studies 
reporting on “symptom clusters” associated with EGFRIs were found.  
Separate searches using the same databases for each EGFRI drug (afatinib, 
cetuximab, erlotinib, gefitinib, lapatinib, panitumumab) using the “AND” operator with 
the term “symptom clusters” and “symptom experience” yielded few relevant studies.  
Publications related to the outcomes of interest using MeSH terms skin 
diseases/psychology AND epidermal growth factor receptor inhibitor as well as 
psychology AND epidermal growth factor receptor inhibitor resulted in several relevant 
citations, although none included a discussion of symptom clusters (Wagner, 2007; 
Wagner & Lacouture, 2007; Coleman, Kovtun, Nguyen, Pittelkow, & Jatoi, 2010; Joshi 
et al., 2010; White, Roydhouse, & Scott, 2011; Boers-Doets et al., 2013).   
No research exploring the symptom clusters associated with EGFRIs and their 
impact on the outcome of quality of life, while explicitly addressing functional 
performance and psychological status was found.  Quality of life (Jatoi, Green, Rowland, 
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Sargent, & Alberts, 2009; Andreis et al., 2010; Joshi et al., 2010; Ensslin, Rosen, Wu, & 
Lacouture, 2013) associated with EGFRIs has been explored, and four studies using a 
qualitative approach exploring the symptom experience of patients receiving EGFRIs 
have been published (Wagner & Lacouture, 2007; Coleman, Kovtun, Nguyen, Pittelkow, 
& Jatoi, 2011), including three focused on instrument development  (Wagner & 
Lacouture, 2007; Boers-Doets et al., 2013; Wagner et al., 2013).   
Qualitative Research Related to EGFRI Therapy 
Four qualitative papers, primarily using structured interviews and content analysis 
(although this was not always explicitly stated), have explored the symptom experience 
of EGFRI therapy.  In a brief report, Wagner and Lacouture (2007) reported on 
interviews of 20 patients about their experiences with an EGFRI-related rash, generating 
new information about the overall EGFRI-related symptom experience beyond 
dermatologic symptoms, but also confirming the distressing nature of the dermatologic 
effects of these therapies.  
This was the first outward physical appearance of the disease...it's a pretty 
significant burden to carry around...people look at you and say, 'What is wrong 
with that woman?' Where before they did not know... before, you could choose 
who you told about your cancer...and that puts a burden on you, it creates a 
dynamic that did not exist before...when before you could keep your privacy.  
(Wagner & Lacouture, 2007, Discussion Section, para. 5) 
The above comment illustrated that the facial rash caused by cetuximab became a sign of 
cancer made visible, with the impact of violating the privacy of the patient (Boers-Doets 
et al., 2013). This outward sign might require an explanation of the rash to others with 
consequences to psychological status. 
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The distress caused by physical symptoms associated with EGFRIs was 
emphasized, as noted by a participant. 
I could not get away from the dryness. The dry, cracking...It felt like I had been 
sitting in the Arctic in the elements, the rawest elements—the salt, the wind, the 
abrasion, and the cold. And there was no sense of humidity for like months. It had 
basically torn away the entire skin and it felt this way...so I would say it was the 
dryness, the sensitivity and the burning, and the inflammation of the actual 
pustule. (Wagner & Lacouture, 2007, Results Section, para. 3) 
 
The authors also described other physical symptoms associated with EGFRIs, as 
illustrated in the following quote:  
It was difficult to sleep because it hurt.  And the burn.  I had to lay sitting up so 
the skin would not move because it hurt so much.  It was hard to wash.  You 
could not put on any makeup, combing my hair hurt like hell because I have had a 
lot of hair loss. (Wagner & Lacouture, 2007, Results Section, para.4)  
 
In an extension of this work, the authors reported on additional interviews with 
patients that reinforced the premise that physical symptoms are most relevant to quality 
of life.  Items highly endorsed by patients reflected skin hurting, burning or stinging, skin 
irritation, concern about hair loss or change in texture, and pain in fingers and toes 
(Wagner et al., 2013).  
Another qualitative study of 15 patients who had developed an EGFRI-induced 
rash focused on the dermatologic toxicities and associated co-morbidities of EGFRIs 
(Coleman et al., 2011).  Four themes emerged from structured interview content: actual 
physical discomfort, concerns about physical appearance, social isolation, and what the 
authors termed high medical morbidity (Coleman et al., 2011, p.1248), which consisted 
of bleeding or pain that required hospitalization for a morphine drip.  The findings 
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associated with the high medical morbidity theme are novel findings not previously 
reported.   
A paper exploring the utility of the FACT-EGFR-18 in a native-speaking 
population in The Netherlands included a structured interview survey to learn more about 
participant responses.  Boers-Doets et al. (2013) anecdotally reported that physical 
symptoms recorded by the FACT-EGFRI-18 influenced quality of life adversely, with the 
most distressing symptoms having the greatest impact on quality of life, although no 
statistical analysis of items was performed.  
Overall, the impact of EGFRIs on quality of life was considerable, as exemplified 
by the following comments (Boers-Doets et al., 2013). 
Do you see how I look? I even (sic) no longer have a face; I look stupid; that 
makes me sad…I get grumpy; easily irritated. I don’t allow the grandchildren to 
kiss me.  I find it unpalatable…I have very much difficulty with sitting and lay 
down because of pimples between my buttocks… (p. 1922-1924) 
 
In summary, these papers offer important insights into the symptom experience of 
patients receiving EGFRIs, but have several limitations.  Each of the studies included a 
small sample size, ranging from 10 to 20 participants. Two of the papers reported on the 
same sample (Wagner, 2007; Wagner et al., 2013), so the findings discussed above are 
based on the responses of 45 participants in total.  Two of these papers were actually 
focused on instrument development and one on linguistic evaluation, but researchers did 
ask about the most bothersome aspects of dermatologic toxicity associated with EGFRIs 
and their impact on quality of life. Three of the studies were conducted at a single site, 
which in all cases was a tertiary care center in the Midwest, so findings may not be 
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applicable in other settings; the last was conducted at three hospitals in the Netherlands, 
so the findings may not be generalizable to patients in the United States.  
Quantitative Research Related to EGFRI Therapy 
Studies exploring the impact of EGFRIs on the performance outcomes of quality 
of life, functional performance and psychological status are summarized here. In addition, 
a review of symptoms associated with EGFRIs, largely derived from clinical trials work, 
will also be presented in order to help characterize the physical symptoms associated with 
EGFRIs.  
 EGFRIs and quality of life.  Several papers have explored quality of life as an 
outcome measure using dermatology-specific quality of life instruments (Osio et al., 
2009; Andreis et al., 2010; Jatoi et al., 2010; Joshi et al., 2010) with some evidence of a 
negative impact of these treatments on quality of life.  Osio expressed concern that 
because of this impact on quality of life, treatment interruption or dose reduction could be 
required. Andreis et al. (2010) reported on the impact on quality of life in advanced colon 
cancer patients receiving EGFRIs (presumed to be cetuximab and panitumumab).  
Women between the ages of 55-65, as well as patients who experienced a partial 
remission (as opposed to those with no response to treatment), and those with most 
severe symptoms, demonstrated the greatest declines in quality of life as measured by the 
Skindex-29.  Joshi et al. (2010) also reported on the impact of EGFRI toxicity (rash, 
xerosis, paronychia, and pruritus) on QOL, using the Skindex-16, and found no 
difference with respect to cancer type, gender, or treatment type with regard to 
symptoms, emotions, function or overall score. In the Joshi study, about half the patients 
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were treated with erlotinib (49.3%), so this variation in treatment and primary cancer site 
(i.e. lung cancer) may have contributed to an inconsistent impact on quality of life.     
In another group of patients receiving a variety of EGFRIs (described as erlotinib 
or other small molecule inhibitors and cetuximab or other monoclonal antibody), skin 
symptoms, including itching, burning and stinging, and psychological symptoms, such as 
worry and embarrassment, were reported. These symptoms accompanied the occurrence 
of rash, and negatively impacted self-reported quality of life as measured by the Skindex-
16 (Jatoi et al., 2010, p. 1021), but results by age and gender were not reported, so how 
these findings relate to the above studies is not clear.  
A recent study comparing quality of life as measured by the Skindex-16 in 
patients receiving targeted therapy vs. non-targeted therapies revealed  that quality of life 
in patients on targeted therapies was worse, and that rash and pruritus had the greatest 
adverse impact on quality of life (Rosen et al., 2013).  In addition, these patients had 
more adverse events than patients on non-targeted therapies. Both the total Skindex-16 
score and the emotion subdomain were significantly different between the two groups.   
 Despite the general agreement by the above studies that these therapies impact 
quality of life adversely, it is possible that effective treatment with EGFRIs may also 
ameliorate symptoms and result in improved quality of life, as has been documented 
repeatedly in clinical trials.  A study reporting quality of life outcomes in a sample of 
Chinese patients with EGFR mutation-positive advanced NSCLC receiving erlotinib or 
chemotherapy found that the erlotinib arm compared favorably with the chemotherapy 
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group on several measures (Chen et al., 2013), but a different quality of life instrument, 
not specific to dermatologic therapy, was used in this study.   
Another trial that added afatinib to best supportive care reflected improvement of 
several symptoms (cough, dyspnea, pain, fatigue) as well as in physical functioning and 
health-related quality of life (Hirsh, 2011; Hirsh et al., 2013).  Gefitinib therapy was also 
associated with improvement in health-related quality of life when compared with 
combination chemotherapy, although symptom improvement varied by EGFR mutation 
status, showing greater improvement in EGFR-mutated tumors, as would be expected 
(Thongprasert et al., 2011). Similarly, another study documented  improvements in global 
quality of  life, functioning, cough, pain and dyspnea  in patients with EGFR mutations 
(Di Maio et al., 2012).    
To summarize, although there is evidence of an adverse impact on quality of life 
with EGFRI therapy, improvement in quality of life has also been documented, possibly 
reflecting changes in health status and relief of disease-related symptoms resulting from 
successful treatment. In addition, the various targeted therapies may exert differing 
impacts on quality of life (Joshi et al., 2010), and variations in the measurement strategy, 
such as the specific quality of life instrument used in each study, may also play a role in 
these inconsistent results.  However, it can be concluded that quality of life is among the 
most important patient-reported outcomes. A large study exploring content validity of a 
quality of life in lung cancer patients revealed that quality of life, independence and 
performance, rather than physical symptoms, were ranked as most concerning  by 
patients (Gralla, Hollen, Msaouel, Davis, & Petersen, 2014).   
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 EGFRIs and functional status. Functional status, or performance status, has 
been described as the ability to engage in the performance of normal daily activities 
required to address basic needs, to engage in role performance, and to maintain health 
and well-being (Leidy, 1994; Wilson & Cleary, 1995). The capacities to ambulate, to 
function in chosen roles, and to work are all activities that fall within the realm of 
functional status.   
In symptom cluster research, the available evidence suggests that the more 
numerous and severe symptoms are, the greater the impact on functional status (Dodd, 
Miaskowski, et al., 2001; Given et al., 2001; Gift et al., 2004; Barsevick, Dudley, & 
Beck, 2006; Chen & Tseng, 2006; Fox & Lyon, 2006; Chen & Lin, 2007; Chow, Fan, 
Hadi, & Filipczak, 2007; Fox et al., 2007; Fox & Lyon, 2007; Ferreira et al., 2008; Hadi. 
et al., 2008; Dodd, Cho, Cooper, & Miaskowski, 2010; Ryu et al., 2010; Tsai, Wu, Chiu, 
& Chen, 2010; Dodd et al., 2011; Roiland & Heidrich, 2011; Kim, Barsevick, Beck, & 
Dudley, 2012).  Although functional status has not been studied extensively with 
EGFRIs, several authors reported that activities of daily living and social activity were 
affected by EGFRI treatment (Joshi et al., 2010; Boers-Doets et al., 2013).  
 EGFRIs and psychological status. While most people treated for cancer have 
normal psychological functioning  (Kornblith, 1998), a significant number of patients can 
experience distress and other disruptions of psychological status, with estimates of 29 to 
43 percent of patients experiencing such distress (Zabora, Brintzenhofe Szoc, Curbow, 
Hooker, & Piantadosi, 2001). A cancer diagnosis, cancer treatment, and living with the 
associated life changes can both generate distress and exacerbate existing psychological 
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issues (Adler & Page, 2008). In general, patients undergoing cancer therapy are at risk for 
distress and disruption of psychological well-being (Fox & Lyon, 2006, 2007), and 
patients with severe symptoms are at risk for concurrent psychoneurologic symptoms 
(Kim, Barsevick, Beck, et al., 2012).   
The logically consistent conclusion relating rash to psychological distress may not 
be so clear cut. Paradoxically, development of rash was perceived by some patients as a 
sign of hope and effectiveness of therapy, reflecting the suggested correlation of the rash 
occurrence to treatment effectiveness. In fact, in patients receiving erlotinib, there is 
evidence to suggest that skin rash is associated with improved response and survival time 
(Pérez-Soler et al., 2004; Wacker et al., 2007); similar findings have been reported with 
cetuximab, panitumumab, and gefitinib (Lacouture, et al., 2011).  
In patients receiving EGFRI therapy, psychologic distress was reported in 41% of 
Italian patients receiving cetuximab for advanced colon cancer (Romito et al., 2010), but 
when compared to an instrument validation sample, there were no significant differences 
found (p = 0.583). While the impact of EGFRI-related symptoms on psychological well-
being is presumed,  patients did not rate items related to social function as highly 
important to quality of life as often as clinical experts did in instrument development 
work for the EGFRI-18 (Wagner, 2007); rather, patients ranked social well-being items 
as less distressing than items affecting physical and functional well-being.  However, in 
open-ended interviews, items reflecting an impact on social well-being were identified by 
patients as being somewhat important.  The ambiguity around patient ratings of items that 
impact quality of life related to EGFRI therapy, as well as the lack of congruence 
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between the ratings of patients and professionals, warrants further exploration (Boers-
Doets et al., 2013).   
Research Related to Influencing Factors and EGFRI Therapy 
The following discussion summarizes available research related to the influencing 
factors of age and gender, both with respect to symptoms in general, as well as to 
symptoms associated with EGFRI therapy. 
 Age.  It has been suggested that in patients with advanced cancer, symptom 
severity for common symptoms decreases with age (Kirkova, Rybicki, Walsh, & Aktas, 
2012), and older patients had lower occurrence rates for many symptoms, as well as 
lower severity, frequency, and distress ratings for some symptoms when compared to 
younger patients (Cataldo et al., 2013). However, a recent study comparing cancer 
patients in various older age groups (60-69, 70-79, and 80-89) with regard to 
psychological and somatic symptoms suggests that the impact of age on the symptom 
experience may not be linear, with the 70-79 year old group reporting the lowest scores 
for depressive, anxiety and somatic symptoms, while those 80 and older reported the 
highest (Cohen, 2014), suggesting that comorbidities may be related to symptom severity 
in older patients. The relationship between age and the symptom experience demands 
further study as findings have also varied with specific symptoms, with fatigue and 
drowsiness more common in younger patients (Cheung, Le, Gagliese, & Zimmerman, 
2011).  
The overall impact of age on EGFRI-related symptoms in oncology patients also 
requires further study, but the literature seems to suggest possible, but inconsistent 
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relationships.  For example, rash related to erlotinib is more likely to be associated with 
age older than 70 (as well as nonsmokers and people with fair skin), while cetuximab 
rash is associated with age younger than 70 (Lacouture et al., 2011). In another study, 
Jatoi et al. found that men, and those under 70, receiving cetuximab, were more likely to 
develop a Grade 3 or 4 rash. Age was further explored by treating it as a continuous 
variable, with the subsequent discovery of an inverse relationship between severity of 
rash and age. The risk factors of male sex and younger age were described as additive, 
with age less than 70 and male sex resulting in an 8% risk of rash (Jatoi et al., 2009, p. 
122). However, two studies specifically designed to explore the impact of age on 
cetuximab- and erlotinib-related rash did not find it to be a predictor of appearance, 
duration and grade of the rash (Giuliani & Marzola, 2013a, 2013b), although the age cut-
off was 65 (as opposed to 70 in other studies), and the sample sizes were small.  
Jatoi et al. (2009) suggested that the purported less dramatic dermatologic toxicity 
in the older patient may be a function of fewer epidermal growth factor receptors and 
therefore fewer targets for EGFRIs, but it is unclear whether this is true across different 
therapies.  In fact, no relationship between rash development and various risk factors, 
including age and type of therapy, was found in a subsequent retrospective analysis of 
over 4,000 patients with a variety of cancer diagnoses (Solomon & Jatoi, 2011). 
Inconclusive evidence linking age to rash severity for cetuximab and erlotinib has also 
been reported, so much remains to be discovered about this potential relationship 
(Giuliani & Marzola, 2013a, 2013b). 
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As noted earlier in the discussion of quality of life, age may be a factor with 
respect to perceived quality of life. An interaction between age and quality of life has 
been reported with the EGFRIs, with patients younger than 50 reporting a greater impact 
on QOL than older participants with similar symptom profiles (Jatoi, et al., 2009; Joshi, 
et al., 2010).   
 Gender.  The role of gender in the cancer symptom experience is not clear.  In 
early work in this area, research in lung cancer patients suggested that there was no effect 
of gender on symptom scores (Kurtz, Kurtz, Stommel, Given, & Given, 2000); this 
finding was similar to the conclusions of other studies (Cooley, Short, & Moriarty, 2003; 
Gift et al., 2004; Hoffman, Given, von Eye, Gift, & Given, 2007).  However, gender was 
found to contribute to distress scores in patients with metastatic cancer, where women 
had worse scores for anxiety and appetite (Zimmermann, Burman, & Follwell, 2010), and 
to a higher incidence of depression in female patients with colon cancer (Kurtz, Kurtz, 
Stommel, Given, & Given, 2002).  
Recent work on symptom clusters in advanced cancer has not yielded consistent 
findings with respect to gender, most likely because of disparate patient populations and 
cancer diagnoses.  An increased prevalence of a gastrointestinal symptom cluster in 
women has been reported in one study (Jiménez et al., 2011); in another study,  women 
reported worse nausea scores than men (Cheung et al., 2011).  Gender may play a role in 
the severity of rash associated with the EGFRIs, as suggested by a preliminary secondary 
analysis of 933 stage III colon cancer patients treated with surgery and cetuximab, where 
more men than women developed a Grade 3 rash, odds ratio 2.0, 95% CI [1.14–3.88] 
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(Jatoi et al., 2009), so the authors speculated about a hormonal influence on rash 
development.    
Symptoms Experienced by Patients on EGFRI Therapy 
In order to provide a basis for understanding the overall symptom experience of 
patients who receive EGFRI therapy, which is the major aim of this study, a review of 
symptoms caused by these agents is included here.  As noted in chapter one, the most 
common dermatologic symptoms related to EGFRI therapy include changes in skin such 
as rash, xerosis (dry skin), erythema, telangiectasia, hyperpigmentation, and nail and hair 
changes.  
 Rash.  The EGFRI-related skin toxicity most frequently reported in the literature 
is a papulopustular rash occurring from two to eight weeks after the start of treatment, 
with a peak intensity occurring at about four weeks, although there is variability in 
patients, among agents, and with respect to dosage and  treatment schedule. Often 
incorrectly described as acneiform, but more correctly characterized as a folliculitis, the 
rash generally appears on the scalp, face (forehead, cheeks, nose and chin), chest, upper 
back, shoulders, and behind the ears, all areas replete with sebaceous glands (Segaert et 
al., 2009). 
The genesis of EGFRI-related rash is not completely understood, but has been 
described as inflammation of the pilo-sebaceous follicle (Peuvrel et al., 2012 ) and as a 
superficial, predominantly neutrophilic, suppurative folliculitis with disruption of the 
epithelial lining (Brodell et al., 2013).  The pathophysiology of these changes is related to 
disruption of the normal hair cycle and the disruption of normal EGFR activity in the 
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basal keratinocytes, with a resultant proliferation of pro-inflammatory cytokines and an 
attendant inflammatory response.  Although not yet definitive, preliminary evidence 
suggests that skin phototype correlates to some extent with rash severity in patients 
receiving erlotinib, wherein lower phototypes (i.e. lighter skin that burns more easily 
when exposed to sunlight) tend to be more likely to exhibit severe rash (Luu, Lai, Patel, 
Guitart, & Lacouture, 2007; Lacouture et al., 2011). However, more research is required 
as others have found no correlation with skin phenotype (Joshi et al., 2010).  Genetic 
changes to the EGFRs may contribute to the occurrence of rash in patients receiving 
EGFRIs (Parmar et al., 2013), but other factors may also play a role, with nonsmokers, as 
well as patients over the age of 70 more commonly exhibiting rash in patients treated 
with erlotinib (Rosen et al., 2013; Balagula & Lacouture, 2014).  Conversely, age 
younger than 70 has been associated with rash in male patients receiving cetuximab.   
Rash is a symptom prevalent across all EGFRIs, with reviews citing an incidence 
of 83% in patients receiving TKIs (Curry et al., 2013), and  85-93% in patients on 
cetuximab or panitumumab (Molinari, De Quatrebarbes, Andre, & Aractingi, 2005; Curry 
et al., 2013).   In general, a higher grade rash occurs with greater frequency in patients 
treated with monoclonal antibodies (10-17%) in comparison to the small molecule 
tyrosine-kinase inhibitors (5-9%) (Lacouture et al., 2011), but studies have included 
patients on a variety of therapies, so the impact of each agent is not entirely understood.  
Regardless of grade, these adverse effects constitute far more than a nuisance, causing 
dose reductions, treatment interruptions, poor adherence, and even infections, all of 
which can impact treatment outcomes (Boone et al., 2007).    
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In one series, 96 of 138 individuals (69%) who received cetuximab, panitumumab 
(MOABs) or erlotinib (a TKI) developed a rash (Solomon & Jatoi, 2011), consistent with 
findings in another study where 65% experienced papulopustular rash (Chan & Tan, 
2011).  This trend was confirmed by a subsequent meta-analysis of 13 studies reporting 
EGFRI-related rash that revealed an overall risk difference of 74% for all rashes, and 
12% for Grade 3 and 4 rashes in patients receiving cetuximab and panitumumab when 
compared with those on non-EGFRI therapy (Mittman, 2011).   
A literature review assessing severe (Grade 3-4) folliculitis, when focused on an 
analysis of lung cancer patients, demonstrated a greater incidence with cetuximab (9%) 
and erlotinib (8%) in comparison to gefitinib (2%) (p < .0001) (Bachet et al., 2012), 
suggesting a comparable rate of rash between a TKI and a MOAB, as well as a 
differential impact between two TKIs. These findings confirm earlier work documenting 
that in the small molecule kinase inhibitors, rash was reported in 44% of  patients 
receiving gefitinib, with an expected higher incidence of 49-75% in patients receiving 
erlotinib  (Lacouture, Mitchell, et al., 2010).  Mild rash and acneiform lesions were 
reported in 73% of patients on afatinib, with a grade 3 rash seen in about 13% (Lacouture 
et al., 2013).  In addition, palmar-plantar erythrodysesthesia was reported in 7% of 
patients on afatinib, and bullous, blistering lesions have also been reported.  
 Xerosis.  Dry skin, or xerosis, develops after several weeks in some patients 
taking EGFRIs, and virtually all patients receiving these therapies for six months will 
develop this cutaneous manifestation, which can evolve into a chronic form of eczema.  
A further complication associated with xerosis is infection and inflammation, as the 
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barrier protection of the skin is compromised.  Painful fissures of the fingertips and on 
the feet have been described (Osio et al., 2009; Segaert et al., 2009).  
 Nail changes.  Nail changes occurred in approximately 10-15% of patients treated 
with EGFRIs after four to eight or more weeks of treatment (Osio et al., 2009; Becker, 
van Wijk, Smit, & Postmus, 2010; Lacouture, Maitland, et al., 2010).  In a meta-analysis 
(n = 2107) of EGFRIs and nail toxicity, the overall incidence reported was 17.2%, 95% 
CI [13.8%, 21.3%], with a risk of high grade nail toxicity suggested to be relatively small 
at 1.4%, 95 CI [0.9%, 2.1%] (Garden, Wu, & Lacouture, 2011).  No statistically 
significant difference in nail changes were noted among the EGFRIs included in the 
meta-analysis, suggesting a general effect of EGFRI inhibitors on keratinocytes in the 
vicinity of the nail (Garden et al., 2011).  
Nail fold inflammation (paronychia) often involves the great toe, although other 
toes, as well as fingernails, are often affected. Granuloma-like lesions may result in nail 
bed inflammation and onycholysis (described as a loosening or separation of the nail 
plate from its supporting structures), although this occurs rarely (Stevenson & El-Modir, 
2011). Onychodystrophy, or nail malformation, as well as slower nail growth and nail 
brittleness, have also been described.   
 Hair changes.  EGFRI treatment that spans from seven to ten weeks or longer has 
been linked with an array of hair growth changes. Trichomegaly, which describes curly, 
long, and rigid eyelashes, and trichiasis, or misdirected eyelashes, as well eyebrow 
overgrowth, can develop following long-term treatment with EGFRIs. Interestingly, scalp 
alopecia also may occur, and both frontal and total alopecia, as well as scarring alopecia 
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have been reported (Pongpudpunth, Demierre, & Goldberg, 2009).  Other hair 
abnormalities, such as facial hypertrichosis in women, reduced facial hair growth in men, 
loss of hair on arms and legs, and changes in texture, color, and overall manageability of 
hair have been documented (Segaert & Van Cutsem, 2005; Osio et al., 2009; 
Pongpudpunth et al., 2009; Segaert et al., 2009; Balagula, Lacouture, & Cotliar, 2010). 
 Ocular toxicities.  About one third of patients receiving EGFRIs experience 
ocular reactions (Basti, 2007), most commonly blepharitis and dysfunctional tear 
syndrome (i.e. dry eye) (Borkar, Lacouture, & Basti, 2013), but also including 
iridocyclitis, and corneal epithelial defect, as well as conjunctivitis, meibomitis and 
periocular skin changes (Fraunfelder & Fraunfelder, 2012).  
 Pruritus.  A meta-analysis of studies including many different targeted therapies 
found an incidence of  17.4%  all-grade pruritus (Ensslin et al., 2013).  An early theory 
accounting for the pathophysiology of pruritus or itching is the accumulation of mast 
cells in the skin tissue, as demonstrated in a small sample of patients treated with 
erlotinib (Gerber et al., 2010).  
 Associated mucocutaneous symptoms.  Depending on the specific agent, 
EGFRIs may also cause mucocutaneous symptoms such as erythema, flushing, radiation 
dermatitis, balanitis, hyposalivation, mucositis and taste changes (Osio et al., 2009; 
Lacouture, Maitland, et al., 2010; Katakami et al., 2013).    
 Other symptoms.  Other symptoms reported to occur with EGFRIs include 
anorexia, fatigue, nausea (Ross et al., 2010), insomnia, anxiety (Wagner & Lacouture, 
2007), electrolyte imbalances and diarrhea (e.g. erlotinib and afatinib) (Hirsh, 2011; 
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Katakami et al., 2013), infusion reactions (e.g. cetuximab) (Ouwerkerk & Boers-Doets, 
2010), interstitial lung disease and associated pulmonary symptoms, (Nguyen & Neal, 
2012; Katakami et al., 2013), and pain (Wong et al., 2010).  
Gaps in the Literature 
 The purpose of the current study was to describe the symptom experience of 
patients receiving EGFRIs and to explore their impact on performance, including quality 
of life, functional status and psychological status. The symptom experience of the patient 
undergoing EGFRI therapy has not been fully described, and concurrent symptoms or co-
occurring symptoms associated with these targeted therapies have not yet been 
systematically explicated in the nursing literature.  Most of the EGFRI symptom-oriented 
literature published to date focuses on specific aspects of EGFRI therapy, such as the 
dermatologic effects of these agents (Garden et al., 2011; Wu et al., 2011; Ensslin et al., 
2013; Urban & Anadkat, 2013); hypersensitivity or infusion reactions (Lenz, 2007); or  
reflects the grading of toxicities as in clinical trials. No nursing studies exploring 
symptoms or symptom clusters associated with EGFRIs have been published at this 
writing, and none explore the impact of EGFRIs on outcomes.  
The symptom experience resulting from treatment with these agents, as well as 
from a diagnosis of cancer, includes an array of symptoms that go beyond skin, hair and 
nails changes, and may affect quality of life, functional performance and psychological 
status, so gaps in knowledge on this topic remain.  The current health care environment 
requires that care be delivered as cost-effectively as possible. Proactive identification and 
treatment of high incidence symptoms should be implemented whenever possible in order 
  
to enhance the effectiveness and efficiency of care processes, but even more importantly, 
to help maintain and improve every patient’s quality of life, psychological status and 
functional performance.  
 
 
Figure 1.  Revised Theory of Unpleasant Symptoms Model
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Figure 2. Application of the Theory of Unpleasant Symptoms 
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CHAPTER THREE 
METHODS 
The purpose of this cross-sectional descriptive study was to describe the symptom 
experience of patients receiving any currently available FDA-approved epidermal growth 
factor receptor inhibitors (EGFRIs) (such as erlotinib, gefitinib [continuing patients], 
afatinib, lapatinib, cetuximab and panitumumab) as part of their cancer therapy, which 
could include those diagnosed with breast, colorectal, head and neck, lung, and pancreatic 
cancers. 
Specific Aims 
The specific study aims were to:  
1. Describe the symptom experience (symptom frequency and distress) of 
patients receiving EGFRI therapy. 
2. Describe the quality of life, functional performance and psychological status 
of patients receiving EGFRI therapy.   
3. Identify any co-occurring symptoms or symptom clusters in patients receiving 
epidermal growth factor receptor inhibitors. 
4. Explore the relationships between any identified symptom clusters and key 
variables, including gender, age, primary cancer, EGFRI, and the outcome 
variables of quality of life, functional performance and psychological status.   
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Design and Setting 
A cross-sectional, descriptive, correlational design using primarily a web-based 
format (with an option for paper format) has been used for this study.   Because EGFRI 
therapy is appropriate for only a small percentage of patients with breast, colorectal, head 
and neck, lung, and pancreatic cancers, recruitment for this study included several 
strategies designed to reach a large potential volunteer pool. See Figure 3 for a graphical 
depiction of recruitment strategies. In order to achieve an optimal sample size, direct 
recruitment of participants from online support sites and patient support communities, as 
well as indirect recruitment of participants through health care providers, was 
implemented. The goal was to achieve a sample size of 100.  
Recruitment Procedures 
1. Indirect recruitment. 
Letters describing the study were sent to health care providers, including 
oncologists and oncology nurses, from Illinois, Wisconsin and Indiana.   
Descriptive flyers providing information about study participation and 
eligibility criteria were included in the mailing for distribution to potential 
participants.  Mailing lists were purchased for this purpose, and approximately 
3000 first-class mailings were sent to members of these lists. 
2. Direct recruitment through health care settings.  
Following initial Institutional Review Board (IRB) approval at Loyola 
University Health System, additional IRB permission was sought at another 
health care system and at Northwestern University (NU).  The Northwestern 
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IRB reviewed the Loyola IRB determination and the study protocol and did 
not require a separate submission to the NU IRB.  Clinicians at NU agreed to 
share the flyers with patients who might be eligible, so flyers were supplied 
for this purpose.  
3. Direct recruitment through patient support settings. 
Participants were also recruited from patient support organizations in the 
Midwest.  Flyers were posted at patient support centers in The Cancer Health 
Alliance, including Wellness Place (Palatine), Wellness House (Hinsdale), 
Cancer Wellness Center (Northbrook), The Cancer Support Center 
(Homewood and Mokena), Living Well Cancer Resource Center (Geneva), 
and also at Gilda’s Club (Chicago) and at the Rush University Medical Center 
Gilda’s Club site. Flyers were made available at a Breathe Deep LUNGevity 
community event.     
4. Direct recruitment through online support groups. 
Informational flyers, web site links, or study descriptions (depending on what 
was allowed by site administrators) were posted on the web sites of a variety 
of online patient support groups.   Information was posted on the Cancer 
Support Community, Colon Cancer Alliance, Inspire.com, Lung Cancer 
Alliance, LUNGevity Foundation, Metavivor.org, Pink-Link.org, National 
Lung Cancer Partnership, Navigating Cancer and Blood Disorders, and the 
Pancreatic Cancer Action Network Survivors Network. Postings were also 
shared via social media to reach a broader audience. Despite positive 
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responses to initial queries about posting these announcements, many other 
sites ultimately opted not to post study announcements, citing their own 
research agenda, changes in policy about posting third party requests, inability 
to evaluate research requests, and their desire not to inundate participants with 
such requests.  Many site administrators simply never responded to repeated 
email requests.  Using a similar strategy, one researcher reported receiving 
300 responses and 135 usable data sets from participants who responded to a 
study announcement on an online support group web site (e.g. LUNGevity) (J. 
Cataldo, personal communication).  In another study, a mailed survey about 
symptoms and quality of life sent to 140 members of an online support group 
of brain tumor patients generated a 52% response rate (Fox et al., 2007), but 
specific mailing lists such as this were not available for this study.    
5. Direct recruitment through study web site.  
For all potential volunteers, an informational web site was available, and 
participants originally were able to contact the researcher by phone or email if 
they had questions about the study.  
The original procedure required potential participants to contact the researcher to 
be screened for eligibility.  However, the procedure requiring contact with the 
investigator was in place only for the first few months of recruitment. After  several 
months of recruitment activities with a low accrual rate (8 participants), and in order to 
facilitate more rapid recruitment, a direct link to the study and screening questions was 
51 
 
 
provided on a study web site and was updated at patient support communities after 
consultation with the IRB and the doctoral advising committee.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Direct and Indirect Study Recruitment 
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Sample 
 The sample for this study included participants receiving EGFRIs who responded 
to online or other posted announcements at support sites, or who were told about the 
study by their health care provider.   
Inclusion criteria were as follows:  
1. Treatment with an EGFRI (either a MOAB or a TKI) for at least four weeks.  
These agents include afatinib (Gilotrif®), erlotinib (Tarceva®), gefinitib 
(Iressa®) (continuing patients), lapatinib (Tykerb®), and the monoclonal 
antibodies cetuximab (Erbitux®) and panitumumab (Vectibix.)  
2. Ability to speak, read, write and understand English.  
3. Age 18 years or over.  
4. Ability and willingness to consent to participate in the study.  
5. Ability and willingness to complete study activities, including completion of 
required questionnaires online, or by completion of paper instruments.    
 Exclusion criteria were as follows: 
1. Patients who self-reported significant dermatologic disease unrelated to cancer 
treatment, such as severe acne vulgaris, erythema multiforme, psoriasis or 
rosacea. 
2. Patients with a poor performance status unable to complete the survey 
instruments, which required 20-30 minutes to finish.  
 Participants responded to the following item which included the first exclusion 
criteria: “I do not have one of the following skin conditions: acne vulgaris, erythema 
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multiforme, psoriasis or rosacea.”  The second exclusion criteria would have resulted in 
patients not completing the survey, so submission of the survey assumes adequate 
performance status.  
Sample Size Calculation 
Aims 1 and 2 were descriptive and did not require sample size calculation. Aim 3 
required factor analyses for identification of symptom clusters or co-occurring symptoms, 
and will be discussed further below.  Sample size calculation for Aim 4, assuming a 
medium effect size and a power of 0.8 at a 0.05 level of significance, ranged from 85-92 
with 5 variables included in the model.  If an additional two variables were entered, to 
total 7, required sample size would increase to 103-104 (Newton & Rudestam, 1999), so 
the initial proposed sample size was 100. 
Sample Size for Factor Analysis 
Sample size for this study, however, was primarily driven by the use of 
exploratory factor analysis for deriving symptom clusters as described in Aim 3. Power 
analysis is not used to generate a sample size for factor analysis, and there is no standard 
method for calculation of an appropriate sample size.  
Factor analysis procedures traditionally have been thought to require a large 
sample size, but opinions vary regarding ideal sample sizes for factor analytic procedures.  
Although several rules of thumb governing sample size for factor analysis appear in the 
literature, stringency in their application has diminished.  Traditional practice has 
suggested that in order for factor analysis results to be reliable, they must be generated 
from very large samples (i.e. at least several hundred up to 1000), or that sample size 
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should range from 2-10 times the number of variables (Kline, 2002; Costello & Osborne, 
2005; Mundfrom, Shaw, & Tian, 2005). Kline (1994) argued that the ratio of subjects to 
factors should be a consideration when determining sampling adequacy, with a goal of 
accruing more than 20 subjects for each factor. Ideally, a larger sample size is preferred, 
but an efficient solution can result from more modest sample sizes.  
The actual characteristics of the data have emerged as an important influence on 
sample size (MacCallum, Widaman, Zhang, & Hong, 1999; Costello & Osborne, 2005). 
The number of variables and their associated loadings constitute one important element 
when considering results of a factor analysis. Stevens (2002) suggested that a factor is 
reliable when one of the following conditions are met: 3 or more variables, with any n 
and loadings of 0.8; 4 or more variables, with any n, and loadings of 0.6; 10 or more 
variables with loadings of 0.4 and n larger than 150; factors with only a few loadings 
require a sample size greater than 300 (p.395).   
Other characteristics of the data, including high communalities (greater than 0.6), 
overdetermination, and simple, non-overlapping factor structures, are more relevant to 
the determination of an adequate sample size than just the number of variables 
(MacCallum et al., 1999).  Communality (h 2) reflects the percent of variance for a given 
variable that is accounted for by all identified factors, and is the sum of squared loadings 
across factors for that variable. When communalities are greater than 0.6, a sample size 
of less than 100 may be adequate.  When communalities are lower, a sample size of at 
least 100 is preferred.  Overdetermination, which occurs when each factor has several 
high loadings, also may mitigate the need for a larger sample size.  In research designed 
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to test the stability of factor solutions, samples meeting the characteristics of high 
communalities and a desirable level of overdetermination maintained factor structures 
with a sample size as low as 60 (MacCallum et al., 1999).  Mundfrom et al. (2005) 
extended this work with similar samples and found adequate factor solutions with sample 
sizes of 35-75.  With a fairly simple factor structure, such as the one derived in the 
current study, it has been noted that a sample size of 50-100 would be acceptable 
(Darlington, n.d.). 
Large sample sizes have generally been recommended as a strategy to overcome 
measurement error. In the clinical setting, however, it has been argued that patients 
symptom reports may so accurate that larger samples are not necessary (Olson, Hayduk, 
& Thomas, 2014).  
Statistical Analysis 
 Descriptive statistics, correlations, exploratory factor analysis, cluster analysis 
and multiple regressions were used in this study.  Data analysis was performed using 
IBM Statistical Package for the Social Sciences (SPSS Version 22).  Descriptive statistics 
were generated for the following variables: age, educational level, gender, marital status, 
primary cancer diagnosis, stage of disease, and tobacco use.  Descriptive statistics for 
symptom frequency, symptom distress, quality of life, EGFRI-related quality of life, 
MSAS-SF (adapted), performance status and psychological status are reported.  
A variety of statistical approaches have been employed to generate symptom 
clusters, such as correlations, structural equation modeling, factor analysis, principal 
component analysis and cluster analysis. Factor analysis based on Pearson correlation has 
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demonstrated stability in the identification of symptom clusters from different 
measurement tools (Miaskowski et al., 2007; Henoch, Ploner, & Tishelman, 2009), so 
exploratory factor analysis was selected as the primary method to identify symptom 
clusters in the present study.  A scree plot, eigenvalues, the Kaiser-Meyer-Olkin test and 
Bartlett’s test of sphericity were examined to determine the adequacy of the factor 
structure.   
Factor analysis explores a given set of variables to determine if they possess an 
underlying latent structure which can be used to explain correlations among the variables.  
Kline describes a factor as a “dimension or construct which is a condensed statement of 
the relationships between a set of variables” (Kline, p. 5).  Royce (1963), as quoted by 
Kline, stated that “a factor is a construct operationally defined by its factor loading” 
(Kline, p. 5). Factor loadings are described as the relationships or correlations of a 
variable with a factor (Kline, 1994).  Correlation coefficients for factor loadings can 
range from -1 to 1.0 (Johnson & Wichern, 2002).   
Hierarchical cluster analysis was also used to confirm the symptom clusters. 
Hierarchical cluster analysis procedures do not require a specific sample size as they are 
an exploratory approach “without an inferential test” (Kim, Barsevick, Beck, et al., 
2012). Hierarchical cluster analysis has been used in other studies on symptom clusters, 
so reexamining symptoms with this approach provides some additional support for the 
clusters identified via factor analysis with the relatively small sample available in this 
study (Hockenberry, Hooke, McCarthy, & Gregurich, 2011; Chen, Nguyen, Cramarossa, 
et al., 2012; Chen, Nguyen, Khan, et al., 2012).  
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Correlations and multivariate procedures were employed to explore the 
relationships between the symptoms, the derived symptom clusters and the dependent 
variables of performance status, psychological functioning and quality of life, as well as 
any differences by age, gender, treatment or disease.  
Instruments 
The instruments selected for data collection include are listed in Table 1 and are 
discussed below.  
 
Table 1. Model Components, Variables and Measures 
 
Model Component Variable  Measures 
Influencing Variables  
 
     Age 
     Gender 
     Primary Diagnosis  
     Specific EGFRI 
Demographic tool 
Symptoms    Symptoms 
  Symptom clusters  
 
MSAS-SF (ADAPTED)  
Performance    Functional performance        
  Psychological status         
  Quality of life                                                 
 Dermatologic QOL 
ECOG PS 
MHI-5 
FACT-G
FACT-EGFRI-18 
Note. EGFRI: epidermal growth factor receptor inhibitor; MSAS-SF (adapted): 
Memorial Symptom Assessment Scale- Short Form; ECOG PS: Eastern  
Cooperative Oncology Group; MHI-5: Mental Health Index-5; FACT-G: Functional  
Assessment of Cancer Therapy-General; FACT-EGFRI-18: Functional  
Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18  
Subscale: QOL: Quality of Life.  
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Memorial Symptom Assessment Scale (MSAS-SF) (adapted) 
The Memorial Symptom Assessment Scale-SF (MSAS-SF) was selected for this 
study because it offers the most comprehensive cancer symptom inventory available, 
measures symptoms along several dimensions, and has established psychometric 
properties (Kim et al., 2009b).  The original long form MSAS was developed to measure 
the frequency, severity and distress of 32 symptoms associated with a cancer diagnosis, 
and has established psychometric properties (Portenoy et al., 1994a; Portenoy et al., 
1994b; Portenoy et al., 1994c). The MSAS-SF is a modified version of the instrument 
which also measures 32 symptoms; distress and frequency are measured for 28 physical 
symptoms while frequency is measured for four psychological symptoms (Chang, 
Hwang, Feuerman, Kasimis, & Thaler, 2000).  The MSAS-SF was used in this study 
instead of the longer original version in order to reduce response burden. Both versions of 
the instrument contain blank spaces to allow for the addition of symptoms not included 
on the tools, so the MSAS-SF has been adapted for this study to include additional 
symptoms prevalent in this patient population. Items added to the scale included changes 
in my fingernails or toenails, other changes to my fingers and toes, dry skin, changes in 
hair growth on my face, changes to my eyelashes, and other changes to scalp hair.  
 Scoring.  The scoring of the MSAS-SF is different than the original MSAS 
scoring.  Physical symptoms are rated with regard to the degree of distress they cause. 
Participants select from the following descriptors for every physical symptom they 
endorse:  “no distress,” “a little bit of distress,” “somewhat distressing,” “quite a bit of 
distress,” and “very much distress.” These descriptors are then coded and scored as 
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follows. If a symptom is not present, it is scored as a 0.  If it is present, and causes no 
distress, it is scored as a 0.8., if it causes a little bit of distress, the score is 1.6, if it is 
somewhat distressing, the score is 2.4, if there is quite a bit of distress, it is scored at 3.2, 
and if a symptom is associated with very much distress, the score is 4.0   
Psychological symptoms are rated in terms of prevalence: “rarely,” 
“occasionally,” “frequently,” and “almost constantly.”  Participants select one of those 
descriptors for every psychologic symptom they endorse. When symptoms are present, 
the scoring is as follows:  1 if the symptom is present but occurs rarely; 2 if the symptom 
is present and occurs occasionally; 3 if the symptom is present and occurs frequently; and 
4 if the symptom is present and occurs almost constantly. The two scoring methods 
reflect the distress associated with the symptom for physical symptoms and the 
prevalence of the symptom for psychological symptoms.  Subscales for physical (PHYS) 
and psychological (PSYCH) symptoms, as well as a global distress index (GDI), can be 
generated from the MSAS but were not included in this study because additional items 
were included as symptoms. Future work could explore this aspect of the scoring.  
 Reliability and validity.  The original, condensed, and short forms of the MSAS 
have been used to measure symptoms in multiple studies in oncology (Chang et al., 2000; 
Kris & Dodd, 2004; Gwede, Small, Munster, Andrykowski, & Jacobsen, 2008 ; Kim et 
al., 2009b; Kim et al., 2009a; Molassiotis, Wengstrom, & Kearney, 2010; Webber & 
Davies, 2011; Cataldo et al., 2013; Oksholm et al., 2013; Kenne Sarenmalm, Browall, & 
Gaston-Johansson, 2014; Miaskowski et al., 2014; Ritchie et al., 2014). MSAS tools have 
also been used to measure symptom clusters in in other patient populations, despite the 
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original purpose as an oncology symptom inventory. Representative studies of non-
oncology patients  include nonalcoholic fatty liver disease (Houghton-Rahrig et al., 
2013),  heart and lung disease (Blinderman, Homel, Billings, Portenoy, & Tennstedt, 
2008; Song, Moser, Rayens, & Lennie, 2010; Strada, Homel, Tennstedt, Billings, & 
Portenoy, 2013), and HIV (Aouizerat et al., 2010). 
 MSAS-SF psychometrics.  In a sample of 299 cancer patients, the Cronbach 
alpha coefficient, assessing internal reliability, ranged from 0.76 to 0.87 in repeated 
administration of the MSAS-Short Form (Chang et al., 2000). Subscales of the FACT-G, 
the Karnofsky Performance Status, and extent of disease served to establish criterion 
validity and convergent validity for the MSAS-SF.  Repeatability was evaluated by a test-
retest measurement at one day (0.86 to 0.94) and one week (0.40 to 0.84).  
Correlation coefficients were reported to be in the appropriate direction for the 
subscales of the MSAS-SF and for the FACT-G: r = -0.74 (p < 0.001) for the PHYS and 
FACT-G physical well-being subscales; r = -0.68 (p < 0.001) for the PSYCH and FACT 
emotional well-being subscales, and r = -0.70 (p < 0.001) for the GDI and FACT total 
QOL subscales. MSAS scores reflecting a higher symptom burden would be larger, while 
FACT-G scores reflecting a good quality of life would also be higher, explaining the 
negative correlation.  
FACT-G 
In the present study, the FACT-G was used as a global measure of quality of life. 
The FACT-G (Functional Assessment of Cancer Therapy-General) Version 4 is 27-item 
questionnaire with well-established reliability and validity that measures quality of life 
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across four domains: physical well-being (PWB), social and family well-being (SWB), 
emotional well-being (EWB) and functional well-being (FWB) (Cella et al., 1993; 
Webster, Odom, Peterman, Lent, & Cella, 1999).  The FACT-G can be self-administered 
or scored by an interviewer and can be completed in 5-10 minutes (Danhauer et al., 
2007).  An item related to sexuality was not included in the present study as a similar 
question about problems related to sexuality was asked on the MSAS-SF. Two 
participants did not complete all items on the FACT-G Social Well-Being (SWB) 
subscale, and one did not complete all items on the Functional Well-Being (FWB) 
subscale, so these were scored in accordance with the procedure outlined for missing 
data.  
The FACT instruments have been widely used in the oncology population, and 
are applicable across various cancer diagnoses. The FACT-G correlated well with most 
subscales of the SF-36, and it discriminated between patients with cancer and community 
dwelling elders (p < 0. 002) (Overcash, Extermann, Parr, Perry, & Balducci, 2001).  
 Scoring.  All items are scored from 0-4, anchored at “not at all,” with a score of 
zero,  “a little bit,” “somewhat,” “quite a bit,” to  “very much.”  Some items are scored 
straightforwardly, but negatively worded items are reverse scored, and all items are then 
summed to obtain a subscale or total score. Higher scores indicate a better quality of life. 
A total score is calculated as the sum of all four subscales, given that 80% of items have 
been completed, resulting in a total score for all items that can range from 0-108 points.  
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FACT-EGFRI 18 
 In order to more fully characterize the quality of life of patients receiving 
EGFRIs, the Functional Assessment of Cancer Therapy-Epidermal Growth Factor 
Receptor Inhibitor (known as the FAST-EGFRI-18 or FACT-EGFRI 18) was also used in 
the present study. The EGFRI-18 is a self-report tool that was recently developed to 
describe the impact of 18 EGFRI-related skin, nail and hair toxicities on the four 
dimensions of quality of life incorporated in the Functional Assessment of Cancer 
Therapy (FACT) instruments.  This instrument provides additional condition-specific 
quality of life assessment and is a companion module to the core FACT-G items.  
As is customary with the construction of these additional modules, the developers 
used a triangulation method, including literature review, qualitative data collection via 
patient (n=20) and expert panels (n=12), and quantitative surveys, on candidate items in 
order to generate the items for the EGFRI-18 (Wagner & Lacouture, 2007; Wagner et al., 
2010; Wagner et al., 2013). The initial version of the EGFRI-18 incorporates 18 items 
assessing the effect of skin, nail and hair treatment-related symptoms on quality of life. 
Although there are other dermatology quality of life instruments (e.g. Skindex 
instruments) (Chren, Lasek, Quinn, & Covinsky, 1997), they were not specifically 
designed to address the dermatologic toxicities associated with EGFRI therapy.  The 
authors developed this tool in response to a lack of EGFRI standardized patient-reported 
outcome measures (Wagner et al., 2013), so for this reason it was selected for the present 
study.  
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As this is a newer tool, psychometric properties have not yet been published, and 
a large cooperative group study is currently underway to validate this questionnaire in 
patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib 
(S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With 
Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib 
Hydrochloride, 2013), but no data has been reported yet.    
Mental Health Inventory-5 (MHI-5) 
 
Psychological functioning was operationalized by the mental health subscale (also 
known as the MHI-5, and referred to as such in this study), which is a 5-item 
questionnaire designed to assess for mental health concerns. The Mental Health Inventory 
(MHI-5) has been validated as a simple tool for as a measure of general mental health and 
for detecting depressive symptoms and anxiety in both a healthy population and in those 
with a variety of chronic illnesses, including cancer (Ganz et al., 2003). 
Respondents answer questions about their psychological well-being selecting 
responses of “all of the time,” “most of the time,”  “some of the time,” “a little bit of the 
time,” and “none of the time.” The MHI-5 was recently evaluated in oncology patients 
and was found to be brief, simple to administer, and easy for patients with a sixth to ninth 
grade reading level to understand (Johns et al., 2013). The items were scored and 
transformed to a scale ranging from 0 to 100, with a higher score indicating a more 
optimal level of functioning.  Evaluation of the MHI-5 as a screen for psychological 
function revealed areas under the curve of 0.739 for anxiety disorders to 0.892 for major 
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depression (Berwick et al., 1991), and 0.73 for some anxiety disorders, such as 
generalized anxiety disorder (Cuijpers, Smits, Donker, ten Have, & de Graaf, 2009).  
Eastern Cooperative Oncology Group  
Performance Status (ECOG PS) 
 
In this study, functional status is measured by the ECOG Performance Status 
scale. Performance status scales such as the ECOG PS assess the impact of illness on the 
activities of daily living and overall functional well-being. The ECOG PS quantifies a 
continuum of self-care and activity, ranging from fully active and able to perform all 
normal activities, to unable to perform self-care and completely disabled.  In the clinical 
trials and treatment setting, functional or performance status is typically scored by the 
clinician.  However, self-rating using the one-item ECOG PS scale has been explored, 
and has been described as reasonable since  patients are more attuned to their physical 
condition than others may be (Ando et al., 2001). The descriptors used for each level of 
the ECOG PS are self-explanatory and easily completed by patients. For example, 
patients in the process of being diagnosed with lung cancer produced reliable ratings of 
performance status, so the researchers concluded that patients could viably assess their 
own performance status (Blagden, Charman, Sharples, Magee, & Gilligan, 2003).  
In a study exploring whether performance status could be described by patients 
using the Performance Status Visual Analog Scale (PS-VAS), which is a different 
instrument, Gralla confirmed that patients were able to rate their own performance status, 
and demonstrated adequate correlation between the scale and both the ECOG (r =.43) and 
Karnofsky (r =.46) Performance Scales, suggesting that reasonably equivalent 
information could be gained from any of these instruments (Gralla et al., 2005). 
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The value of patient-reported performance or functional status is highlighted by 
studies revealing variations in these scores between patient ratings and health care 
provider ratings. One study examined ratings between patients and a variety of clinicians, 
reporting that the correlations between patient- and provider-reported ECOG PS scores 
varied from 0.51 (patients and registered nurses) to 0.64 (patients and radiation therapy 
students as well as physicians), providing evidence of only moderate agreement (de 
Borja, Chow, Bovett, Davis, & Gillies, 2004); another also found a lack of congruence in 
over half of patient and physician ratings at diagnosis, with patients rating their functional 
status as lower than physicians (Dajczman et al., 2008). 
Ethical Considerations 
Protection of Human Subjects 
The Loyola University Medical Center Institutional Review Board (IRB) 
classified this study as exempt as no identifiable information was collected.  Anonymity 
for all study participants was protected.  Any study related data, including data input for 
analysis, has been maintained in password-protected files managed by the investigator.  
Potential risks to participants were minimal, but could include heightened stress due a 
greater awareness of potential symptoms attributable to their therapies.   
The web-based survey was housed by the software vendor on the secure Qualtrics 
web site and all data was time-stamped and encrypted in transmission. Network security 
on Qualtrics includes a Transport Layer Security (TLS) encryption connection, firewall 
protection, intrusion detection and prevention, and security scans. The vendor is 
prevented through confidentiality agreements from accessing or disclosing information in 
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the database. Servers are located in a data center with security and environmental controls 
and are backed up nightly.  All data at rest are encrypted and all deprecated hard drives 
where data is stored are destroyed by the United States Department of Defense methods 
and delivered to a third-party destruction service (Qualtrics, 2014).  A unique identifier 
for each response masked each survey response, and no identifying information, 
including IP address, was recorded. Survey responses are viewable to the researcher only 
via a username and password. 
Participants could complete the survey using the device of their choice as the 
survey was optimized for mobile formats, and could be viewed on tablets, smartphones or 
personal computers. In addition, completion of the instruments took approximately 20 
minutes (most completed the online version in approximately 8-15 minutes, although 
longer time frames were recorded), and  may have taken more time if there were 
connectivity or other technical issues. Participants were allowed to start the web-based 
survey and return later to complete it if necessary.  
For participants completing the web-based survey, eligibility requirement were 
presented and then a consent form appeared prior to the study instruments. Participants 
reviewed it and checked a statement indicating that they agreed to participate in the study 
(“I agree to participate in this study”).  Volunteers who agreed to the consent and 
affirmed that they met the inclusion criteria advanced to the study questionnaire. 
Participants who did not meet the study criteria or who did not agree to participate in the 
study received a message thanking them for their time, but indicating that they were not 
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eligible to participate. The survey software recorded the consent as part of the 
questionnaire.  
Participants completing paper surveys checked off the same eligibility and 
informed consent prior to study enrollment. In addition, their completion of the survey 
return by mail was evidence of their consent. All participants who completed the paper 
survey were provided stamped, pre-addressed envelopes for return of the survey to the 
investigator. The investigator’s return address was pre-printed on the return envelopes, 
and in no case did any participant include their own address or any other identifying 
information in the returned surveys.  Data from the paper surveys was entered into the 
Qualtrics’ site and paper copies were destroyed by the investigator. 
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CHAPTER FOUR 
 
RESULTS 
 
The present study was designed to explore the symptom experience of patients 
receiving EGFRIs, including the identification of symptom clusters, and the impact of 
any identified symptom clusters on patient outcomes.  The theory of unpleasant 
symptoms (TOUS) provided a useful framework from which to explore the symptom 
experience in study participants.  The TOUS model allowed for the measurement of 
distress and frequency of symptoms, and also for evaluation of the impact of symptoms 
on patient-reported outcomes, including performance, quality of life, and psychological 
status.  Findings from the current study can inform future work in this area and can be 
replicated in larger and more purposeful samples.  
Data Analysis 
 Statistical procedures included descriptive methods (frequencies, percentages, and 
measures of central tendency), Pearson correlations, one-way ANOVA, nonparametric 
Mann-Whitney U, independent t-tests, exploratory factor analysis, hierarchical cluster 
analysis procedures and regressions.  The demographic characteristics of participants are 
presented as percentages for age range, gender, educational level, living arrangements 
and relationship status.  Clinical characteristics, including primary cancer diagnosis, stage 
of disease, duration of EGFRI therapy and tobacco use are also reported.   ECOG 
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Performance Status scores are reported by percentage and frequency. For all scales and 
the selected subscales, measures of central tendency were used for analysis. Data 
collected using the FACT-G, EGFRI-18, MHI-5, and ECOG Performance Scale were 
assessed for normality by examining skewness and kurtosis values, visual inspection of 
the Kolmogorov-Smirnov (Ghasemi & Zahediasl, 2012) or Shapiro-Wilk tests of 
normality, and deviations from normality are reported.  The internal consistency 
reliability of each instrument and relevant subscales for the FACT-G were confirmed 
using Cronbach’s alpha.  
Exploratory factor analysis, using principal axis factoring with an oblique rotation 
was used to identify co-occurring symptoms, or symptom clusters.  Multiple factor 
analyses were run, using various methods and rotations, in order to find the best 
solutions. The Kaiser-Meyer-Olkin measure of sampling adequacy, communalities, 
Bartlett’s test of sphericity, diagonals on the anti-image correlation matrix, and inter-item 
correlation coefficients were examined to determine the appropriateness of the data for 
factor analysis. 
Because of the small sample size, an alternative approach to deriving symptom 
clusters was also implemented.  Hierarchical cluster analysis was used as a comparison to 
factor analysis, as HCA can be used with small samples.  This additional procedure 
allowed for comparison of symptom clusters identified using different statistical 
approaches.  
Independent t-tests, one-way ANOVAs, and non-parametric tests were used to 
assess the differences on outcome variables between the identified symptom clusters. 
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Variables with statistically significant Pearson correlations with the outcome variables of 
quality of life, functional performance and psychological status were included in a forced 
entry linear regression model to explore their effect on outcomes. Analyses were 
performed using IBM Statistical Package for the Social Sciences (SPSS Version 22).    
Sample Characteristics 
A total of 56 participants were eligible for inclusion in the study during the 
recruitment period and are included in this analysis.  Participants were able to complete 
the study online or on paper; 44 participants completed online surveys and 12 completed 
surveys on paper.  
For the online version, a total of 86 participants entered the study site over a ten 
month period from June, 2013 to May, 2014, after being directed to the survey site by the 
investigator or after directly responding to survey recruitment materials that were posted 
on online support groups, on the survey web site, at support group settings or at health 
care sites.   Of this group, 69 participants completed one or more items.  However, 19 
failed to respond affirmatively to the study eligibility criteria, and were redirected out of 
the study site.  In total, 50 participants completed the consent and gained access to the 
questionnaire. Six of this group started the survey, but stopped after answering a few 
questions, so responses for those participants were largely incomplete and are not 
included in the analysis, resulting in a completion rate for the online version of 88% 
(44/50 who accessed the questionnaire and were eligible to complete it). 
Most participants who completed paper copies had received information about the 
study from a nurse (n =11) who had received a study recruitment letter directed to health 
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care professionals. One received the paper survey from the investigator after responding 
to postings about the survey. Paper copies of the surveys were supplied to participants, 
and all of the distributed paper surveys were returned by pre-addressed stamped 
envelope, with a completion rate of 100%.  The completed surveys were anonymous, and 
no identifying information was collected. All paper surveys were completed by 
December, 2013.  
These procedures resulted in a total of 56 participants who completed most survey 
instruments and are included in the data analysis, with a total of 55 who completed all 
instruments. One participant did not complete the EGFRI-18, so data is presented for the 
participants who did complete these instruments. Overall, a total of 55 participants 
completed all measures as procedures for missing data could be applied for the FACT-G.  
As the participants were anonymous, there was no follow-up procedure for missing data.  
Demographic Characteristics 
Demographic characteristics of the sample are presented in Table 2.  Nearly two-
thirds of the participants included in this sample are female.  About 10% reported that 
they were younger than 50 years of age, with about one-third of patients between 50-59, 
and another third between 60-69 years of age. This sample, as might be anticipated in a 
study conducted primarily online, appears to be well-educated, with 82% reporting that 
they have received a college or graduate degree.  The majority of participants (75%) are 
married, and a corresponding number of participants live with a spouse (60%) or a spouse 
and children (16%).  Relationship status and living arrangements for participants in this 
sample suggest a significant amount of social and psychological support.   
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Table 2. Participant Characteristics (N=56) 
 
Characteristic  Age        Percentage  
Characteristic                                                 N            Percentage 
 
Gender 
   
 Male  20 35.7 
 Female 36 64.3 
 
Age    
 30-39 1 1.8 
 40-49 5 8.9 
 50-59 18 32.1 
 60-69 17 30.4 
 70-79 2 21.4 
 >80 3 5.4 
Educational Level    
 Elementary 0 0 
 High School  10 7.9 
 College 29 51.8 
 Graduate School  17 30.4 
Relationship Status    
 Married  42 75.0 
 Single  1 1.8 
 Divorced 10 17.9 
 Widowed 3 0.4 
Living Arrangements    
 Live with spouse 33 58.9 
 Live with spouse and children 9 16.1 
 Live with children 3 5.4 
 Live alone  10 17.9 
 Live with others not listed  1 1.8 
 
.  
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Clinical Characteristics 
Clinical characteristics are reported in Table 3. Only two participants (3.6%) 
reported receiving radiation therapy concurrent with the study, but 18 of 59 (30%) 
indicated that they were receiving other treatments, including various chemotherapy 
agents and other drugs, including trastuzumab, carboplatin, 5-fluorouracil, 5-fluorouracil 
and carboplatin, cabozantinib, paclitaxel protein-bound and carboplatin, paclitaxel and 
carboplatin, capecitabine, zoledronic acid, irinotecan, denosumab, letrozole, exemestane, 
and experimental drug  MK-2206.  A total of nine participants were receiving cytotoxic 
chemotherapy, including concurrent carboplatin as a single agent reported by five 
participants, trastuzumab reported by four participants, and 5-FU reported by three 
participants. The remaining agents listed above were reported by one or two participants, 
and several participants were taking multiple agents.    
Co-morbidities were reported as follows:  eight participants reported a diagnosis 
of diabetes; and two reported osteoporosis.  A respiratory disorder, a gastrointestinal 
disorder, Graves’ disease, Hashimoto’s disease, an unspecified thyroid condition, 
hypertension, hemolytic anemia, and rheumatoid arthritis were each reported by one 
participant.   
More than half of the participants (57%) reported applying a cream that their 
health care professional recommended.  Sixteen reported using an oral medication, with 
seven reporting doxycycline and five reporting minocycline; others reported using an 
unspecified antibiotic, nystatin or Zyrtec.  
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Tobacco use (smoking) was reported by 7% (n=4) of participants; 0 reported 
using other tobacco products.  The majority of participants (88%) (N=52) reported that 
they did not currently use tobacco products, and 5% (n=3) indicated that they quit using 
tobacco products on diagnosis. 
 
 
Table 3. Clinical Characteristics 
 
Characteristic  N            Percentage 
Diagnosis    
 Breast cancer 10 17.9 
 Colorectal cancer 
Head and neck cancer 
Lung cancer 
Pancreatic cancer 
Unknown 
7 
10 
29 
0 
0 
12.5 
17.9 
51.8 
0 
0 
 
Stage of disease    
 Stage I 1 1.8 
 Stage II 3 5.4 
 Stage III 2 3.6 
 Stage IV 50 89.3 
Educational Level    
 afatinib 2 3.6 
 erlotinib 24 42.9 
 lapatinib 10 17.9 
 cetuximab 16 28.6 
 
 
Therapy duration 
panitumumab 4 7.1 
 At least four weeks 
More than four weeks 
More than eight weeks 
5 
9 
42 
 
8.9 
16.1 
75 
Tobacco use    
 I currently use  tobacco products 
I quit using tobacco at diagnosis 
0 
3 
0 
5 
 I do not currently use tobacco 52 88 
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Study Aim 1 
The first aim of this study was to describe the symptom experience (symptom 
frequency and distress) of patients receiving EGFRI therapy. 
 The following discussion will present information from the MSAS-SF in order to 
characterize the symptom experience of the participants.  Additional information on 
identified symptom clusters will be presented in the discussion of Aim 3.  
Memorial Symptom Assessment  
Scale-Short Form (Adapted) 
 
A total of 38 symptoms were included in the MSAS-SF (adapted), including 
several not on the original instrument that are frequently experienced by patients taking 
EGFRIs. As listed in Table 4, items added for this study included changes in my 
fingernails or toenails, other changes to my fingers and toes, dry skin, changes in hair 
growth on my face, changes to my eyelashes, and other changes to scalp hair. As 
expected, several of the symptoms added to the scale were retained through factor 
analysis, lending support to their inclusion in the adapted tool.  
 Symptom occurrence.  Participants reported a mean of 11.71 symptoms (SD, 
5.7; range, 1-28) over the previous week, which is consistent with other studies using the 
MSAS (Portenoy et al., 1994a; Chang et al., 2000; Deshields et al., 2011; Ritchie et al., 
2014).   Items marked in italics were added to the MSAS-SF for this study. The most 
common symptoms included dry skin, lack of energy, dry mouth, changes in skin, feeling 
sad, changes to finger or toenails, feeling worried, diarrhea, problems with sexual interest 
or activity, changes in facial hair growth, and difficulty sleeping.  The most frequently 
occurring symptoms in a large heterogeneous sample of oncology patients reported 
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similar findings using the MSAS, with lack of energy, difficulty sleeping, problems with 
sexual interest or activity, pain, and feeling drowsy the most frequently endorsed 
symptoms in the overall sample (Deshields et al., 2011).  
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Table 4. Symptom Occurrence (N=56) 
 
 Percentage N 
Dry skin 67.9 38 
Lack of energy   65.5 36 
Dry mouth   57.1 32 
Changes in skin 55.4 31 
Feeling sad 53.6 30 
Changes to my finger or toe nails 53.6 30 
Worrying 50 28 
Diarrhea  48.2 27 
Feeling drowsy 46.4 26 
Problems with sexual interest or 
activity   44.6 
25 
Changes in hair growth on my face 44.6 25 
Difficulty sleeping 44.6 25 
Feeling nervous 42.9 24 
Numbness/tingling in hands/feet 42.9 24 
Feeling irritable 41.1 24 
Changes in the way food tastes 39.3 22 
Other changes to the hair on my scalp 39.3 22 
Changes in my eyelashes 37.5 21 
Hair loss 37.5 21 
Difficulty concentrating 35.7 20 
Itching 33.9 20 
Cough  32.1 19 
Weight loss 32.1 18 
Pain  30.6 18 
Lack of appetite  30.4 17 
Nausea 28.6 16 
Shortness of breath 26.8 15 
Other changes to my fingers or toes 25 14 
Mouth sores 25 14 
Constipation 21.4 12 
"I don't look like myself" 21.4 12 
Difficulty swallowing   19.6 11 
Dizziness   16.1 9 
Sweats   16.1 9 
Feeling bloated 10.7 6 
Vomiting 8.9 5 
Problems with urination  8.9 5 
Swelling of arms and legs 8.9 5 
   
Note. Items in italics were added to MSAS-SF for this study.  
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 Symptom distress and prevalence.  Using the MSAS-SF (adapted), physical 
symptoms were measured by the amount of distress caused, whereas psychological 
symptoms were measured by their prevalence. The overall distress and prevalence 
rankings are reported in Appendix A. When evaluated by the distress associated with 
physical symptoms, or prevalence of psychological symptoms, the symptoms of dry skin, 
lack of energy, worry, changes to finger and toe nails, problems with sexual interest and 
activity, changes in skin, dry mouth, feeling sad, and diarrhea, were ranked as most 
distressing or prevalent.  While lack of energy and worry have long been considered very 
common and distressing symptoms in oncology, the emergence of dermatologic 
symptoms as major contributors to distress is remarkable when compared to previous 
work on cancer symptoms and symptom clusters. 
 Physical symptoms.  The most distressing physical symptoms are highlighted in 
Table 5, and include five symptoms that can be described as dermatologic or 
mucocutaneous, three of which were added to the adapted version of the MSAS-SF for 
this study. Dry skin is the physical symptom causing the most distress in this study, 
followed by lack of energy. It is notable that nausea, vomiting, and lack of appetite, 
which long have been associated with cancer treatment, are less likely to be distressing in 
the setting of EGFRI therapy. 
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Table 5. Most Distressing Physical Symptoms (N=56) 
 
 Mean S. D. 
Dry skin  1.757 1.4902 
Lack of energy  1.657 1.3802 
Changes to my finger or toe nails  1.429 1.4925 
Problems with sexual interest or activity  1.429 1.6552 
Changes in skin  1.414 1.3814 
Dry mouth  1.386 1.4269 
Diarrhea  1.286 1.5077 
Changes in hair growth on my face  1.100 1.3522 
Difficulty sleeping  1.029 1.2646 
Numbness/tingling in hands/feet  1.000 1.3495 
  
  
Note: Items in italics were added to the MSAS-SF for this study.  
 
 
 
Psychological symptoms.  The prevalence of psychological symptoms 
is included in Table 6. Psychological symptoms are rated by prevalence, so 
that each of these symptoms occurred at least occasionally in the study 
sample.  Worry was the item with the highest prevalence rating.    
 
 
Table 6. Prevalence of Psychological Symptoms (N=56) 
 
  Mean                                      S. D. 
Worrying  1.60 1.2746 
Feeling sad  1.35 1.1666 
Feeling nervous  1.23 1.1907 
Feeling irritable  1.19 1.1349 
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Relationship of symptom distress and prevalence to key demographic 
variables.  The independent variables of gender, diagnosis, specific EGFRI therapy and 
age were examined to identify any significant differences in symptom distress and 
prevalence.  
 Gender.  Overall, men reported more symptoms (M = 13.95, SD = 5.24) than 
women (M =10.75, SD = 5.74), with significant differences in occurrence between 
genders for the symptoms lack of energy, dry mouth, problems with sexual interest or 
activity and dry skin. The most frequently reported symptoms were analyzed in terms 
distress (for physical symptoms) and prevalence (for psychologic symptoms).  Significant 
findings are reported in in Table 7.  
 
 
 
Table 7. Significant t-Tests of Symptoms by Gender with Descriptive Statistics 
 
Symptom Group 95% CI for 
Mean 
Difference 
  
 Male  Female   
 M SD n  M SD n t df 
Dry skin  2.24 1.18 20  1.49 1.6 36 -1.5, -.003 
-2.0** 49 
Dry mouth 2.32 1.39 20  .867 1.17 36 -2.15, -.75 -4.16*    54 
Worrying .95 1.05 20  1.97 1.25 36   .36, 1.69 3.01**    54 
 
          
 Note: Only significant results are shown. * p < .05, ** p < .01 
 
 
 
 Diagnosis.  Symptoms by prevalence and distress were examined for any 
significant variations by primary cancer diagnosis as illustrated in Table 8. Of the most 
frequently occurring symptoms, distress scores differed significantly across the diagnoses 
for three symptoms: worrying, diarrhea, and dry mouth.  Worry caused the most distress 
in lung cancer patients.  Breast cancer patients reported a higher incidence of diarrhea, 
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which is not an unexpected finding, as diarrhea is a known side effect of lapatinib and 
grade 1 or 2 diarrhea occurs in about 40% of patients (Moy & Goss, 2007). Similarly, 
there was considerable variation across the diagnoses for dry mouth, with head and neck 
cancer patients reporting a higher incidence of distress associated with this symptom. 
Head and neck cancer patients may have received radiation therapy, and xerostomia is a 
well-known effect of this treatment.  
 
 
Table 8. Symptom Distress or Prevalence by Diagnosis 
________________________________________________________________________  
               Symptom  
         Worrying         Diarrhea       Dry Mouth  
________________________________________________________________________  
Diagnosis               N               Mean       SD           Mean       SD          Mean       SD 
Breast cancer 9 1.667 1.0000    2.844 1.3333    .533 1.1314 
Colorectal cancer 7 .571 1.1339   1.143 1.1178 2.057 1.1178 
Head and neck  10 1.400 1.4298     .640 1.3492 2.640 1.5572 
Lung cancer 29 1.828 1.1973   1.103 1.4409 .966 1.1188 
 
 
 
 
A one-way between groups ANOVA was conducted to compare the effect of 
diagnosis on symptom distress (physical symptoms) and prevalence  
(psychological symptom) are highlighted in Table 9. 
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Table 9. One-Way Analysis of Variance Symptoms by Diagnosis  
 
 
Sum of 
Squares df 
Mean 
Square F Sig. 
Dry mouth Between Groups 58.409 4 14.602 6.388 .000** 
Within Groups 116.573 51 2.286   
Total 174.982 55    
Diarrhea Between Groups 44.993 4 11.248 3.815 .009** 
Within Groups 150.364 51 2.948   
Total 195.357 55    
Worrying   Between Groups 15.105 4 3.776 2.594 .047* 
Within Groups 74.252 51 1.456   
Total 89.357 55    
Note: **p < 0.01, * p <.05 
 
 
 
Specific EGFRI.  An independent t-test demonstrated a significant difference in 
symptom distress (physical symptoms) and prevalence (psychologic symptom) for 
several symptoms between participants taking small molecule tyrosine kinase inhibitors 
(TKIs) (lapatinib, afatinib, erlotinib) and those receiving monoclonal antibodies 
(MOABS) (panitumumab and cetuximab).  Drugs were grouped together by a mechanism 
of action (TKIs: afatinib, erlotinib, lapatinib; MOABS: cetuximab and panitumumab) due 
to the small number of participants taking one option of each class of drug (afatinib, n = 
2; panitumumab, n = 4).   Of the symptoms most frequently reported, participants 
receiving MOABs experienced greater distress or prevalence with all of the symptoms, 
with the exception of worrying, which was more often prevalent in the TKI group.   
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Table 10. Descriptive Statistics and Independent t-Test Comparing  
Symptoms Distress and Prevalence by Type of EGFRI 
 
Symptom Type of EGFRI   
 MOAB   TKI 
 
 
 
 M SD n M SD n 
 
t df 
Lack of energy 
2.44 1.11 20 1.22 1.33 36  
-
3.6** 
45 
Dry mouth 
2.4 1.29 20 .822 1.17 36  
-
4.6** 
54 
Feeling drowsy 
1.48 1.28 20 .6 1.00 36  
-
2.8** 
54 
Numbness/tingling 
in hands/feet 
1.72 1.51 20 .6 1.07 36  
-
3.2** 
54 
Changes in skin 2.00 1.43 20 1.09 1.26      36  -2.5* 54 
Worrying 1.15 1.27 20 1.86 1.22 36  2.06* 54 
 
 
Note: **p < 0.01, * p <.05 
 
 
In order to better understand the contribution of each specific agent to the distress 
associated with each symptom, distress and prevalence scores are reported in Table 11 for 
the three most frequently reported symptoms: dry skin, lack of energy and dry mouth. 
For the symptom changes in skin, the distress scores are as follows: panitumumab 
(M = 3.5, SD = .577), cetuximab (M = 2.25, SD = 1.9), erlotinib (M = 1.71, SD = 1.71) 
and lapatinib (M = .80, SD = 1.033). Dry mouth, as noted in Table 10, caused greater 
distress in the MOAB group, with group means of cetuximab (M = 3.06, SD = 1.61), 
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panitumumab (M = 2.75, SD = 1.61), while less symptom distress was reported with 
lapatinib (M = 1.1, SD = 1.9) and erlotinib (M = 1.08, SD = 1.3).   
Lack of energy also was reported with higher frequency in participants receiving 
MOAB therapy, with group means as follows: panitumumab (M = 4.25, SD = .95), 
cetuximab (M = 2.75, SD 1.3426), lapatinib (M= 2.3, SD =1.7), afatinib (M= 1.5, SD = 
2.12), and erlotinib (M= 1.21, SD =1.58). In addition, diarrhea appears to be associated 
with lapatinib therapy (M = 3.2, SD = 1.93), F(1,3) =2.978, p = .028, with other group 
means reported as follows: panitumumab (M = 2.0, SD = 1.41), afatinib (M = 1.5, SD = 
2.12),  erlotinib (M = 1.42, SD = 1.86,  and cetuximab (M = 0.81, SD = 1.5). 
 
 
Table 11. Symptom Distress by Specific Agent 
____________________________________________________________________ 
               Symptom  
         Dry Skin       Dry Mouth      Lack of Energy  
____________________________________________________________________ 
Specific Agent            N               Mean       SD           Mean       SD        Mean       SD 
____________________________________________________________________ 
 
Cetuximab  2.25 1.9 3.06 1.61 4.25 .95 
Panitumumab  3.5   .577 2.75 1.61 2.75 1.35 
Afatinib  1.67 1.0   1.5 2.12 
Erlotinib  1.71 1.71 1.08 1.3 1.21 1.58 
Lapatinib  .80 1.03 1.1 1.9 2.3 1.7 
        
 
 
 
 Age.  An analysis of variance demonstrated no significant difference in distress 
(physical) or prevalence (psychologic) with regard to the most frequently reported 
symptoms by age of participant.  
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Independent t-tests found no differences in the most frequently reported 
symptoms on distress or prevalence in those who completed the study online vs. on 
paper, but when all symptoms were compared, those who completed a paper survey 
reported greater distress associated with feeling drowsy. Analysis of variance found no 
significant differences by educational level for symptom distress or prevalence.  
Comparisons between participants receiving therapies in addition to EGFRIs 
yielded several significant findings with regard to severity of reported symptoms, with 
the those patients reporting a greater lack of energy (M =2.73, SD = 1.609), t(54) =2.384 , 
p = .021, diarrhea (M =2.32, SD = 2.102 ), t(36.4) = 2.230 , p = .032 and problems with 
sexual interest or activity (M =2.55, SD =1.993 ), t(54) = 2.295, p = .026 than those 
participants receiving EGFRIs alone.  This finding is consistent with what would be 
expected in patients receiving multiple treatment modalities.  
 Other symptoms.  Participants reported on any other symptoms they experienced 
that were not included in the items presented to them.  Responses included the following: 
severe dry eye described as “very distressing;” dry eye that caused blurred vision, 
requiring the use of artificial tear drops and ophthalmic ointment at night; swollen eyelids 
oozing  a “quasi liquid that hardens into a dry crust and is painful to remove;” excessive 
nasal mucous that hardens into a dry crust;” almost constant fatigue; problems with my 
fingernails “get so bad that I cannot use a knife and a fork;” swelling of lips; occasional 
long bone pain at night; uncertainty, “I don't know what I am supposed to be doing with 
my life;” sun avoidance that has “resulted in my giving up golf, biking and vacations at 
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beach.  I run from the sun and must wear a hat at ALL times.  I find this very confining;” 
changes to eyebrows; and foot pain.  
Symptom clusters.  Several procedures were used to generate factors (symptom 
clusters) of symptoms based on reported frequencies. These procedures included: 
exploratory factor analysis based on review of data characteristics with multiple 
iterations; exploratory factor analysis based solely on original communalities; and 
hierarchical cluster analysis as an alternative procedure to identify symptom clusters.  
Factor analytic procedures resulted in the identification of three symptom clusters: 
Factor 1, a psychological-cognitive cluster; Factor 2, a dermatologic skin and hair cluster;   
and, Factor 3, a mucocutaneous and fatigue cluster.  Factor 1 is very similar to clusters 
previously described, Factor 2 has not been previously described, and Factor 3 is similar 
to clusters previously described, but includes a treatment-related symptom.  More 
information on these clusters will be presented in the section on Study Aim 3.  
Study Aim 2 
Describe the quality of life, functional performance and psychological status of 
patients receiving EGFRI therapy.   
Quality of Life 
Quality of life was measured in the present study by a general quality of life 
instrument, the FACT-G, and a treatment-specific scale, the EGFRI-18.  The FACT-G 
family of instruments includes the basic core questionnaire and additional add-on panels 
specific to disease or treatment. When separate disease or treatment related panels are 
used, such as the EGFRI-18, the scores can be summed to yield a Total Quality of Live 
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(Total QOL) score.  However, both FACT-G QOL and Total QOL scores are reported in 
the present study.   Because the FACT-EGFRI-18 must still be refined, its sensitivity to 
variations in treatment-related dermatologic quality of life is not established.  
Results for these two instruments are presented here.  
 FACT-G.  The FACT-G measures quality of life across several domains, 
including Physical Well-Being (PWB, score range 0-28) with 7 items; Social/Family 
Well-Being (SWB, score range in original instrument 0-28) with 6 items in this version 
(score range 0-24), as a question about sexuality as not included for scoring, so this item 
was prorated; Emotional Well-Being (EWB) with 6 items (score range,  0-24);  and,  
Functional Well-Being (FWB) with 7 items (score range 0-28).   The FACT-G items 
includes a Likert scale with five responses from 0-4, (0 = Not at all; 1 = A little bit;  
2 = Somewhat; 3 = Quite a bit; and 4 = Very much).  A total FACT-G score is derived by 
adding all of the subscales.  Negatively worded items are reverse scaled, resulting in a 
higher score signifying a better quality of life for both the subscales and total scale.  The 
overall FACT-G displayed a high level of internal consistency, as demonstrated by a 
Cronbach's alpha of 0.930.   
 Reliability statistics for the subscales are as follows: PWB subscale consisting of 
7 items (α = .819); SWB subscale consisting of 6 items (α = .904); EWB consisting of 6 
items (α = .847); and FWB consisting of 7 items (α = .883). As noted earlier, the current 
study, the item on sexuality was deleted as there was another variable that assessed 
problems with sexuality of sexual function as part of the MSAS-SF (adapted).    
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 When more than 50% of the subscale items are answered, the subscale can be 
prorated by the following procedure: the sum of the subscale is multiplied by the number 
of items in the subscale, and then divided by the number of items that have been 
answered. The resulting subscale can be added to the other sub-scale scores to yield a 
total quality of life score. At least 22 of 27 FACT-G items must be completed, as well as 
at least 50% of the items of each subscale, in order for this procedure to be valid. All of 
the subscales are required to have a total subscale score (consistent with the above 
procedures) in order to calculate a total quality of life scale  (Fairclough & Cella, 1996).  
 Results for the FACT-G are presented in Table 12, with the mean score 
suggesting minimal effect on quality of life in this sample.  
 
Table 12. FACT-G Quality of Life Descriptive Statistics (N=56) 
                                                           Sample                                         General Norms 
Subscale                                Range Min Max Mean SD       Mean    SD 
Social Well-Being  (SWB) 28 .00 28 21.68 6.59    19.1     6.8  
Emotional Well-Being (EWB) 20 4 24 15.91 4.95     19.9     4.8 
Physical Well-Being (PWB) 17 11 28 20.71 4.86      22.7    5.4 
Functional Well-Being (FWB) 25 3 28 17.66 6.67       18.5    6.8 
Total Quality of Life 77 29 106 75.96 18.59      80.1  18.8 
Note: General population norms are shown in italics, and are from Brucker, P. S., Yost, 
K., Cashy, J., Webster, K., & Cella, D. (2005). General population and cancer patient 
norms for the Functional Assessment of Cancer Therapy-General (FACT-G) Evaluation 
& the Health Professions. 2005(28), 192–211.  
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For purposes of comparison, mean scores on the total FACT-G for the general 
population have been reported as  80.1 and 78.4 (Brucker, Yost, Cashy, Webster, & 
Cella, 2005) and 80.2 and 80 (Espie et al., 2008), 77.95 (15.16)  (Yanez, Pearman, Lis, 
Beaumont, & Cella, 2013), and  78.4 (22.6) in patients with cancer (Danhauer et al., 
2007). Yanez et al. reported subscale scores as follows: PWB (M = 20.17, SD = 15.16); 
SWB (M = 22.67, SD = 4.76); EWB (M = 17.52, SD = 4.48: FWB (M = 17.6, SD = 5.86). 
In this sample, it is interesting to note that SWB compares favorably with the general 
population means, suggesting that the participants, consistent with their relationship 
status and living arrangements, benefit from close relationships.  
FACT-EGFRI-18.  The FACT-EGFR-18 is a companion dermatologic quality of 
life instrument that addresses EGFRI treatment-related concerns. Statistics for the FACT-
EGFRI-18 for this sample are presented in Table 12, including percentages of total score 
(where 100 percent would reflect the highest quality of life rating), in order to make the 
results easier to interpret. Complete results for each item in the FACT-EGFRI-18 are 
included in Table 13. Internal consistency using Cronbach’s alpha for the overall FACT-
EGFRI-18 was .886, with following reliability statistics for each of the subscales: 
physical (7 items, α = .757); social-emotional (6 items, α = .772); and functional (5 items, 
α = .750). When the both the FACT-G and the EGFRI-18 scales are combined as they are 
in the current study to yield a total quality of life score, Cronbach’s alpha for all 44 items 
is 0.915.   
Despite similar subscales, there is discordance in the results of the two 
instruments.  When used as part of a total quality of life score along with the FACT-G, 
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adding the EGFRI-18 effectively raised the quality of life score. As a result, the current 
original version of the EGFRI-18 should be explored further with regard to sensitivity to 
dermatologic quality of life in patients receiving EGFRI therapy. Participants had lower 
scores on emotional and functional well-being scores on the FACT-G than on the EGFRI, 
which may suggest declines in emotional and functional well-being globally, rather than 
specifically related to EGFRI therapy. Since the EGFRI-18 is a new instrument, there is 
no psychometric information available for comparison, but these discrepancies between 
the tools are areas for further inquiry.  
 
 
Table 13. EGFRI-18 Dermatologic Quality of Life (N=56) 
Sub-scale                               Mean (SD)     Range     Percentage 
Physical  17.9  (5.6)        4-28     89 
Social-Emotional              19.4  (4.6)                    6-24                81 
Functional             17.6  (3.2)                    5-20                87 
Total  54.9   (12)      14-72    76 
Note: No norms available.   
 
 
 Test of normality.  Tests of normality for the total QOL score (FACT-G added to 
FACT-EGFRI-18) score were non-significant.  A visual inspection of the histogram, Q-Q 
plots also showed that the scores were approximately normally distributed for the FACT-
G and the combined FACT-G and FACT-EGFRI-18 scales (Total QOL). However, the 
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Kolmogorov-Smirnov test was significant for the FACT-EGFRI-18 scale alone. In 
addition, the FACT-EGFRI-18 demonstrated a negative skew, with skewness of -.994 
(SE =.322) and kurtosis of 1.161 (SE = .634), indicating a long tail to the left (few lower 
scores) and many higher values, again calling into question the sensitivity of the 
instrument to impact of treatment on quality of life. However, since the outcome variable 
of quality of life is based on the mean sum scores of the FACT-G and FACT-EGFRI-18, 
described above as Total QOL, this variable will also be treated as a normal distribution. 
Psychological Status 
MHI-5.  The MHI-5 is brief questionnaire that is used to assess mental health, 
including anxiety and depression, and was used to measure psychological status in the 
current study. There are several versions and available scoring procedures published, but 
for this study, a five-point scale was used, and the MHI-5 score was transformed to yield 
a total score of 0-100, with a higher score indicative of positive mental health 
(Hoeymans, Garssen, Westert, & P., 2004). The MHI-5 scale demonstrated a high level 
of internal consistency with a Cronbach's alpha of 0.906. 
The MHI-5 has demonstrated good reliability (Rumpf, Meyer, & Hapke, 2001; 
Friedman, Heisel, & Delavan, 2005). No formal cut-off point for the MHI-5 has been 
agreed upon in the literature, with various studies citing scores from 72 (Hoeymans et al., 
2004), to 76 to (Kelly, Dunstan, Lloyd, & Fone, 2008) to  ≥ 80 as consistent with good 
general mental health (Clough-Gorr, Stuck, Thwin, & Silliman, 2010).  An MHI-5 score 
of 52 or less has been cited as indicative of depressive symptoms (Kroenke et al., 2005; 
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Whang et al., 2009; Whang et al., 2012), and a score of < 65 is suggestive of mood 
disorders (Rumpf, Meyer, Hapke, & John, 2001; Biddulph et al., 2014).  
The MHI-5 score in the present study suggests a minimal impact on psychological 
status in this sample (M =74.9, SD=16.3, range 28-100), with a negative skew and a long 
tail to the left with more high scores (indicative of positive mental health).  The MHI-5 is 
known to have a negative skew, but previous research suggests that response models are 
robust to departures from normality (Fone, Dunstan, John, & Lloyd, 2007). So although 
the mean score does not approach the levels described above associated with depression 
or mood disorders, the mean MHI-5 score in this sample suggests that assessment for 
psychological well-being would be advisable because there appears to be some effect of 
EGFRI therapy.  This score compares with the FACT-G Emotional Well-Being subscale 
score (M =15.9, SD = 4.95, range 4-24), which suggests some impact on emotional 
dimension of quality of life.  
Tests of normality.  As noted above, the MHI-5 score is negatively skewed 
(skewness =-.752, SE= .319). Statistical tests for normality were not in agreement, with 
the Kolmogorov-Smirnov non-significant and the Shapiro-Wilk significant W = (56) 
.947, p =.016. Inspection of the histogram, P-P and Q-Q plots indicated minor deviation 
from a normal distribution, so this outcome variable will be treated as normally 
distributed.  
 Functional performance/performance status.  The Eastern Cooperative 
Oncology Group Performance Status (ECOG PS) is widely accepted as a measure for 
assessment of functional status of patients. Descriptive statistics for the ECOG 
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Performance Scale are depicted in Table 14, indicating that almost 98% of participants 
reported a good or very good performance status overall.  No participant reported being 
completely disabled and incapable of self-care. 
 Tests of normality.  In advance of conducting inferential tests on this outcome 
variable, checks of normality were conducted and, results for this variable were non-
normal with a skewness of .930 (SE = .319). Kurtosis was acceptable at .689 (SE = .628), 
but the Shapiro-Wilks test for normality of data was highly significant.  Inspection of the 
histogram and the P-P and Q-Q plots indicated a significant deviation from the normal 
distribution. A log 10 transformation, including the addition of a constant due to the 
presence of zero values, improved the skewness, but the Shapiro-Wilks test was still 
highly significant, so the non-parametric Mann-Whitney U test was used on the original 
data to examine differences in this outcome variable between members of each cluster 
and non-members.   In addition, the ECOG score is categorical variable and may not be 
appropriate for multiple regression.  
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Table 14. ECOG Performance Status 
 
N=56 Score N Percentage 
Fully active, able to carry on all pre-disease 
performance without restriction. 
 
0 26 46.4 
Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house 
work, office work. 
 
1 24 42.9 
Ambulatory and capable of all self-care but 
unable to carry out any work activities. Up 
and about more than 50% of waking hours. 
 
2 5 8.9 
Capable of only limited self-care, confined to 
bed or chair more than 50% of waking hours.  
3 1 1.8 
 
 
Study Aim 3 
Identify any co-occurring symptoms or symptom clusters in patients receiving 
EGFRI therapy. 
Symptom Clusters 
 Symptom clusters have been described as two or more symptoms that co-occur 
and that may or may not share the same etiology (Kim, McGuire, Tulman, & Barsevick, 
2005).  In oncology symptom cluster research, a basic concept is that there is a shared 
basis for a set of symptoms, whether caused by the treatment or the disease.  This same 
premise is implicit in factor analysis, in that there is an underlying or latent dimension, 
possibly unobserved, that is shared by a set of variables.  
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 Factor analysis.  Factor analysis is a multivariate procedure that enables the 
researcher to reduce a set of variables into a smaller number of variables, known as 
factors. Factor analysis is based on correlation between items (e.g. symptoms).  
Types of factor analysis 
Clarification of the definition of factor analysis used in this context is essential.  
There are two types of factor analysis: confirmatory factor analysis and exploratory factor 
analysis.  In exploratory factor analysis, the primary aim is to explore and discover key 
constructs in a set of data, while confirmatory factor analysis allows the researcher to test 
hypotheses (Kline, 2002). Confirmatory factor analysis provides an opportunity for 
hypothesis testing to determine if a proposed relationship between variables and 
constructs actually exists.   
Exploratory factor analysis.  The current research used exploratory factor 
analysis in order to discover symptom clusters in patients receiving EGFRIs.  Exploratory 
factor analysis is a non-inferential statistical procedure, and can be understood as a 
heuristic technique, in that it allows the researcher to engage in a process of discovery of 
relationships among variables.  No statistical confirmatory test for an appropriate factor 
analysis exists, and there is a significant amount of subjectivity that can come into play. 
Factors derived from the same data could conceivably vary, depending on decisions made 
by the researcher. However, the final factor solution is one that should be defensible. The 
goal of factor analysis should be to derive a parsimonious solution of factors that makes 
sense in the context of the data, while explaining variance in the data (Walker & Maddan, 
2013).  
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Factor analysis resonates with some symptom cluster researchers because factors 
can be used to understand the relationship, and perhaps a shared biological cause, among 
various symptoms, and perhaps better inform their collective management.  However, as 
noted, this statistical approach is based on a series of decisions that are inherently 
subjective (Kim & Abraham, 2008), and which should be based on an understanding of 
clinical scenarios.  For this reason, the series of iterative decisions contributing to the 
final factor solution are described below. 
Steps in exploratory factor analysis. A general series of steps should be 
undertaken in order to produce interpretable factors.  First, a series of variables are 
selected and measured. Various characteristics of the variables, such as normality, 
skewness, and kurtosis, are observed.  Inspection and evaluation of communalities is 
performed in order to identify possible variables to exclude, because items with low 
communalities will not contribute to the factor solution.  Correlation coefficients are 
examined to determine which variables to retain, as items that do not correlate with 
others will not contribute to a factor solution.  Along each step of the process, measures 
of sampling adequacy (Kaiser-Meyer-Olkin statistic and Bartlett’s test of sphericity) are 
ascertained.  
Various approaches to factor extraction and rotation (oblique vs. orthogonal) are 
evaluated in light of the purpose of the factor analysis, and all of these procedures are 
repeated on an iterative basis in order to identify a clear factor structure. Decisions about 
the number of factors to retain are made, using several rules of thumb, such as the scree 
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plot, eigenvalues greater than 1 (Kaiser criteria) and total variance explained. Finally, 
results must be interpreted in a meaningful way that has relevance to the application.        
Measures of Sampling Adequacy 
There are several measures to consider regarding the appropriateness of factor 
analysis for a set of data, including the Kaiser-Meyer-Olkin (KMO) Measure of Sampling 
Adequacy, Bartlett’s test of sphericity, and the anti-image correlation matrix, which are 
all included the factor analysis procedures in SPSS.   
The KMO statistic represents the amount of variance in a set of variables that may 
be resulting from underlying factors. KMO values, which are based on correlations and 
partial correlations, have been characterized by Kaiser (Zilmer & Vuz, 2010) in the 
following way: .90 or above “marvelous,” .80 or above, “meritorious,” .70 or above 
“middling,” .60 or above, “mediocre,” .50 or above “miserable,” and below .50 as 
“unacceptable.” As previously noted, a KMO for a set of variables of at least 0.6 is 
suggested for factor analysis (Tabachnik & Fidell, 2001), or the variables included in the 
solution should be reexamined or a larger sample generated (Field, 2009, p. 647). 
Individual variables with a KMO of less than 0.5 should be considered for elimination 
(Walker & Maddan, 2013). Elimination of variables with low KMO values is 
recommended, and will have the effect of raising the overall KMO statistic for the entire 
set of variables. As variables are removed, and factor analysis procedures are repeated, 
changes occur in the individual and overall KMO statistic.  
Correlation provides the basis for factor analysis, so there must be some 
correlation among variables in order for them to “hang together” so that factors can be 
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identified. Bartlett's test of sphericity determines whether a correlation matrix is an 
identity matrix, where all diagonal values are 1 while off-diagonal values are 0.  An 
identity matrix would be evidence of a lack of correlation among variables, and a set of 
such variables would not generate factors. In Bartlett’s test of sphericity, if the p value is 
significant, the null hypothesis that the population matrix is an identity matrix would be 
rejected.  Rejecting the null hypothesis is required for a set of data to be factor analyzed. 
However, Bartlett’s test is often significant, and relying solely on this parameter to 
determine sampling adequacy is inadvisable.  
Another step in determining sampling adequacy is inspection of the anti-image 
correlation matrix, which displays the negative of the partial correlations. Since this is an 
anti-image, desirable values should be low, closer to zero.  Large values are problematic 
as such variables will have low correlations with other variables, and they should be 
considered for elimination from factor analysis if a theoretical or methodologic argument 
can be made for doing so (Walker & Maddan, 2013).  
Decision-Based Factor Analysis Procedure 
 
The first step in the process of generating a factor analysis in the current study 
was to examine the 38 symptoms included in the MSAS-SF (adapted) in order to 
determine which items should be retained and which could be removed due to low 
correlations with other symptoms. In a study with many variables, there may be 
thousands of correlations, and “without a simplifying procedure such a matrix would be 
incomprehensible” (Kline, 2002, p.4).  With the original correlation that included all 
measured symptoms, the initial KMO measure of sampling adequacy was unacceptable at 
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.384, indicating that the current set of variables were not suitable for factor analysis, 
although Bartlett’s test of sphericity was significant, providing an example of its frequent 
significance and lack of reliability as a measure of sampling adequacy.   Additional 
examination of the data was required.  Several approaches were used to identify which 
symptom variables to retain, including examination of inter-item correlations, 
consideration of symptom occurrence and prevalence as a criterion for retaining variables 
(symptoms), and iterative examination of the anti-image correlations. 
Following the convention suggested by others, the criteria of symptom occurrence 
of at least 20% -25% was used as a first step for consideration of variables to include in 
the factor analysis (Gleason et al., 2007; Kim et al., 2009b; Baggott, Cooper, Marina, 
Matthay, & Miaskowski, 2012).  Symptom severity or distress has also been used as a 
basis for deciding which symptoms to retain in factor analysis (Kim et al., 2009b), but 
there is not much difference between ranking the symptoms occurrence and severity, so 
frequency or prevalence  was chosen as the approach here.  
Using symptom frequency or prevalence as a criteria for exclusion, the following 
eight symptoms were removed, with their communalities shown in parentheses: problems 
with urination (.081), swelling of arms and legs (0.149), vomiting (0.142), feeling bloated 
(.095), dizziness (0.179), difficulty swallowing (0.232), and sweats (0.04). The 
communalities of all of the removed variables were low, which made them good 
candidates for removal from factor analysis. However, despite removing these symptoms, 
the KMO remained unacceptable at 0.436.  
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Inter-item correlations were then examined for all symptom variables, and those 
with correlations below .300, including the symptoms changes in finger and toe nails, 
difficulty sleeping, and itching, were removed from the factor analysis, which improved 
the KMO to 0.500, with Bartlett’s test of sphericity remaining significant.  
Communalities were again inspected, and variables deleted from the exploratory factor 
analysis due to low communalities were pain, diarrhea, changes in the way food tastes, 
nausea, numbness and tingling in fingers and toes, problems with sexual interest or 
activity and shortness of breath.  Using this approach improved the KMO to 0.730, 
x
2(105) = 301.994, (p = .000).  
The anti-image correlation matrix was then examined for measures of sampling 
adequacy. The anti-image correlation matrix includes the KMO values for each 
individual variable along the diagonal, and, as noted earlier, any values less than .500 
suggest that the item should be removed from analysis (Field, 2009, p. 659).  All of the 
remaining items had measures of sampling adequacy greater than 0.639.  The off-
diagonal elements should be close to zero, which was the case for many. The determinant 
for this set of factors was .002. In addition, each variable had at least one inter-item 
correlation at or near 0.400, and all communalities were above .300, ranging from .339  
to .791.   
As noted above, the goal of a factor analysis is to develop a solution that makes 
sense with regard to its application, is relatively easy to interpret, and possesses a simple 
structure with few or low cross-loadings. The iterative procedures described here resulted 
in such a factor structure. In the final solution, principal axis factoring using an oblique 
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rotation (Oblimin with Kaiser normalization) retained the following variables: difficulty 
concentrating, “I don't look like myself,” changes in my eyelashes, dry skin, feeling sad, 
worrying, feeling irritable, feeling nervous, other changes to scalp hair, hair loss, dry 
mouth, lack of energy, feeling drowsy, changes in hair growth on my face and other 
changes to my fingers or toes. In this model, the three factors retained explained 48.03% 
of the total variance, and is shown in Tables 15 and 16.  
 Rationale for oblique rotation.  As factor analysis is an exploratory procedure, 
multiple procedures were run through SPSS in order to identify the optimal factor 
structure and to explore the effect of various methods of rotation and extraction.  
Principal components analysis was executed on the symptom variables in order to explore 
the data and to compare the results with iterations using other factor analysis procedures, 
including principal axis factoring (PAF), using both orthogonal (Varimax) and oblique 
(Oblimin and Promax) rotations.  Maximum likelihood rotation and unweighted least 
squares methods, using both orthogonal and oblique rotation, were also performed, and 
each procedure yielded very similar results, but the above model best fit the data.   
Selection of oblique rotation 
Ideally, because the symptom variables in this study are derived from patient self-
report, they would best be examined through an oblique rotation, which allows variables 
to load on several factors.  Additionally, correlation coefficients in the factor structures 
were high, supporting the use of oblique rotation. In a real world setting, it is very likely 
that there would be variables that would cross-load on more than one factor, so oblique 
rotations, such as Oblimin with Kaiser normalization should be strongly considered.  In 
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other applications, orthogonal solutions might be preferred due to the inherent 
simplification of their interpretation, so this type of rotation was also explored. However, 
in a clinical setting, a symptom in one factor might very likely also be present in another 
factor, and oblique rotation allows this redundancy to occur, and has been suggested as a 
reasonable approach in symptom cluster research (Skerman, Yates, & Battistutta, 2009). 
Factor Solutions 
As noted above, a three factor solution was derived:  Factor 1: a psychological-
cognitive cluster (feeling nervous, feeling sad, worrying, feeling irritable, difficulty 
concentrating, and “I don't look like myself”); Factor 2: a dermatologic skin and hair 
cluster (changes in eyelashes, dry skin, hair loss, changes in facial hair growth and other 
changes in scalp hair); and, Factor 3: a mucocutaneous-fatigue  cluster of dry mouth, 
feeling drowsy, lack of energy, difficulty concentrating, and other changes to fingers or 
toes.  Note that lack of energy and difficulty concentrating loaded on Factors 1 and 3, 
lending justification to an oblique solution.  Difficulty concentrating is a common 
symptom in patients being treated for cancer, so cross-loading is not problematic. 
Factor loadings are presented in Table 15 and 16 and include the structure 
(correlations between factors and variables) and pattern (factor loadings) matrices.  With 
an oblique rotation, it is important to report both the structure and the pattern matrix 
(Pett, Lackey, & Sullivan, 2003; Thompson, 2004).  Each factor had several excellent or 
very good loadings, and as previously described, high loadings of .600 or more with four 
or more variables can mitigate somewhat a small sample size (Stevens, 2002).  
Cronbach’s alpha for this set of symptoms (n=15) was .739. The factor loadings are 
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generally in the categories considered good  to excellent ( > .70 – excellent;  .63 - very 
good; > .55 – good; > .45 – fair; > .32 – poor) (Comrey & Lee, 1992).  
Eigenvalues for each factor are as follows: Factor 1 (psychological-cognitive), 
with an eigenvalue of 4.046 (23.96% of variance explained); Factor 2 (dermatologic skin 
and hair), with an eigenvalue of 2.497 (13 % of variance explained); and, Factor 3 
(mucocutaneous and fatigue cluster), with an eigenvalue of 2.162 (11.07% of variance 
explained. A cumulative explained variance of 48.03 % resulted with this factor solution.  
In all iterations of factor analytic procedures, the scree plot (a graphic plot of 
eigenvalues) was examined.  In the final solution, the scree plot suggested at least a three 
factor solution (Figure 4).  Although a 4 factor solution was also generated, few items 
loaded on this fourth factor.   
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Table 15. Principal Axis Factor Analysis with Direct Oblimin Rotation  
Structure Matrix Based on Iterative Process (N=56) 
____________________________________________________________________________ 
Structure Matrix 
Symptom  Factor 1   Factor 2  Factor 3  
Feeling nervous   .885   
Feeling sad  .805   
Worrying   .782   
Feeling irritable  .667   
“I don't look like myself” .525   
Other changes scalp hair  .618  
Dry skin  .676  
Changes in eyelashes  .619  
Hair loss  .588  
Changes in facial hair growth   .549  
Other changes to fingers or toes   .633 
Dry mouth    .620 
Feeling drowsy   .579 
Lack of energy   .584 
Difficulty concentrating  .476  .533 
Note: Factor loadings under .450 are suppressed.   
Factor 1 Psychologic-Cognitive Eigenvalue of 4.046 (23.96% of variance explained)          
Factor 2 Dermatologic Skin and Hair Eigenvalue of 2.497  (13.00 % of variance explained) 
Factor 3 Mucocutaneous and Fatigue Eigenvalue of 2.162  (11.074% of variance explained)  
Cumulative variance of 48.031% explained.  
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Table 16. Principal Axis Factor Analysis with Direct Oblimin Rotation Pattern Matrix 
Based on Iterative Process (N=56) 
 
 Pattern Matrix Factor 
Loadings 
  
Symptom  Factor 1      Factor 2     Factor 3  
Feeling nervous   .877               
Feeling sad  .827    
Worrying   .814    
Feeling irritable  .603    
“I don't look like myself” .494    
Other changes scalp hair  .636   
Dry skin  .663   
Changes in eyelashes 
 .646   
Hair loss  .568   
Changes in facial hair growth   .531   
Other changes to fingers or toes 
  .716  
Dry mouth 
  .629  
Feeling drowsy 
  .543  
Lack of energy 
  .561  
Difficulty concentrating  
  .449 
 
 
Note: Factor loadings under .40 are suppressed. 
 
  
Figure 4.  Scree 
 
 
 
Factors Based on Communalities
The previous discussion detailed an iterative process of examining the symptom 
variables and taking steps to ensure that the data was appropriate for factor analysis. 
order to confirm the set o
and the original communalities for the full set of variables 
a communality value below 0
run using PAF with an oblique rotation in an effort to replicate the derived factors.  
Although elimination of variables with communalities below 0.5 has been recommended, 
Plot for Factor Solutions 
 
f factors derived, the complete set of variables was
were reviewed. Variables with 
.300 were eliminated, and factor analytic procedures were 
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the cut-off of .300 was chosen so that variables demonstrating some evidence of 
correlation could be retained.   
Using the single criteria of communality, variables removed for the first iteration 
of factor analysis included: diarrhea (0.026), sweats (0.04), changes in finger and toe 
nails (0.064), problems with urination (0.081), bloating (0.095), pain (0.100), itching 
(0.112), problems sleeping (0.116), changes in the way things taste (0.133),  vomiting 
(0.142), swelling of arms and legs (0.149), numbness and tingling of fingers and toes  
(0.168), dizziness (0.179), cough (0.189), nausea (0.201), lack of appetite (0.206), 
constipation (0.211), mouth sores (0.211), problems with sexual interest or activity 
(0.219),  shortness of breath (0.224), difficulty swallowing (0.232), and weight loss 
(0.255), and changes in skin (0.279).   
The resulting set of symptoms for factor analysis included: feeling nervous, 
feeling sad, worrying, feeling irritable, feeling drowsy, lack of energy, difficulty 
concentrating, “I don’t look like myself,” dry mouth, hair loss, other changes to scalp 
hair, changes to hair growth on my face, dry skin,  changes in my eyelashes, and other 
changes to my fingers and toes.  The KMO for this set of variables was .732 (x2 (120) 
=331.416, p = .000).  
For this set of variables, the scree plot and eigenvalues > 1 (Kaiser rule) suggested 
a three or four factor solution.  A four factor solution was examined, but variables 
(feeling drowsy, “I don’t look like myself,” dry mouth, difficulty concentrating, lack of 
energy, changes in hair growth on my face, hair loss, dry skin and feeling irritable) cross-
loaded and factor loadings were low (<.400) for eleven variables. Therefore, a three 
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factor solution generated by PAF (Oblimin with Kaiser normalization) was selected and 
included: Factor 1 (psychological-cognitive), with an eigenvalue of 4.154 (23.02 % of 
variance explained); Factor 2 (dermatologic skin and hair cluster), with an eigenvalue of 
2.638 (13.02% of variance explained); and Factor 3 (mucocutaneous-fatigue), with an 
eigenvalue of 2.226 (10. 8% of variance explained).  A cumulative variance of 46.85% 
was explained by this solution (Table 17). 
 Approaches comparison for factor analysis.  The factors generated by these 
two methods (the first which took repeated iterations) are very similar, and provide 
validation of the first method.  The first set of factors was used to generate the factor 
scores used to explore differing effects on outcome variables. All further discussion 
regarding factors and the identified symptom clusters will relate to those developed using 
the first (iterative approach) method.   
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Table 17. Exploratory Factor Analysis Results Based on Communalities (N=56) 
 
 
   Factor Loadings  
Symptom  Factor 1   Factor 2  Factor 3  
Feeling nervous   .885   
Feeling sad  .803   
Worrying   .779   
Feeling irritable  .664   
“I don't look like myself” .524   
Other changes scalp hair  .610  
Dry skin  .652  
Changes in eyelashes  .578  
Hair loss  .615  
Changes in facial hair growth   .526  
Dry mouth       .646 
Feeling drowsy      .602 
Lack of energy      .548 
Difficulty concentrating  .405     .497 
______________________________________________________________________ 
Note: Factor loadings under .40 are suppressed.  
Factor 1 Psychologic-Cognitive      Eigenvalue of 4.154 (23.02 % of variance explained) 
Factor 2 Dermatologic Skin and Hair   Eigenvalue of 2.638 (13.02% of variance explained) 
Factor 3 Mucocutaneous and Fatigue  Eigenvalue of 2.226 (10. 8% of variance explained) 
Cumulative variance of 46.85% explained.  
 
 
Factor Correlation Matrix 
For the final solution using the first method described, the factor correlation 
matrix indicates that Factor 1 is not correlated with Factor 2 (.099), and is only weakly 
correlated with Factor 3 (.228).  Factor 2 is not correlated with Factor 3 (.034).  
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Correlations less than 0.1 are negligible. So despite an oblique rotation where factors are 
“allowed” to correlate, the factors in this solution do not correlate, so the three factor 
solution is supported. Only one item (difficulty concentrating) loads on multiple factors 
(Factors 1 and 3), and this is logical given the clinical meanings of both of these clusters.  
 Symptom clusters.  Three symptom clusters were generated using the procedures 
described above.  A psychological-cognitive cluster, a dermatologic skin and hair cluster, 
and a mucocutaneous and fatigue cluster.  Each of these clusters will be discussed in 
more depth in chapter five in the context of previous work on symptom clusters.  
 Factor 1: Psychological-cognitive.  A mood-related, affective, emotional, or 
psychoneurologic cluster, including the symptoms of feeling irritable, feeling nervous, 
worrying, feeling sad, difficulty concentrating and “I don’t look like myself” was 
identified in this sample. Previous oncology symptom cluster research has provided 
ample evidence for similar clusters in patients with various cancer diagnoses.  
 Factor 2: Dermatologic skin and hair cluster.  The second cluster includes dry 
skin, changes in eyelashes, hair loss, changes in facial hair growth and other changes in 
scalp hair, and can be interpreted as an EGFRI treatment-related dermatologic skin and 
hair cluster.  Although these symptoms have been previously described (Lacouture et al., 
2011), the finding of a symptom cluster generated by factor analytic procedures is novel. 
A skin and hair-related symptom cluster would have been expected to occur in this 
sample. Nail changes did not cluster with these symptoms.  
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 Factor 3: Mucocutaneous and fatigue cluster.  The third factor identified 
includes dry mouth, feeling drowsy, lack of energy, difficulty concentrating, and other 
changes to fingers or toes, so it echoes previous work, but includes a new element (other 
changes to fingers and toes) reflecting EGFRI therapy. This cluster has two components: 
dry mouth and changes to fingers and toes being the mucocutaneous aspect, and feeling 
drowsy, lack of energy and difficulty concentrating contributing to the fatigue aspect.   
Hierarchical Cluster Analysis 
In view of the small sample size for this study and the caveats regarding factor 
analysis with small samples, the data were assessed by hierarchical cluster analyses 
(HCA) using Ward’s method with squared Euclidean distances.  This method has been  
used to generate symptom clusters in patients with heart failure using a version of the 
MSAS (MSAS-HF) (Song et al., 2010). 
Like factor analysis, cluster analysis allows for discovery of relationships between 
variables.  In HCA, each variable starts as a separate cluster and the procedure then 
reduces the number of clusters until all items are grouped in one large cluster. Distance 
scores range from 0-25, and as the distance becomes less, the symptoms begin to cluster.  
By observing the dendrograms generated by the procedures, one can identify how items 
cluster at various distances.  The first HCA was run with all 38 symptoms included, and 
generated the dendrogram shown in Figure 5.  Viewing the clusters from right to left, 
there is a clear branching of three large clusters with this first iteration.  The first cluster 
includes difficulty with urination, swelling of arms and legs, vomiting, bloating, sweats, 
dizziness, nausea, difficulty swallowing, mouth sores, “I don’t like the way I look,”  
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numbness and tingling in my fingers and toes, difficulty sleeping, shortness of breath, 
constipation, pain, cough, drowsiness, other changes to fingers and toes and itching.  This 
cluster might be described as a general sickness cluster.  
The second cluster derived by HCA of all 38 symptoms includes lack of energy, 
dry mouth, skin changes, feeling nervous, feeling sad, feeling irritable, worrying, 
difficulty concentrating, weight loss, changes in appetite and taste changes. This cluster 
might be described as a mood-anorexia cluster.   
The third cluster generated by the first iteration of hierarchical cluster analysis 
includes changes in eyelashes, scalp hair changes, hair loss, changes in facial hair growth, 
dry skin, diarrhea, problems with sexual interest and performance, and changes in fingers 
and toenails, which could be labeled as a treatment-related dermatologic skin,  hair and 
nail cluster.  
  
Figure 5. Hierarchical Cluster Analysis of All Symptoms
GENERAL SICKNESS CLUSTER 
MOOD ANOREXIA CLUSTER 
DERMATOLOGIC SKIN HAIR AND NAIL CLUSTER
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Another HCA was run with the final set of symptoms included in the initial 
(iterative) exploratory factor analysis procedures previously described.  The dendrogram 
presented in Figure 6 indicates the presence of three symptom clusters which mirror those 
generated by factor analysis. The first cluster (psychological-cognitive) includes 
difficulty concentrating, feeling irritable, feeling nervous, feeling sad, worrying, and “I 
don’t look like myself,” the second cluster (mucocutaneous and fatigue) includes dry 
mouth, lack of energy, feeling drowsy, and other changes in fingers and toes.  Changes in 
eyelashes, other changes in scalp hair, hair loss, changes in facial hair growth and dry 
skin are included in the final cluster (dermatologic skin and hair).  As depicted on the 
dendrogram, symptoms cluster together at lower distance scores.  
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Figure 6. Hierarchical Cluster Analysis with Symptoms  
Retained in Factor Analysis 
 
 
 
  
DERMATOLOGIC SKIN AND HAIR CLUSTER 
MUCOCUTANEOUS FATIGUE CLUSTER 
PSYCHOLOGICAL COGNITIVE CLUSTER 
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Study Aim 4 
Explore the relationships between any identified co-occurring symptoms or 
symptom clusters and key variables, including gender, age, primary cancer, type of 
EGFRI, and the outcome variables of quality of life, functional performance and 
psychological status. 
The factor solution identified by an iterative process in exploratory factor analysis 
(the first method described) was used for all analyses. Factor scores were used to identify 
the symptom cluster membership of each participant so that group differences could be 
explored. Several options are available for generating factor scores, including the three 
so-called “refined” methods: regression, Bartlett, and Anderson-Rubin, all of which are 
included as options in SPSS.  In order to generate factor scores in this study, the 
regression method was selected. In this method, the regression factor score estimates the 
location of each individual on the factor  (DiStefano, Zhu, & Mindrila, 2009).  When 
using this approach to factor score generation, the scores are standardized to a mean of 
zero and a standard deviation equal to the squared multiple correlations between factors 
and variables in a PAF (Tabachnik & Fidell, 2001). 
First, regression factor scores were obtained, and then the scores were described 
by quartile.  Each participant was then assigned a 0 or 1 to describe membership in each 
of the three factors (symptom cluster groups).  If a participant’s factor score was at or 
above the 70th percentile, they were assigned to the factor; scores below the 70th 
percentile were not described as exhibiting that symptom cluster.  Because an individual 
could be experiencing multiple symptoms, membership in more than one cluster was 
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permitted. Members of the symptom cluster group could then be compared on outcome 
variables to non-members of the cluster. An alternative approach was also used, 
examining the correlation of the regression scores for each participant with the outcome 
measures.  Results from each of these methods are described below.  
 For the hierarchical regression procedures, the regression factor scores were then 
used as independent variables in a multiple regression model to identify predictors of the 
outcome variables: quality of life, functional performance, and psychological status.  
Independent t-tests and one-way ANOVA assessed the impact of membership in each 
symptom cluster on psychological status and quality of life.  The impact of symptom 
clusters on performance was tested using a non-parametric test. All of these findings 
should be replicated in an adequately powered sample.  
Factor 1: Psychological-Cognitive Cluster 
Independent t-tests compared members with non-members of this cluster. Both 
psychological status and quality of life were significantly different in the psychological-
cognitive cluster.  The psychological outcome, measured by the MHI-5, demonstrated a 
highly significant difference.  As would be expected, participants with this symptom 
cluster experienced an effect on psychological status as illustrated by lower mean scores 
on MHI and FACT-G (Tables 18 & 19). 
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Table 18. Independent Samples t-Test Comparing Means of Psychological-Cognitive 
Cluster to Others 
 
  
          t  df Sig. (2-tailed)          M      SD 
Psychological Status         
Factor 1 (n=17) 
Others  (n=39) 
 -5.357 54 .000 60.47 16.55 
    81.23 11.72 
Total QOL       
Factor 1 
Others 
 -2.544 54 .014 118.06 19.04 
    135.03 24.41 
FACT-G       
Factor 1 
Others 
 -3.101 54 .003 65.12 17.98 
    80.69 16.98  
——————————————————————————————————— 
 
 
Quality of life, as measured by the Total QOL score (FACT-G plus EGFRI-18), 
was also significantly different between the two groups, with members of the cluster 
(N=17) indicating a lower QOL (M = 118.06, SD = 19.04, N = 17) compared to non-
members (M = 135.02, SD = 24.41, N = 39), t(54) = -2.544, p = .014.  Scores for the 
FACT-G, as well as three of the four subscales, (SWB, PWB, EWB), which are not 
shown here, were also significant, with cluster group members indicating a lower quality 
of life. Non-parametric Mann-Whitney U independent t-tests were also run including 
these dependent variables, confirming these results. 
Using the alternative approach examining correlations, the Cluster 1 factor score 
demonstrated highly significant negative correlations with the MHI-5 scores (r = -.726,  
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p = .000), the FACT-G score (r = -.559, p = .000), and the Total QOL score (r = -.416,  
p = .001), again confirming the association between the presence of the psychologic-
cognitive factor and lower psychological well-being and quality of life.  
Factor 2: Dermatologic Skin and Hair Cluster 
An interesting finding related to quality of life emerged when examining the 
group means for Factor 2, the dermatologic skin and hair cluster.  Contrary to 
expectations, no significant difference between the Factor 2 members (M =51.47, SD = 
14.75, N = 17) and non-members (M =56.42, SD = 10.49, N = 38) was demonstrated on 
the EGFRI-18 score, which is designed specifically to measure quality of life in this 
patient population. The sensitivity of the EGFRI-18 to the impact of dermatologic skin 
and hair symptoms on quality of life should be further explored.    
However, the Total QOL score (FACT-G plus EGFRI-18 scores), and the PWB 
subscale t(54) =-3.245, p =.002 all revealed significant differences, suggesting a differing 
impact of this cluster on QOL.  In addition, the results for the MHI-5 (psychological 
status) were significant, indicating a negative effect of this cluster on psychological status 
when compared with the group without this symptom cluster. A nonparametric Mann-
Whitney U was run because of non-normality of the FACT-G and ECOG scales, with 
significant results for both the FACT-G QOL (p = .014) and the Total QOL (p = .031) 
confirming a significant impact of the dermatologic skin and hair cluster on quality of life 
and performance.  
  
120 
 
 
Table 19. Independent Samples t-Test Comparing Means of Dermatologic Skin and 
Hair Cluster to Others 
 
  t df Sig. (2-tailed) Mean SD 
Psychological status  
 
Factor 1  (n=17) 
Others    (n =39) 
  
 
-2.162 
 
 
54 
 
 
.035 
 
 
68.00 
 
 
19.13 
    77.95 14.21 
Total QOL 
 
    
  
Factor 1  
Others  
 -2.320 54 .024 119.00 23.82 
    134.62 22.87 
FACT-G QOL 
 
    
  
Factor 1 
Others   
 -2.331 54 .024 67.53 16.79 
    79.64 18.32 
  
 
 
In the alternative approach using regression scores in a correlation procedure, 
Factor 2 correlated with the Total QOL score (r =-.344, p =.00), the FACT-G (r =-.344, p 
=.01), the ECOG Performance Scale (r =-.409, p =.002), and the MHI (r =-.282, p 
=.035), suggesting an impact of this cluster on all outcome variables.  
Factor 3: Mucocutaneous and Fatigue Cluster 
For Factor 3, the mucocutaneous and fatigue cluster, there are several statistically 
significant findings.  FACT-G scores were significantly different in a positive direction 
between members of this cluster and non-members. This trend continued for two 
subscales of the FACT-G, with the both the FWB subscale scale score higher (M = 21.06, 
SD = 5.14, N = 17) than non-members (M = 16.18, SD = 6.77, N = 38), t(39.763) = 
2.953*, p =.005, and the SWB subscale higher (M =24.65 , SD =4.07 , N = 17) than non-
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members (M =20.38 , SD = 7.08, N = 38), t(49.64) = 2.83*, p =.007, two-tailed, 
indicating a better QOL in cluster members.  
Conversely, there appears to be a negative effect of Factor 3 membership on the 
EGFRI-18 score (dermatologic quality of life) compared to non-members. This is an 
interesting finding, as the only dermatologic symptom retained in this cluster was other 
changes to my fingers and toes, so further exploration of this relationship is warranted. 
However, this statistical significance did not hold for the total QOL score (FACT-G and 
EGFRI-18), which indicated no difference between the groups. 
 
 
Table 20. Independent Samples Comparing Means of Mucocutaneous-Fatigue  
Cluster to Others 
 
      t     df Sig. (2-tailed)      Mean  SD 
 
  
Dermatologic QOL       
  
  
 
Factor     (n=17) 
Others    (n =38) 
  
-2.689 
 
 
      53 
 
.010    
                    
  48.70 
  57.66 
 
13.79 
10.21 
  
QOL      
  
  
 
Factor 3  (n =17) 
Others    (n =39)  
    2.71              45 .010 
  84.35 12.99   
    
  72.31 19.59 
 
  
 
 
 
 
Since both the FACT-G and the EGFRI-18 (separately) are not normally 
distributed, a nonparametric Mann-Whitney U test was performed for each of these 
outcome variables, and both confirmed a significant difference  associated with cluster 
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membership in cluster members for both the FACT-G, U = 208.5, p = .028, and the 
EGFRI-18, U = 187.00, p = .013.  The test for ECOG was non-significant.  
In the alternative procedure, the EGFRI-18 score yielded the only significant 
finding (r = -.429, p <.001), suggesting a relationship between Cluster 3 and 
dermatologic quality of life. 
Symptom Clusters and Outcomes 
The relationship between the identified symptom clusters and outcomes is 
summarized in Table 20.  Both Factors 1 and 2, the psychologic-cognitive cluster, and the 
dermatologic skin and hair cluster have a negative relationship with quality of life.  
Factor 3, the mucocutaneous-fatigue cluster, has a highly significant negative impact on 
dermatologic quality of life, but the other symptom clusters do not.  Both the 
psychological-cognitive cluster and the dermatologic skin and hair cluster (Factors 1 and 
2) are related to psychological status, with the greatest negative correlation between 
Factor 1 and this outcome. A positive correlation between Factor 2, the dermatologic skin 
and hair cluster and functional performance suggests a possible connection between 
treatment with EGFRI therapy and improvement in performance status, but this possible 
relationship requires further study.  All of these findings should be confirmed in an 
adequately powered sample.  
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Table 21.Correlation between Symptom Clusters and Outcome Measures 
 
 Factor 1 Factor 2 Factor 3 
Dermatologic 
QOL 
n=55 
 
  
-.429 
 
  .001 
 
  
 
Psychological 
status 
n =56 
 
-.727 -.282  
 
.000 .035  
 
  
 
Total QOL 
 
n=56 
 
-.416 -.389  
 
.001 .003  
 
  
 
Quality of Life 
 
n=56 
 
-.559 -.344  
 
.000 .009  
 56 56  
Performance/ 
Functional 
Status 
n=56 
 
 .409  
 
 .002  
 
 
 
 
Note: Factor 1 is the psychological-cognitive symptom cluster; Factor 2 is the 
dermatologic skin and hair cluster; Factor 3 is the mucocutaneous-fatigue cluster.  
 
 
 
Multiple Regressions 
Stepwise hierarchical multiple regressions were used to determine which, if any, 
of the independent variables, including symptom clusters, significantly predicted the 
various outcome variables. Demographic variables, including gender, level of education, 
age, stage of illness, primary diagnosis, concurrent therapy, relationship status, method of 
survey completion (online vs. paper), length of EGFRI therapy, and specific EGFRI 
therapy were entered into each regression. The results of the regression are as follows.  
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Quality of Life 
Factors 1 and 2 predicted the Total QOL score (sum of the FACT-G  
and EGFRI-18), explaining about 31 % of the variance of the overall score, 
R2 =.311, F (2, 53) =11.95, p < .001. For the FACT-G alone, Factors 1 and 2 predicted 
about 41% of the variance in quality of life R2 =.415, F (2, 53) =18.79, p < .001. 
For dermatologic quality of life, as measured by the EGFRI-18, Factor 3 predicted 18%  
 
of the variance, R2=.184, F(1,53)= 11.95, p < .001.  Regression models for quality of life 
are presented in Tables 22 and 23. As noted, results should be confirmed in a larger, 
adequately powered sample.  
 
 
Table 22. Regression Model with Predictors for Quality of Life 
 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
 Total QOL       
      
 (Constant) 129.875 2.720  47.749 .000 
Factor 2 -10.134 3.116 -.371 -3.252 .002 
Factor 1 Score -10.133 2.894 -.400 -3.501 .001 
 FACT-G QOL      
      
 (Constant) 75.964 1.935 
 
39.253 .000 
Factor 1 -10.675 2.059 -.545 -5.183 .000 
Factor 2 -6.742 2.217 -.320 -3.041 .004 
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Table 23. Regression Model with Predictors for Dermatologic Quality of Life  
 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
 EGFRI-18      
      
 (Constant) 54.944 1.482  37.083 .000 
 
Factor 3 
 
-5.79 
 
1.675 
 
-.429 
 
-3.457 
 
  .001 
      
 
 
 
 Psychological status. The independent predictors Factor 1 (psychological-
cognitive), Factor 2 (dermatologic skin and hair), as well as marital status, significantly 
contributed to the prediction of scores on the MHI-5, as noted on the regression model in 
Table 24. These variables explain about 63% of the variance in this measure, with Factor 
1 explaining the largest proportion of variance in psychological status scores, R2 =. 528, 
F(1, 54 ), p < .001.  
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Table 24. Regression Model with Predictors for Psychological Status 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
 
      
      
 (Constant) 69.348 2.633  26.333 .000 
Marital status 3.634 1.468 .216 2.476 .017 
Factor 1 -13.207 1.493 -.767 -8.844 .000 
Factor 2  -5.076 1.570 -.274 -3.234 .002 
Note: Dependent variable is MHI-5.  
 
 
 
Inspection of the correlations of the (Table 25) psychological symptoms with the 
MHI-5 reveals that all of the symptoms had a highly significant and negative correlation, 
yielding preliminary evidence of the importance of addressing psychological symptoms 
in an effort to improve patient outcomes such as psychological status. These results 
should be replicated in an adequately powered sample. Clearly, psychological symptoms 
exert a major impact on outcomes in patients receiving EGFRIs, so psychological 
assessment should be conducted on all patients receiving these medications.  
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Table 25. Correlations of Psychological Symptoms and Outcomes 
  
 FACT-G QOL Total MHI-5 ECOG PS 
Feeling sad   -.566** -.458** -.769**  
 
.000 .000 .000  
 
    
Worrying   -.473** -.291* -.572**  
 
.000 .029 .000  
 
    
Feeling irritable   -.288* -.272* -.506**  
 
.032 .043 .000  
 
    
Feeling nervous   -.530** -.411** -.682** .284* 
 
.000 .002 .000 .034 
 
    
Note. QOL Total includes FACT-G: Functional Assessment of Cancer Therapy-General; 
FACT-EGFRI-18: Functional Assessment of Cancer Therapy-Epidermal Growth Factor 
Receptor Inhibitor-18 subscale; ECOG: Eastern Cooperative Oncology Group; MHI-5: 
Mental Health Index-5.  ** indicates p < .001, * indicates p < .05, two-tailed.  
 
 
 
 Performance status.  For the ECOG scale, Factor 2 explained 16% of the 
variance in functional status, but the other symptom clusters did not contribute to the 
model, R2 =. 167, F(1, 54 ) + 10.857, p < .002. 
 
 
  
128 
 
 
Table 26. Regression Model with Predictors for Performance Status 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
 
      
      
 (Constant) .661 .089  7.452 .000 
      
Factor 2 .334 .101 .409 3.295 .002 
 
Note: Dependent variable is ECOG PS. 
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CHAPTER FIVE 
DISCUSSION 
This study was designed to characterize the symptom experience of patients 
receiving EGFRI therapy and to describe how this experience affects key outcome 
variables, including quality of life, performance and psychological status.  Patients with 
solid tumors including lung cancer, colon cancer, head and neck cancer, and breast cancer 
who were receiving an EGFRI for at least four weeks were included in the sample.  This 
chapter will review the key findings from this study, highlight new data, and integrate 
this information with current knowledge on this topic.   
The theory of unpleasant symptoms guided the conception and design of this 
study.  In this model, the symptom experience is viewed as multidimensional, 
encompassing aspects of distress, quality, intensity and timing. Consideration is given 
within the model’s framework to the coexistence of symptoms and their collective impact 
on performance, as well as to the idea that symptoms may both influence and be 
influenced by the interaction of situational, psychological and physiologic factors.  
Performance in this study was conceived broadly to include the dimensions of quality of 
life, psychological status and functional performance.  The collective impact of 
symptoms (as symptom clusters) on these outcomes was explored. Three symptom 
clusters were identified, including one that is well-established in the literature, a novel 
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dermatologic skin and hair cluster likely related to EGFRI therapy, and a third cluster 
similar to another well-established cluster, but with an additional mucocutaneous 
component that is also related to EGFRI therapy.  
Study Aim 1 
Describe the symptom experience (symptom frequency and distress) of patients 
receiving EGFRI therapy. 
Symptom Experience 
An extensive symptom battery, the MSAS-SF (adapted), was used to capture the 
most common and distressing symptoms associated with EGFRI therapy, using the past 
seven days as a time frame.  The instrument included 38 symptoms, and participants were 
asked to select the symptoms that they experienced over the last week, and to indicate 
how much the symptom distressed them (physical symptoms) or how frequently the 
symptom occurred (psychological symptoms).  Participants were also asked to identify 
any symptoms they were experiencing that did not appear on the instrument.  
As noted in chapter four, several symptoms known to occur with frequency in 
patients taking EGFRIs were added for the purposes of this study.  Although all 
symptoms were endorsed by some patients, the symptoms that were selected by over 40% 
of participants are discussed below. The EGFRI-18, a dermatologic quality of life 
instrument specifically designed for use with EGFRIs, was also used to gain an additional 
understanding of the symptom experience, and will be discussed in the section on 
outcomes.   
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Most Frequently Identified Symptoms 
The most frequent symptoms identified by over 40% of participants included dry 
skin, lack of energy, dry mouth, changes in skin, feeling sad, changes to fingers or toe 
nails, worrying, diarrhea, feeling drowsy, problems with sexual interest or activity, 
changes in facial hair growth, difficulty sleeping, feeling nervous, numbness or tingling 
in hands or feet, and feeling irritable.  The most distressing or prevalent symptoms were 
dry skin, lack of energy, worrying, changes to finger and toe nails, problems with sexual 
interest or activity, changes in skin, dry mouth, feeling sad, diarrhea, feeling nervous, 
feeling irritable, and changes in facial hair growth.  
These symptoms differ substantially from the typical set of symptoms associated 
with cancer treatment. Recognition of the unique symptom profile of the EGFRIs by 
health care providers is essential.  Recently, following a systematic review of the 
literature and consensus process, a panel of experts recommended a set of 12 symptoms 
to be included as patient-reported outcomes for clinical trials.  The group recommended 
that fatigue, insomnia, pain, anorexia, dyspnea, cognitive problems, anxiety, nausea, 
depression, sensory neuropathy, constipation and diarrhea be included in this dataset 
(Reeve et al., 2014). Approximately half of these symptoms are not relevant in to this 
study, but they are symptoms that have been prominent in oncology care for a prolonged 
period of time.  Whether all patients are best served by this core set of measures remains 
to be evaluated, and this study suggests that traditionally important symptoms may still 
be important, but are being eclipsed by the side effects of new treatments.  
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 Symptom prevalence and distress studies in oncology are limited by the 
instruments used to measure them, and most of the common symptom measurement 
batteries do not include symptoms relevant to the patient receiving EGFRI therapy.  This 
same scenario probably applies to other novel agents as well, so practitioners, educators, 
and researchers should be aware of this when reviewing and adopting assessment tools 
and instruments for research, as well as when consulting the literature for patient 
management issues.  
 Participant-identified symptoms.  Eleven participants responded to a question 
asking them to list other symptoms that did not appear on the study questionnaire. Two 
participants mentioned severe dry eye, with one describing it as very distressing and 
another noting that in interfered with vision, caused blurring and required the use of 
artificial tear drops and eye ointment at night.  One participant described “swollen eyelids 
with oozing quasi liquid that hardens into a dry crust,” and that was painful to remove. 
Another noted excessive nasal mucous that hardened into a crust that was also painful to 
remove. The additional symptoms identified by participants are similar to responses 
provided in an evaluation of the EGFRI-18, where nasal crusts and eye sensitivities were 
also among several additional suggested by patients (Boers-Doets et al., 2013).  These 
findings point to the need for possible ophthalmologic or oncodermatology referral for 
patients receiving EGFRI therapy.  
Several items appeared on the instrument but were understood differently by 
participants, so they were suggested as additions, including “fatigue” (lack of energy),  
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“rash” (changes in skin), and “changes to my eyebrows” (changes to hair growth on my 
face).  Other physical symptoms each mentioned by one participant included occasional 
long bone pain at night, lip swelling quite a bit, and feet hurting in the morning.  Finally, 
one participant offered “I don’t know what I am supposed to be doing with my life. 
Uncertainty, I guess.”  This comment underscores the existential plight of the patient with 
advanced cancer, and draws attention to the need to address not only physical, but 
psychological symptoms as well in assessment, care and research related to oncology 
patients.  
Additional work is needed to identify an optimal set of items to measure the 
EGFRI symptom experience, as the current study captured most, but not all relevant 
symptoms.  In future research on EGFRIs, more explicit reference to a rash that is more 
specifically described would be beneficial, rather than addressing it generally as changes 
in skin. Additional symptoms such as eye changes and crusting, changes in eyebrows, 
and nasal crusts should also be included. In the present study, more general items 
(changes to skin and changes to hair growth on my face) were chosen in an effort to 
minimize the number of variables, but they may not have fully captured the nuances of 
the dermatologic toxicities experienced by patients. Future studies could continue to 
refine the list of symptoms relevant to EGFRI therapy, and to explore the validity and 
reliability of a revised MSAS instrument, the MSAS-EGFRI. 
Study Aim 2 
Describe the quality of life, functional performance status and psychological 
status of patients receiving EGFRI therapy.   
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 As described in chapter four, participants in this study reported reasonably good 
quality of life, functional performance status and psychological well-being. The impact of 
EGFRI therapy on these outcomes was not consistent, with the most significant effects 
seen on dermatologic quality of life and psychological well-being, so these are areas that 
should be explored further.   
 Various instruments should be compared in order to identify the optimal 
measurement strategy for these outcomes.  Whether the EGFRI-18 is the best 
dermatologic quality of life instrument for this patient population remains an open 
question, so comparisons with other tools are suggested.  Future studies could compare 
the relative merits of the Skindex instruments with the EGFRI-18 in order to establish an 
optimal dermatologic quality of life measurement strategy in the setting of EGFRI 
therapy. The MHI-5 is a simple instrument that could be used more frequently in the 
clinical setting, and could also be compared to other instruments that assess 
psychological distress.  
Study Aim 3 
Identify any co-occurring symptoms or symptom clusters in patients receiving 
epidermal growth factor receptor inhibitors. 
Symptom Clusters 
Data derived from MSAS-SF (adapted) provided the basis for identification of 
symptom clusters using exploratory factor analysis. A three cluster solution was 
identified, including one symptom cluster similar to others previously identified (a 
psychological-cognitive cluster), a novel cluster possibly related to treatment 
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(dermatologic skin and hair cluster) that has not been previously identified in symptom 
cluster research, and a third cluster similar to previously described clusters (lack of 
energy, difficulty concentrating, feeling drowsy) but with a mucocutaneous component 
(dry mouth and other changes to fingers and toes), which may reflect the impact of 
EGFRI therapy and is labeled as a mucocutaneous and fatigue cluster.  The symptom 
clusters are identified here both by their factor number, indicating the order in which they 
were identified by factor analysis, and the descriptive name given to them to characterize 
the symptoms that grouped together.  All three of these clusters must be replicated using 
a larger sample and a longitudinal design. 
Factor 1, the psychological-cognitive cluster, comprised of feeling irritable, 
feeling nervous, worrying, feeling sad, difficulty concentrating, and “I don’t look like 
myself,” is similar to clusters described in other work, as stated in chapter four.  Although 
there are several similar clusters described in the literature, they are not identical, largely 
due to differences both in instrumentation (instruments with fewer or different 
symptoms) and in the sample (e.g. all breast cancer patients). These psychoneurologic 
clusters often include sleep disturbances, as well as anxiety, depression and other mood-
related symptoms.  However, despite some variation in specific symptoms, this type of 
symptom cluster does seem to be prevalent and consistent across many different studies 
(Kirkova, Walsh, Aktas, & Davis, 2010; Jiménez et al., 2011; Kirkova, Aktas, Walsh, & 
Davis, 2011; Yennurajalingam et al., 2013; Thomas et al., 2014), and is consistent with 
the experience of living with advanced cancer. 
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Researchers have theorized that clusters including emotional or behavioral 
symptoms and general sickness symptoms may be attributable to underlying 
psychological or neurological dysfunction (Kim, Barsevick, Fang, & Miaskowski, 2012), 
with the suggestion that a common biological pathway, such as proinflammatory 
cytokines, the hypothalamic-pituitary-adrenal axis system and the 5-HT system, may 
contribute to the development of these symptoms.  Sickness symptoms have been linked 
to cytokine neuroimmunologic mechanisms (Lee et al., 2004; Myers, 2008), as has been 
demonstrated in the animal model, with comparisons drawn to the responses seen in 
oncology patients (Cleeland et al., 2003).   
Although definitive work in this area remains to be conducted (Dantzer, Meagher, 
& Cleeland, 2012), those experienced in caring for oncology patients recognize that these 
symptoms often cluster together.  Symptoms such as fatigue, reduced appetite, sleep 
disorders, and altered mood and cognition may be related to the expression of 
inflammatory mediators that can affect the brain and the subjective symptom experience 
(Dantzer, O’Connor, Freund, Johnson, & Kelley, 2008). Beginning evidence that EGFRIs 
play a role in cytokine regulation has been published  (Paul et al., 2014).  In vitro work in 
EGFRI-treated head and neck cancer cells suggested that EGFRIs are associated with the 
production of proinflammatory cytokines, but the mechanisms for this need to be more 
fully explained and then explored in the clinical setting (Fletcher et al., 2013).   
Factor 2, a possibly treatment-related dermatologic skin and hair cluster has not 
been described before in symptom cluster research using factor analytic procedures.   
This cluster includes dry skin, changes in eyelashes, hair loss, changes in facial hair 
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growth and other changes in scalp hair. Notably, nail changes and changes in fingers and 
toes did not correlate with the other symptoms in this cluster, which is an unexpected 
finding. As noted in chapter four, other treatment-related and diagnosis-related symptom 
clusters have been described, but no EGFRI-related clusters have yet been identified 
using factor analytic techniques or any other statistical approach. This work represents 
the first documentation of a symptom cluster that appears to be associated with EGFRI 
therapy, and this finding should be replicated in a larger sample. 
Other treatment-related symptom clusters have been previously described in 
various patient populations (Honea, Brant, & Beck, 2007; Kirkova et al., 2011), such as 
in  patients receiving chemotherapy (Aprile, Ramoni, Keefe, & Sonis, 2008; Yamagishi, 
Morita, Miyashita, & Kimura, 2009; Hockenberry et al., 2010; Baggott et al., 2012); 
chemoradiation (Wang et al., 2006) and radiation therapy (Kim et al., 2009b; Kim et al., 
2009a), but not in patients receiving EGFRIs.  Treatment-related clusters have also been 
identified in patients with breast cancer (Kim, Barsevick, Tulman, & McDermott, 2008); 
in head and neck cancer, with symptoms including radiodermatitis, dysphagia, pain, taste 
disturbance, fatigue, radiomucositis, and dry mouth (Xiao et al., 2013); in patients treated 
with specific therapies for liver cancer, as evidenced by a gastrointestinal symptom 
cluster with higher severity scores (Wang, O'Connor, Xu, & Liu, 2012); with brain 
tumors, including a language cluster and a mood cluster (Gleason, et al., 2007);and in 
patients with prostate cancer where bowel and bladder symptoms were observed 
(Maliski, Kwan, Elashoff, & Litwin, 2008).  
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Factor 3, a mucocutaneous and fatigue cluster, includes dry mouth, other changes 
to fingers or toes, feeling drowsy, lack of energy and difficulty concentrating. While lack 
of energy, dry mouth and psychological symptoms have long been documented in 
oncology patients, skin and nail changes have not been commonly reported in previous 
work.  Skin, hair and nail issues, as well as mucocutaneous symptoms, have emerged as 
key problems for intervention in this population of patients, so their inclusion in a 
symptom cluster is an important finding.  Aside from the symptom other changes to 
fingers and toes, clearly linked to EGFRI therapy, this symptom cluster could also be 
related to the same proinflammatory mechanisms described above in the discussion on 
Factor 1.  
Others have described similar clusters (without the changes to fingers or toes) that 
include feeling drowsy and lack of energy, albeit with some variation in the symptoms 
secondary to instrumentation. Similar fatigue-related clusters have included  lack of 
energy, feeling drowsy, difficulty sleeping, problems with urination, feeling irritable 
(Kim et al., 2009a);  pain, lack of energy, feeling drowsy, difficulty sleeping, and  sweats 
(Kim et al., 2009b); fatigue, sleep disturbance, lack of appetite, and drowsiness (Chen & 
Tseng, 2006); fatigue, weakness, anorexia, lack of energy, dry mouth, early satiety, 
weight loss, and taste change (Walsh & Rybicki, 2006); sadness, dry mouth, drowsiness, 
shortness of breath, sleep disturbance, appetite changes, fatigue, pain, and numbness 
(Wang, Tsai, Chen, Lin, & Lin, 2008). 
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Findings Contrary to Previous Studies 
Contrary to previous work in symptoms clusters (Chen & Lin, 2007; Fan et al., 
2007; & Skerman, Yates, & Batistutta, 2012), gastrointestinal symptoms were not 
reported by a majority of patients, and no appetite or gastrointestinal symptom cluster 
was identified in the present study.  In previous studies, an array of different 
gastrointestinal clusters have been documented, often including nausea and vomiting, 
lack of appetite, feeling bloated, dry mouth, changes in the way food tastes, and similar 
symptoms (Cherwin, 2012), often associated with chemotherapy or radiation therapy.  
However, in the present study, the majority of patients did not receive concurrent 
chemotherapy.  
Dry mouth was a very prevalent and distressing symptom for participants in this 
study, experienced by over 57%, and ranked fifth in distress.  However, it did not seem to 
cluster with other gastrointestinal symptoms.  Although diarrhea and changes in the way 
food tastes were experienced respectively by 48.2 and 39.3% of participants, these 
symptoms also did not correlate strongly with other gastrointestinal symptoms, or even 
any other symptoms at all as they were not retained in factor analysis.   
Other symptoms long associated with cancer therapy, including weight loss, lack 
of appetite, nausea, mouth sores, constipation, feeling bloated, and vomiting, also did not 
occur in a majority of participants.   Perhaps these findings may be a function of the 
smaller sample size, so it is possible that with a larger sample, such symptoms would 
have emerged with greater frequency.  However, this variation from previous research is 
likely explained by the prevalence of targeted therapies in this sample, with only 19 
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participants reporting that they were also receiving additional therapies, as described in 
chapter four, and of this group, only 8 were receiving drugs classified as chemotherapy, 
while two reported receiving concurrent radiation therapy.  
Study Aim 4 
Explore the relationships between any identified symptom clusters and key 
variables, including gender, age, primary cancer diagnosis, EGFRI, and the outcome  
variables of quality of life, functional performance and psychological status.   
 No consistent relationships were identified between any demographic or clinical 
variables, although the distress and prevalence of several symptoms did vary on the basis 
of gender, primary cancer diagnosis, and specific EGFRI therapy.  For example, dry 
mouth was most distressing in head and neck and colorectal cancer patients, who are 
likely to be receiving MOABs, and diarrhea was more common in breast cancer patients 
who could be taking lapatinib.  Gender played a role with regard to some symptoms. Men 
reported more symptoms, and were more likely to report lack of energy, dry mouth, 
problems with sexual interest or activity and dry skin, while women were more likely to 
report worry.  The finding with dry skin is interesting, and may suggest that men are less 
likely to apply lotions and creams as part of routine skin care, so they may need to be 
educated to do so.  
Symptom Clusters and Outcomes 
The relationships between the identified symptom clusters and the outcome 
measures were explored to determine any differing impact of symptom clusters with the 
intention of generating hypotheses for further exploration.  This study is among the first 
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to explore how symptom clusters, including a newly identified symptom cluster, affect 
quality of life, psychological status, and performance.  Although the findings here are 
preliminary, it appears that different symptom clusters can impact outcomes to varying 
degrees. Identifying those symptom clusters that create the most negative impact on 
performance and other outcomes would be beneficial for patients.  
For example, the association between the psychologic-cognitive symptom cluster 
and adverse psychological status should be confirmed, providing evidence of the need for 
more widespread implementation of psychosocial interventions for patients with cancer.  
The effect of symptoms on performance, as postulated in the theory of unpleasant 
symptoms, was demonstrated by a patient comment reflecting the unique impact of 
dermatologic symptoms associated with EGFRI therapies.  This narrative offered by a 
participant highlights the distress and inconvenience of both skin and nail issues, and 
underlines how performance of everyday activities and recreational pursuits can be 
affected: 
The problem with my fingernails sometimes gets so bad that I cannot use a knife 
and fork.  The limitation of having to stay out of the sun has resulted in my giving 
up golf, biking and vacations at beach.  I run from the sun and must wear a hat at 
ALL times. I find this very confining. 
 
Other studies have demonstrated a negative impact in subgroups of patients with 
high levels of predetermined symptoms on functional status and quality of life 
(Miaskowski et al., 2006; Pud et al., 2008; Dodd et al., 2010), but these studies explored 
an a priori symptom cluster of fatigue, sleep disturbance, depression and pain. For 
example, Miaskowski et al. (2006) found that in participants reporting “all high” levels of 
symptom severity for pain, fatigue, sleep disturbance and depression reported a lower 
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quality of life and lower functional status in contrast to those who reported less symptom 
severity.  Future studies with larger samples could evaluate high, moderate and low 
distress in symptom clusters to explore the impact on outcomes.  To some extent, this 
was addressed by comparing symptom cluster members to those without the symptom 
cluster, but this work could be extended.  
Future work in this area could also address the concept of the sentinel symptom, 
which is defined as a candidate symptom that heralds the presence of a symptom cluster 
(Brown et al., 2011), and could further explore the role of age and gender. Based on the 
factor loadings in the present study, the symptoms of feeling nervous, dry skin and 
changes to fingers and toes could be possible sentinel symptoms that could signify other 
symptoms that cluster together.  Assessment strategies that call attention to such sentinel 
symptoms could help prioritize which symptoms to focus on in clinical encounters.  
Limitations 
 
This exploratory study is a preliminary work, and as such, has several significant 
limitations, but perhaps the most relevant to its validity is inherent self-selection. The 
“passive” study recruitment strategy could result in selection bias affecting the findings. 
When respondents opt in to research, there may be pre-existing differences between study 
participants and others who either choose not to participate or who are unaware of a 
study. However, participants may be more likely to self-select when the research is about 
something that affects them.  Women are more likely to complete health-related surveys 
(Eysenbach & Wyatt, 2002), which is reflected in the study sample. Specific issues 
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related to the sample characteristics that impact the validity of this study are outlined 
below. 
Sample Characteristics 
A number of sample characteristics in this study may limit applicability to the 
general population of patients receiving EGFRI therapy, including sample size, 
educational status, social engagement, performance status, and gender.   
Small Sample Size 
Because a larger sample size (n =100) was sought, this study primarily used a 
web-based survey.  This approach was designed to facilitate recruitment and study 
enrollment from a broad population, and the majority (80%) did complete the study 
online.  Participant recruitment occurred over an eleven month time frame, and multiple 
direct and indirect recruitment strategies were utilized.  Recruitment materials were 
posted at multiple sites online, on a study web site, and at cancer support locations; letters 
explaining the study and research flyers were mailed to a large number of practitioners. 
Despite multiple study recruitment procedures over an extended time period, however, 
the desired sample size could not be accrued, so this may limit both the internal and 
external validity of the study.   
Performance Status 
Even with advanced disease, most participants were well enough to use a 
computer or to complete a paper survey.  In addition, most reported a good performance 
status, so the findings of this study are applicable to patients with a similar performance 
status and may not reflect those whose performance is compromised by illness.  
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Participants who completed the study online were well enough to use technology to 
access information and support; those with a limited performance status may not have 
spent the time online that would lead them to study recruitment materials, or they may 
have begun the study, but did not complete it. In addition, those who received recruitment 
flyers from their health care provider may also have had a better performance status, as 
sicker patients may not have been told about the study. 
Race and Ethnicity 
As this was an exploratory study, questions about race and ethnicity were not 
included.  In future work, this information, along with skin phenotype, could be included.  
There is a possible link between skin phenotype and increased skin toxicity (Lacouture, 
2006), as noted in chapter two.  At least one study suggests that erlotinib skin toxicity is 
associated with skin phenotype (Luu et al., 2011), so consideration of this patient 
characteristic could be an area for additional study related to EGFRI-related skin 
symptoms.  
Educational Level and Access to Technology 
Computer literacy and greater comfort with online activities may be associated 
with educational level, so it is possible that the study sample was self-selected with 
regard to comfort with online activities, impacting the external validity of these findings. 
Although a recent survey suggests that over 80% of the US population uses the Internet, 
including an equal number of men and women, there are variations in terms of utilization 
with respect to age, educational level, ethnicity, and household income ("The Web at 
25.," 2014).  Participants in this study were highly educated, with most reporting a 
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college education, so findings may not apply to those with less education or less 
computer literacy. 
Support Group Engagement 
 Because study information was posted in various cancer support groups and in 
cancer support settings, the study may also be biased to reflect the experience of 
participants who are more socially engaged rather than those who are isolated and not 
connected to live or online support groups.  Patients who participate in support groups 
have been described as more likely to be female, younger, educated, without a partner, 
and with more formal support than those who do not choose to participate in such groups 
(Grande, Myers, & Sutton, 2006).  With the exception of partner status, this sample 
reflects these characteristics.   
Although the research on support group engagement is inconsistent, what is 
available suggests that  a minority of patients express an interest in becoming engaged 
with support groups of any kind, whether live or online (Van Uden-Kraan et al., 2011).  
A recent study reported that only about one-third of lung cancer patients planned to 
participate in support groups  (Xu et al., 2014), while another survey of NexCura panel 
participants indicated that only about 25% of patients participated in support groups 
(Morse, Gralla, Petersen, & Rosen, 2014).  As the latter sample was drawn from a 
population of patients who agreed to be a part of an online research panel (inactive as of 
this writing), it is likely that this estimate is high and far fewer patients actually do 
participate in cancer support groups.  Many online studies utilize panels for recruitment, 
and this option was explored with the current study, but was cost-prohibitive.  With 
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funding, a more purposeful sampling strategy could be implemented to reflect 
demographics of patients receiving EGFRI therapy. Since this study was launched, 
additional options for research participant recruitment have become available, and could 
be used in the future.  
Cross-Sectional Design 
Consistent with the descriptive nature of this study, a cross-sectional design was 
used, so changes in symptom clusters over time were not assessed.  The natural course of 
symptoms associated with EGFRI therapy may evolve over time, so this snapshot of the 
patient experience does not characterize its changing course.  The temporal evolution of 
EGFRI-related symptoms is discussed below.  
 Skin changes.  Skin changes, such as folliculitis, are monomorphic, suggesting 
that lesions develop simultaneously at a point in time (Sinclair, 2014). Palliation of these 
changes in order to enhance adherence to therapy may be essential to optimal treatment 
outcomes. More experience has been gained with prophylactic treatment, so it is possible 
that patients in this study benefited from the suggested therapies. Over half of patients 
reported using a special cream, and about one-third indicated that they were receiving a 
medication for treatment of skin changes.  
 Dry skin.  The onset of dry skin (xerosis) often occurs after four weeks of 
therapy, but will increase over time as therapy continues, with almost all patients 
demonstrating this symptom after six months of treatment (Lacouture & Lai, 2006; 
Mitchell, Perez-Soler, Van Cutsem, & Lacouture, 2007; Osio et al., 2009; Sinclair, 2014). 
Because the study was cross-sectional, the extent of dry skin experienced by patients 
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receiving EGFRI therapy in this sample may be underestimated.  However, it is the most 
commonly occurring symptom reported, experienced by about 70% of participants.  
Utilizing a longitudinal approach, this percentage could be significantly higher.   
 Nail changes.  Incidence of paronychia also increases over time, so nail changes 
could be more prevalent in with a longitudinal time frame (Chanprapaph et al., 2014), 
and may be a more distressing and frequent symptom as time on therapy increases.  
 Hair changes.  Hair changes are considered a late toxicity and would also be 
more pronounced after several months of therapy. Therefore, hair changes could become 
a more prevalent symptom over time, a finding that would be noted with a longitudinal 
study design.  Patients treated over six months experience many different changes to hair 
texture and growth, as well as alopecia that can affect the scalp and other areas of the 
body. Although well over a third of participants reported various changes in hair growth, 
the frequency of these changes could also be significantly greater over time.  
Interestingly, there is a tendency for hair growth on the face to increase, particularly in 
patients who receive erlotinib, as well as for changes to occur in eyelashes, with most of 
these changes occurring between 4-8 weeks of therapy and persisting over time (Wu et 
al., 2011).   
Given the changing nature of the symptoms associated with EGFRIs, whether the 
impact of these symptoms on quality of life, functional performance and psychological 
status would be different over time is a question that could be pursued in future research. 
All of these outcomes could be positively impacted by successful therapy, as well as 
adversely affected by failing therapy, so a longitudinal time frame would capture these 
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changes. In addition, more research about basic demographic variables, such as age and 
gender, could reveal new insights into the symptom experience in patients treated with 
EGFRIs.  
Measurement Issues 
 In this exploratory study, a key aim was to describe the symptom experience of 
patients receiving EGFRIs. The MSAS-SF was adapted to include additional symptoms 
associated with EGFRI therapy, including dry skin, changes to my finger or toe nails, 
changes in hair growth on my face, other changes to scalp hair, changes in my eyelashes 
and other changes to my fingers and toes. The results indicate that the EGFRI symptom 
experience differs from that traditionally associated with cancer therapy. Many of the 
symptoms listed on the original MSAS-SF were not selected by respondents to this 
survey, and future studies might include fewer items, eliminating those experienced by 
few patients.  Additional items, as suggested by participants, could include dry eyes, eye 
discharge and crusting, changes to eyebrows, changes to hair texture, eyelid changes, 
itchy scalp, rash and nasal changes. 
 In preparation for this study, the Skindex instruments were reviewed for possible 
inclusion in the study (Chren, Lasek, Quinn, Mostow, & Zyzanski, 1996; Chren et al., 
1997; Chren, Lasek, Sahay, & Sands, 2001).  As the Skindex instruments were not 
specific to this type of oncologic therapy, and were designed for quality of life 
measurement in general dermatologic practice, an instrument specifically designed for an 
oncology population was selected instead.  It would be interesting to revisit these 
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instruments and evaluate them against the FACT-EGFRI-18 in measuring dermatologic 
quality of life in patients receiving EGFRIs.  
As noted in chapter four, the items in the EGFRI-18 selected by most participants 
were included in the Physical subscale (e.g. “My skin or scalp itches,” “My skin or scalp 
feels dry,” “My skin or  scalp feels irritated,” “My eyes are dry.”) or reflected a response 
to a physical symptom (“I am bothered by hair loss.”)  
Implications for Nursing 
Practice 
This exploratory study of the symptom experience of patients receiving EGFRIs 
represents the first attempt to more fully characterize the multidimensional effects of this 
treatment on the whole person and not just on hair, skin and nails.   Previous work has 
been focused primarily on dermatologic side effects of treatment while performance, 
quality of life and psychological well-being have not been holistically assessed (White et 
al., 2011). The present study underscores that although skin, hair and nail changes are 
prominent components of this experience, other symptoms may also be frequent and 
patients would benefit from thorough, systematic assessment and from effective palliative 
and preemptive management.  With an average of 11 symptoms reported by patients in 
this sample, the question is raised as to whether clinicians are addressing that number of 
symptoms in the course of routine care, and if not, how are patients navigating their 
symptom experience?  
As part of the recruitment process for this study, many patient support and 
information sites were visited by the researcher.   Common topics of conversation on 
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these sites included rash and other skin, nail, and hair changes, with patients exchanging 
suggestions and their own experiences.  Some mentioned that their nurse or physician 
provided guidance to them, but many were turning to the wisdom of experienced group 
members for practical suggestions.  If this is where patients gather their self-care 
information, that may be empowering to patients, but it does reflect possible missed 
opportunities for nursing care to guide patients to evidence-based care management 
strategies.  
Consistent with exemplary oncology nursing practice, holistic assessment of the 
patient experience should be the basis of comprehensive patient care that incorporates 
multiple disciplines. Identification of co-occurring symptoms or symptom clusters should 
be a priority in order to streamline and deliver care more effectively and economically. 
Nurses should be aware of the most common and the most distressing symptoms 
experienced by patients, and should be aware of the concept of symptom clusters and 
how to assess them.   
This study suggests that outcomes such as quality of life, performance and 
psychological status may be impacted differently depending on the constellation of 
symptoms, or symptom clusters, that patients may be experiencing.  An awareness of the 
impact of symptom clusters on specific outcomes can guide busy practitioners to provide 
tailored and pre-emptive support, education and self-management strategies for patients 
based on their symptom experience.    
Psychosocial assessments, in particular, should be undertaken with all patients 
receiving these therapies. The first factor to emerge in factor analysis procedures was the 
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psychological-cognitive cluster, which suggests that patients on EGFRI therapy should be 
evaluated as to their psychological status across the treatment continuum. A variety of 
brief screening tools for assessing anxiety, depression and psychological status are 
available, and their implementation at various points along the EGFRI therapy trajectory 
could help identify patients with issues related to psychological status.    
Nursing interventions for the psychological-cognitive cluster could include a set 
of interventions such as skin toxicity management (e.g. antibiotics and topical therapies), 
cognitive behavioral strategies (Wagner & Lacouture, 2007), a telephone or online 
support group, a sleep hygiene plan (pharmacologic and non-pharmacologic), a plan for 
energy conservation, and an exercise program.  This anticipatory guidance would be an 
improvement over the prevailing standard of care which tends to focus primarily on skin 
issues, which if severe enough, might generate a referral for dermatologic care or 
psychological support. Helping patients to continue therapy through enhancing their 
coping skills and by addressing symptoms and associated quality of life issues could 
improve adherence and the effectiveness of treatment.  
Education 
A paradigm shift in the education of oncology nurses to embrace a wider range of 
treatment-related symptoms is underway and should continue as new therapies emerge. 
Competency in the assessment and management of skin, hair and nail changes, as well as 
other symptoms caused by EGFRIs, should be fostered in settings where EGFRIs are 
included in patient treatment plans.  In addition, wider dissemination of the recommended 
management strategies for EGFRI side effects is necessary. Although some patients 
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require referral to dermatologists, nurses working at the top of their licensure are capable 
of making patient self-care recommendations, as well as advising patients about over the 
counter products,  as long as they have participated in continuing education and 
professional development regarding these symptom management strategies. When 
medical management is necessary, the astute nurse can be instrumental in making timely 
referrals.  
Patient education materials highlighting proactive symptom management and 
preventive care strategies should be included in the teaching materials for  patients who 
are receiving EGFRI therapy. As each individual patient may have varying needs based 
on occupation, social roles, activities of daily living, and lifestyle considerations, nurses 
should be attuned to how high frequency and highly distressing symptoms may impact a 
given patient and should augment patient education accordingly.  For example, 
individuals who use their hands frequently in their work, such as homemakers, nurses or 
other health care workers, massage therapists, restaurant workers, clerical and retail staff, 
hospitality and service workers, mechanics and others, as well as those who enjoy 
hobbies requiring manual work like gardening or fishing, are at particular risk for 
exacerbation of EGFRI-related issues.   
Research 
 Skin, hair and nail changes are frequently experienced by patients receiving these 
therapies, but evidence-based therapies are lacking for many of the symptoms. Dose 
modifications and therapy interruption may occur in a significant number of patients 
(Boone et al., 2007), so optimal preventive and management strategies will provide a 
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basis for optimal therapy.  Most recommendations for EGFRI symptom management are 
anecdotal in nature and have not been rigorously evaluated, with some exceptions.  
The Multinational Association for Supportive Care in Cancer (MASCC) Skin 
Toxicity Study Group recently published clinical practice guidelines for the prevention 
and treatment of dermatologic toxicities (Lacouture et al., 2011). Although some of the 
guidelines are based on research, other recommendations are based on expert opinion and 
panel consensus due to a lack of relevant studies.  As noted by MASCC, data from other 
similar skin conditions provided the basis for some recommendations; as a result, it is 
entirely possible that outcomes from these treatments may not be optimal for the 
dermatologic changes caused by EGFRIs. As a result, many opportunities for 
interventional and comparative effectiveness trials remain. 
Nurses have long managed patients’ skin conditions, and oncology nurses have 
claimed symptom management as their forte.  Since patients report itchy, dry, flaky and 
irritated skin, changes in hair, and changes in fingers and toes frequently, nurse-led 
protocols to ameliorate these symptoms should be evaluated in partnership with 
practitioners with dermatologic experience.  While many of the interventions suggested 
by MASCC are pharmacologic agents, many are not, so teams including dermatologists, 
advanced practice nurses and oncology nurses could collaborate on research evaluating 
these treatments. Such interdisciplinary work would be an ideal approach to generating 
evidence-based care protocols.  Implementation of funded, longitudinal research is also 
essential in order to document not only the trajectory of the symptom experience of 
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patients receiving EGFRIs, but also to determine optimal points for intervention across 
the treatment continuum.  
In a sample of colorectal cancer patients receiving panitumumab and combination 
chemotherapy, a pre-emptive skin treatment regimen that included skin moisturizer, 
sunscreen, topical steroids, doxycycline, and an educational video aimed at minimizing 
skin irritation, was compared to a reactive treatment protocol.  Participants kept a diary of 
symptoms that also recorded treatment compliance (Lacouture, Mitchell, et al., 2010).  
Results indicated that patients receiving the pre-emptive regimen experienced a 
significantly lower rate of > Grade 2 or greater skin toxicity (29% vs. 62%).  The reactive 
treatment group demonstrated a greater decline in quality of life scores.  Although this 
regimen only evaluated one EGFRI, the findings are encouraging and might be evaluated 
with other therapies.  Interestingly, diarrhea was also lessened in the pre-emptive 
treatment group, most likely due to treatment with an antibiotic, providing an example of 
how a set of interventions could target multiple symptoms.  
Cognitive-behavioral strategies that address the psychological impact of 
symptoms associated with EGFRIs could be evaluated in collaboration with 
psychologists and social workers as a strategy to address multiple symptoms, such as 
those represented in the psychological-cognitive cluster.   Cognitive-behaviors skills can 
help patients to cope with physical discomfort, and also with mood-related symptoms 
(Wagner & Lacouture, 2007), such as worrying or feeling nervous, and could impact 
overall performance outcomes as well.  Specific strategies, such as symptom reframing 
and positive imagery, have been described (Wagner & Lacouture, 2007).    
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As noted in the discussion on Factors 1 and 2, exploration of the underlying 
mechanisms of the psychological-cognitive cluster and the general sickness cluster, 
including the role of cytokines, is an area for future research.  
Conclusion 
In summary, this study has added to nursing science in several key areas. First, 
the symptom experience of patients receiving EGFRIs has been more fully characterized. 
Evidence has been presented that those patients who receive EGFRI therapy experience a 
significant symptom burden related to their disease and treatment that includes 
dermatologic symptoms, but also includes a wide variety of other symptoms that require 
assessment and management, such as mood and affective symptoms. Not all symptoms 
that are common in the oncology patient population are relevant in these patients, and 
other symptoms that are less well recognized can cause distress and impact performance.  
In addition, psychological symptoms should be assessed as they are commonly 
experienced by patients receiving EGFRIS. Future work should include updated 
symptom instruments that incorporate high frequency symptoms associated with specific 
therapies.  
Secondly, three symptom clusters have been identified in this patient population: 
a psychological-cognitive cluster, which can impact psychological status; a treatment-
related dermatologic cluster with skin and hair changes that has not been previously 
identified as a symptom cluster; and, a mucocutaneous and fatigue cluster which can 
affect performance and elements of QOL and which included a treatment-related 
symptom not previously included in similar clusters. The identification of these symptom 
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clusters offers an opportunity to explore interventions that impact more than one 
symptom and which may enhance care while reducing costs.  
Finally, the theory of unpleasant symptoms (TOUS) provided a multidimensional 
infrastructure for the measurement of symptoms and their impact on outcomes in patients 
receiving EGFRIs. In the TOUS model, a synergistic effect occurs when several 
symptoms are experienced simultaneously and have a multiplicative effect (Lenz et al., 
1997).  Interaction between and among concurrent symptoms resulted in different 
impacts on outcomes, supporting a basic premise of the model. In addition, the notion 
that psychological symptoms should be included in the model, separate and apart from 
psychological influencing factors, was enhanced through this work.  Future work can 
explore and test whether interventions aimed at psychological symptoms can ameliorate 
or modify other symptoms and the subsequent performance outcomes experienced by 
these patients. 
 Future studies should include larger samples, equal numbers by gender, and a 
longitudinal design in in order to confirm the findings of the current study. Because there 
were variations in symptoms experienced by patients receiving TKIs vs. MOABs, future 
studies could compare symptom clusters between these groups in order to further refine 
identified symptom clusters and to enhance tailoring of symptom management 
interventions. Careful evaluation and comparison of instruments to assess symptoms in 
this group of patients should be undertaken, as it is possible that the ideal instrument does 
not exist, and could be developed or further refined in future work. Evaluation of the 
available instruments for dermatologic quality of life is recommended.   In addition, more 
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comprehensive assessment of patients receiving EGFRIs should be undertaken in order to 
identify effects of therapy on psychological status and all facets of quality of life. Care 
management strategies for skin, nail and hair changes should be evaluated in 
interventional studies that include both physiologic and psychological assessments.  
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PSYCHOLOGICAL SYMPTOMS OVERALL 
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N = 56 
 Mean Std. Deviation 
Dry skin  1.757 1.4902 
Lack of energy  1.657 1.3802 
Worrying  1.607 1.2746 
Changes to my finger or toe nails  1.429 1.4925 
Problems with sexual interest or activity  1.429 1.6552 
Changes in skin  1.414 1.3814 
Dry mouth  1.386 1.4269 
Feeling sad  1.357 1.1666 
Diarrhea  1.286 1.5077 
Feeling nervous  1.232 1.1907 
Feeling irritable  1.196 1.1349 
Changes in hair growth on my face  1.100 1.3522 
Changes in the way food tastes  1.057 1.3991 
Difficulty sleeping  1.029 1.2646 
Numbness/tingling in hands/feet  1.000 1.3495 
Hair loss  .971 1.4206 
Changes in my eyelashes  .929 1.3796 
Other changes scalp hair  .929 1.3014 
Feeling drowsy  .914 1.1760 
Difficulty concentrating  .829 1.2009 
Weight loss  .786 1.2440 
Itching  .757 1.1459 
Cough  .729 1.1342 
Pain  .700 1.1320 
Other changes to my fingers or toes  .686 1.2340 
Mouth sores  .686 1.3072 
Lack of appetite  .671 1.1083 
Shortness of breath  .614 1.1415 
“I don't look like myself”  .557 1.1809 
Nausea  .543 .9167 
Constipation  .457 .9262 
Difficulty swallowing  .443 1.0110 
Dizziness  .314 .7423 
Sweats  .286 .7062 
Feeling bloated  .257 .7795 
Vomiting  .186 .6288 
Swelling of arms and legs  .186 .5706 
Problems with urination  .157 .5588 
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N = 55 
 Percent  (n)   Mean, SD  
Physical  
 
I am bothered by a change in my skin’s sensitivity to 
the sun.  
 
  29 (16)  2.84 (1.36)  
 
My skin or scalp itches.  
 
76 (42)  2.31 (1.32)  
My skin bleeds easily. 
 
53 (29)  3.02 (1.15)  
My skin or scalp is dry or “flaky.”  
 
80 (44) 2.07 (1.35)   
My skin or scalp feels irritated.  
 
76 (42) 2.53 (1.20)  
My eyes are dry.  64 (35)  2.62 (1.37)  
I am bothered by sensitivity around my fingernails or 
toenails. 
31 (17)  2.51(1.43)  
 
Social/emotional 
 
My skin condition affects my mood.  
 
35 (19)  3.45 (.899)  
I feel unattractive because of how my skin looks.  35 (19)   3.29 (1.15)  
I am embarrassed by my skin condition.  
 
44 (24)   3.27 (1.05)   
I avoid going out in public because of how my skin 
looks. 
 
16 (9)  3.69 (.79)  
I am bothered by increased facial hair.  
 
44 (24)  3.02(1.31)  
I am bothered by hair loss.  55 (30)  2.71 (1.46)  
Functional  
My skin condition interferes with my social life.  
 
18 (10)  3.29 (1.15)   
Sensitivity around my fingernails makes it difficult to 
perform household tasks. 
 
47 (26)    2.96 (1.31)  
My skin condition interferes with my ability to sleep. 
 
15 (8)         3.76 (.693)  
Changes in my skin condition make daily life difficult. 
 
27 (15)            3.6 (.74)  
The skin side effects from treatment have interfered with 
household tasks.  
29 (16)           3.55 (.84)  
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NAME of HEALTH CARE PROFESSIONAL 
ADDRESS 
Dear Dr. or Nurse: 
I am writing to tell you about an oncology nursing research study being conducted as part of my 
doctoral nursing program at Loyola University, Chicago.   As an oncology clinical nurse 
specialist certified as an advanced practice nurse in oncology, I am interested in learning how to 
help patients manage the symptoms associated with their cancer treatment. This study is an 
anonymous survey that focuses on the symptom experience of patients receiving epidermal 
growth factor receptor inhibitors (EGFRIs) as part of their therapy.   As you know, the 
dermatologic symptoms associated with EGFRIs have been studied, but less is known about the 
overall impact of these treatments on the development of other symptoms, such as pain and 
insomnia, and on health-related quality of life.  
I am asking for your help in identifying patients who may meet the following criteria: 
• At least 18 years old 
• Currently taking one of these medications: cetuximab (Erbitux®), panitumumab 
(Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), and lapatinib (Tykerb®) for at 
LEAST FOUR WEEKS 
• Able to read and understand English 
• Willing to complete an anonymous online or paper survey  
• NOT diagnosed with a skin condition NOT related to treatment, such as acne 
vulgaris, erythema multiforme, psoriasis, or rosacea 
Participation in the study would involve completion of online OR paper instruments.  The survey 
instruments will take no longer than 20-30 minutes to complete. There are no interventions 
associated with this study, and no blood samples or other lab work will be performed.  No 
personal health information or other identifying information will be collected, and participants 
will not be asked for your name or the name of any care providers. 
We hope that the study will benefit future patients receiving these medications. 
Please contact me at 224-735-1118 for questions about the study.   Several patient flyers are 
included in this mailing, so if you have patients who you feel would be appropriate for 
participation, please share this information with them.  Patients may contact me directly if they 
have any questions or an interest in participating and I will pre-screen them for the study.   
Thank you in advance for considering this request for assistance in identifying patients eligible 
for this study.  
Sincerely, 
Josie Howard-Ruben, MS, RN, APN-CNS, AOCN, CHPN  
Doctoral Student, Loyola University 
XXXXXXX(VM)  
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The Symptom Experience of Patients Receiving Epidermal Growth Factor Inhibitors 
(EGFRIs) 
 
 
Would you like to be part of a nursing research study that explores the symptom experience of 
patients who take EGFRIs as part of their cancer treatment?  
EGFRIs include drugs such as cetuximab (Erbitux), panitumumab (Vectibix), erlotinib (Tarceva), 
gefitinib (Iressa), or lapatinib (Tykerb).  
These medications are used to treat several cancers such as breast cancer, colon cancer, head and 
neck cancer, lung cancer, and pancreatic cancer.  
• Are you at least 18 years old? 
• Are you currently taking one of these medications: cetuximab (Erbitux®), panitumumab 
(Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), and lapatinib (Tykerb®)? 
• Have you been taking this medication for AT LEAST FOUR WEEKS? 
• Able to read and understand English? 
• Are you willing to complete an anonymous online or paper survey?  
• Are you NOT diagnosed with a skin condition NOT related to treatment, such as acne 
vulgaris, erythema multiforme, psoriasis, or rosacea? 
If you answered YES to these questions, you may be eligible to participate in a nursing research 
study. 
The purpose of this trial is to create a complete picture of the symptoms experienced by patients 
receiving drugs classified as epidermal growth factor inhibitors (EGFRIs).  These drugs may 
cause skin, nail, and hair changes, as well as other symptoms.   
This study will explore the impact of these symptoms on patient well-being and quality of life.  
To participate in the study, you will complete an anonymous survey.  The survey will take about 
20-30 minutes to complete. 
This study is being conducted as part of a doctoral nursing program at Loyola University, 
Chicago.  
For information and to be screened for participation, please call Josie Howard-Ruben at 224-
XXXXX or email XXXXX@luc.edu.  
 
  
166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX E 
 
WEB SITE CONTENT 
 
 
167 
 
 
 
Home page  
The Symptom Experience of Patients Receiving Epidermal Growth Factor Receptor 
Inhibitors (EGFRIs)  
This nursing research study explores symptoms experienced by patients who are taking 
EGFRIs, and is being conducted by a doctoral nursing student at Loyola University, 
Chicago. 
We are interested in learning more about the symptoms experienced by patients who take 
EGFRIs, as well as the impact of these symptoms on quality of life and well-being.  
If you are taking one of these medications for cancer, you may qualify to participate in 
this study.  Please click on the STUDY PARTICIPATION link at the top of this page.  
If you would like more information, of you have questions about the study, please click 
on the link FOR MORE INFORMATION.  
 
What is an EGFRI? Page  
EGFRIs 
Epidermal growth factor receptor inhibitors (EGFRIs) are a newer kind of cancer 
treatment called targeted therapy.  They are used to treat several different cancers, 
including breast cancer, colon cancer, head and neck cancer, lung cancer and pancreatic 
cancer.  To qualify for this study, you would have to be taking one of the following:  
 •cetuximab (Erbitux) 
 •panitumumab (Vectibix) 
 •gefitnib (Iressa ) 
 •erlotinib (Tarceva)  
•lapatinib (Tykerb)  
 
STUDY PARTICIPATION page  
Do I qualify? 
If you meet the following criteria, you are eligible to participate in this study.  
• You are at least 18 years of age.  
• You are CURRENTLY taking one of these medications: cetuximab (Erbitux®), 
panitumumab (Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), or lapatinib 
(Tykerb®). 
•  You have been taking the medication for at least four weeks.  
• You are able to read and understand English.  
• You are willing and able to complete the study questionnaires, either online or on 
paper. 
• You do NOT have a skin condition UNRELATED TO YOUR TREATMENT, 
such as acne vulgaris, erythema multiforme, psoriasis, or rosacea.  
If you choose to participate in this research study, you will be asked to complete a 20-30 
minute online survey one time only.   
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There are no costs to participating in this survey other than the time you spend 
completing it.   
No information will be collected that will reveal your identity, so the survey is 
anonymous.  
If you prefer a paper copy of the survey, or if you have any questions about the survey, 
please contact Josie Howard-Ruben by email at XXXXXX@luc.edu or by using the For 
More Information link.  
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Q1 The Symptom Experience of Patients Receiving Epidermal  
Growth Factor Receptor Inhibitors 
This study has been approved as exempt by a Loyola University of Chicago Institutional 
Review Board. This nursing research study is being conducted as part of my doctoral 
nursing program at Loyola University in Chicago.   Purpose of the study:   The purpose 
of this survey is to learn more about the symptom experience of patients receiving 
treatment with epidermal growth factor receptor inhibitors (EGFRIs), and to find out how 
these symptoms affect quality of life, well-being and performance.  These treatments may 
cause skin, hair, and nail side effects, and other symptoms.  We would like to know more 
about all of these side effects in order to help patients manage the symptoms better. If 
you have been receiving one of these medications, including cetuximab (Erbitux®), 
panitumumab (Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), afatinib (Gilotrif®)  
and lapatinib (Tykerb) for at least four weeks, you may be eligible for this study.    Use 
the arrow keys at the bottom left to move to the next page. 
 
Q2 Are you eligible to participate?        
You must meet the following criteria to be eligible to participate in this study.           
You must be at least 18 years old.      
You are currently taking one of these medications: cetuximab (Erbitux®), panitumumab 
(Vectibix®), erlotinib (Tarceva®), gefitinib (Iressa®), afatinib (Gilotrif®) and lapatinib 
(Tykerb®).      
You have been taking this medication for at least four weeks.     
You are able to read and understand English.      
You are willing and able to complete the study questionnaires.      
You do NOT have a skin condition UNRELATED TO YOUR TREATMENT, such as 
acne vulgaris, erythema multiforme, psoriasis, or rosacea.         
If you choose to participate in this research study, you will be asked to complete an 
online survey that will take less than 20-30 minutes to finish.     
There are no costs to you for participating in this survey other than the time you spend 
completing it.   If you prefer a paper copy of the survey, one can be mailed to you.    
XXXXX@luc.edu.    
If you would like to volunteer for this survey, please go to the next question where your 
consent will be recorded. 
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Q3   You are invited to participate in a research study about your experiences with 
your cancer treatments.         
We are interested in learning more about the symptoms you are experiencing as a result 
of your treatment and how those symptoms are affecting your quality of life, ability to 
function and well-being.        
The survey will take no more than 20-30 minutes.         
No costs are associated with this survey, and there are no risks associated with 
participation.            
Please verify that the following statements are correct by checking ALL of the boxes. 
 I understand that participation in this study is voluntary. 
 I understand that participation or lack of participation in this study has no effect on 
my care. 
 I have been taking one of the listed medications for at least four weeks. 
 I am at least 18 years old. 
 I can read and understand English. 
 I do not have one of the skin conditions listed: acne vulgaris, erythema multiforme, 
psoriasis or rosacea. 
 I agree to participate in this study. 
If I agree to participate in this study Is Not Selected, Then Skip To End of Survey 
 
Q4    
Thank you so much for agreeing to complete this survey, and your willingness to share 
your experience to help others.       
  
Please answer the following questions so that we can get a complete picture of the 
symptoms you are experiencing.        
 
Ideally, you should complete the survey in one sitting, but you can pick up where you left 
off if you are interrupted. 
                 
Josie Howard-Ruben, MS, RN, APN-CNS, AOCN, CHPN   Doctoral Student   Loyola 
University, Chicago   
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Q5 Which of the following medicines are you currently taking as part of your 
treatment? 
 erlotinib or Tarceva 
 gefitinib or Iressa 
 lapatinib or Tykerb 
 cetuximab or Erbitux 
 panitumumab or Vectibix 
 afatinib or Gilotrif 
 None of the above 
If None of the above Is Selected, Then Skip To End of Survey 
 
Q6 How long have you been on this medication? 
 Less than four weeks 
 At least four weeks 
 More than four weeks 
 More than eight weeks 
If Less than four weeks Is Selected, Then Skip To End of Survey 
 
Q7 Please tell us your gender. 
 Male 
 Female 
 
Q8 Please tell us about your marital status. 
 Married 
 Single, but not widowed or divorced 
 Divorced 
 Widowed 
 
Q9 Please choose the description that best describes your living arrangements. 
 Live with spouse 
 Live with spouse and children 
 Live with children 
 Live alone 
 Live with others not listed 
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Q10 What is your highest level of education? 
 Elementary school 
 High school 
 College 
 Graduate school 
 
Q11 Please tell us your age. 
 18-29 
 30-39 
 40-49 
 50-59 
 60-69 
 70-79 
 80-89 
 90-99 
 
Q12   First, please tell us about your overall health.   Which of these choices best 
describes your health right now? 
 Fully active, able to carry on all pre-disease performance without restriction 
 Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work 
 Ambulatory and capable of all self-care but unable to carry out any work activities. 
Up and about more than 50% of waking hours 
 Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours 
 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 
 
Q13 What is your primary cancer diagnosis? 
 Breast cancer 
 Colorectal cancer 
 Head and neck cancer 
 Lung cancer 
 Pancreatic cancer 
 Do not know 
 Other (please write in below) ____________________ 
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Q14 Do you know the stage of your cancer? 
 Stage I 
 Stage II 
 Stage III 
 Stage IV 
 Do not know 
 
Q15 Are you receiving any other medication for your illness that is not listed above, 
such as chemotherapy? 
 Yes 
 No 
 
Answer If Are you receiving any other medication for your illness t... Yes Is Selected 
Q16 You indicated that you are receiving other chemotherapy treatments.  Can you 
tell us what those medications are? 
 
Q17 Are you receiving radiation therapy at this time? 
 Yes 
 No 
 
Q18 Are you being treated for any of the following illnesses, other than cancer? 
 No 
 Heart disease 
 Diabetes 
 Stroke 
 Respiratory disease, including asthma or COPD 
 Osteoporosis 
 Vascular disease 
 Gastrointestinal disease, including stomach, colon, liver or pancreas 
 Obesity 
 Other ____________________ 
 I choose not to answer this question 
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Q19 Are you receiving any treatment for your skin condition RELATED TO YOUR 
CANCER THERAPY?  You can check all that apply. 
 I am not receiving treatment for my skin. 
 I use a special soap. 
 I use sunscreen. 
 I apply a cream that my health care provider suggested. 
 I take an oral medication. If you know the name of the medication, please write it in 
below. ____________________ 
 
Q20 Please describe your current tobacco use.  
 I currently smoke tobacco products. 
 I currently use other tobacco products. 
 I quit using tobacco products when I was diagnosed with this illness. 
 I do not currently use tobacco products. 
 
Q21 Redacted instrument due to copyright. 
 
Q26 Mental Health Inventory 5 items (MHI-5) (Ware & Sherbourne, 1992)   How 
much, during the past 4 weeks, did you feel very nervous? 
 All the time 
 Most of the time 
 Some of the time 
 A little of the time 
 None of the time 
 
Q27 How much, during the past 4 weeks, have you felt so down in the dumps, 
nothing could cheer you up? 
 All the time 
 Most of the time 
 Some of the time 
 A little of the time 
 None of the time 
 
Q28 How much, during the past 4 weeks, have you felt calm and peaceful? 
 All the time 
 Most of the time 
 Some of the time 
 A little of the time 
 None of the time 
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Q29 How much, during the past 4 weeks, have you felt down-hearted and 
depressed? 
 All the time 
 Most of the time 
 Some of the time 
 A little of the time 
 None of the time 
 
Q30 How much, during the past 4 weeks, have you been happy? 
 All the time 
 Most of the time 
 Some of the time 
 A little of the time 
 None of the time 
 
Q31 Next, we would like to ask you more about your symptoms.  Learning more about 
symptoms you are experiencing may help us to identify better ways to help you manage 
these symptoms.   If you have not experienced the symptom in the last seven days, mark 
"no."If you have experienced the symptom, please tell us how much it has DISTRESSED 
or BOTHERED you.   Please follow the directions below.  
 
Q32 Memorial Symptom Assessment Scale-SF   (Adapted)      
This survey asks about your symptoms.  
Instructions:  Symptoms that patients may experience will be listed. If you have had the 
symptom DURING THE PAST WEEK, please check that symptom.   If you check yes 
for a symptom, you will be asked how much the symptom DISTRESSED or 
BOTHERED you.    
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Q33  During the PAST WEEK, did you have any of the following symptoms?   
Please scroll down the page to make sure you see all the symptoms.  
 
 CHECK If 
you had 
symptom 
in last 
week 
If you checked YES, how much did the symptom 
DISTRESS or BOTHER you? Click on the box and select 
the description for this symptom. 
 YES Not all 
A little 
Bit 
Somewhat 
Quite a 
bit 
Very 
much 
Difficulty 
concentrating 
            
Pain             
Lack of energy             
Cough             
Changes in skin             
Dry mouth             
Nausea             
Feeling drowsy             
Numbness/tingling 
in hands/feet 
            
Difficulty sleeping             
Feeling bloated             
Problems with 
urination 
            
Vomiting             
Shortness of 
breath 
            
Diarrhea             
Constipation             
Sweats             
Mouth sores             
Problems with 
sexual interest or 
activity 
            
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Lack of appetite             
Dizziness             
Difficulty 
swallowing 
            
Changes in the 
way food tastes 
            
Weight loss             
Hair loss             
Other changes to 
the hair on my 
scalp 
            
Changes in hair 
growth on my face 
            
Changes in my 
eyelashes 
            
Swelling of arms 
and legs 
            
"I don't look like 
myself" 
            
Itching             
Dry skin             
Other skin 
changes 
            
Changes to my 
finger or toe nails 
            
Other changes to 
my fingers or toes 
            
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Q34  Below are other commonly listed symptoms.   
Please indicate if you have had the symptom DURING THE PAST WEEK, and if so, 
how OFTEN did it occur?        
 
 IF YES, how often did it occur? Check YES if 
you had the 
symptom in 
the last 
week 
 Rarely Occasionally Frequently 
Almost 
constantly 
YES 
Feeling sad           
Worrying           
Feeling 
irritable 
          
Feeling 
nervous 
          
 
Q35         IF YOU HAD ANY OTHER SYMPTOMS DURING THE PAST WEEK, PLEASE TYPE 
IN BELOW   AND INDICATE HOW MUCH THE SYMPTOM HAS DISTRESSED OR 
BOTHERED YOU. 
 
Q36 Redacted due to copyright.  
 
Q37 Overall, how would you rate the experience of completing this survey? 
 Very Difficult 
 Difficult 
 Somewhat Difficult 
 Neutral 
 Somewhat Easy 
 Easy 
 Very Easy 
 
Q38 Thank you for participating in this nursing research study.  If you would like to learn 
about the results of this study, please visit www.symptomclusters.com where we will 
post information about any publications that result from this research study. You may 
also contact me by email at XXXXXX@luc.edu or by phone at XXXXXX.  THANK YOU! 
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Qualitative Research Matrix: Impact of Epidermal Growth Factor Receptor Inhibitors on Quality of Life 
 
Author/Citation:  
Wagner, L. and Lacouture, M., 
2007. 
Dermatologic toxicities 
associated with EGFR 
inhibitors: the clinical 
psychologist's perspective. 
Author/Citation: 
Wagner, L, Berg, S., Gandhi, M., 
Hlubocky, F., Webster, k., Aneja, 
M., Cella, D., and Lacouture, M. 
(2013)  
The Development of a Functional 
Assessment of Cancer Therapy 
(FACT) questionnaire to assess 
dermatologic symptoms 
associated with epidermal growth 
factor receptor inhibitors. (FACT-
EGFRI-18)  
Author/Citation: 
Coleman, S., Kovtun, I., Nguyen, P. 
L., Pittelkow, M. and Jatoi, A. 
(2011), A qualitative study of the 
ramifications of rash from epidermal 
growth factor receptor (EGFR) 
inhibitors.  
Author/Citation: 
Boers-Doets, C.B., Gelderblom, 
H., Lacouture, M.E., Epstein, J.B., 
Nortier, J.W., & Kaptein, A.A. 
Experiences with the FACT-
EGFRI-18 instrument in EGFRI-
associated 
mucocutaneous adverse events. 
Support Care Cancer. 2013 
Purpose: To explore 
dermatologic-related symptom 
burden and HRQL in patients 
receiving an EGFRI. 
Purpose: To describe the process 
of developing the FACT-EGFRI-
18, used to measure HRQOL in 
patients receiving EGFRIs. 
Purpose: To explore the full impact 
of the EGFRI rash.  
Purpose: The aim of this study 
was to identify how the EGFRI-18 
performed as a measure of quality 
of life in patients taking EGFRIs. 
Theoretical framework:  
Not stated.  
Theoretical framework: Not 
stated, but presumed to be 
HRQOL. 
Theoretical framework:  
Not stated.  
Theoretical framework:  
Not stated. 
Research question:  
What are the most bothersome 
aspects of dermatologic 
toxicities associated with 
EGFRIs?  What is the impact of 
these symptoms on HRQOL? 
Research question:  
What are the most bothersome 
aspects of dermatologic toxicities 
associated with EGFRIs?  What is 
the impact of these symptoms on 
HRQOL? 
Research question: Not stated.  Research question:  
Is the EGFRI-18 linguistically 
valid in a Dutch population?  
Participants/Setting: 
20 oncology patients at 
Northwestern University and 12 
expert clinicians 
Clinicians included four 
Participants/Setting: 
20 oncology patients at 
Northwestern University and 12 
expert clinicians 
Clinicians included four oncology 
Participants/Setting 
15 patients at Mayo Clinic who had 
a past or current rash from an 
EGFRI, including 10 men, and 5 
women with an average age of 58.  
Participants/Setting:  
10 participants in the Netherlands, 
including 6 males, 4 females. Most 
colon cancer, followed by lung 
cancer and breast.  
  
182
 
oncology nurses, three 
oncologists, three 
dermatologists, one 
dermatology nurse and one 
ophthalmologist. 
Patient participants were 
predominantly white women 
with a mean age of 57 years. 
Diagnoses included 55% lung 
cancer, 35% colorectal cancer, 
and 5% pancreatic sample.  
nurses, three oncologists, three 
dermatologists, one dermatology 
nurse and one ophthalmologist. 
In the second part of the study, 
patient participants included 16 
women and 7 male patients 
receiving EGFRIs.  
Diagnoses included colon cancer 
(7), head and neck cancer (5), lung 
cancer (2) and pancreatic cancer (1). 
About half of the patients were 
receiving cetuximab.  
 
 
 
 
Ethics: 
Not discussed  
Ethics: IRB approval 
Northwestern.  
Ethics IRB Approval Mayo Clinic. 
 
Ethics: 
Stated that study was exempt from 
review due to the non-
interventional nature. 
Method: 
Triangulation approach included 
20 interviews with patients and 
12 expert clinicians.   
 
Method:  
A sequential, iterative process 
was described including literature 
review, open-ended qualitative 
interviews with both experts and 
two groups of patients.   
 
Method: 
Structured interview with follow-up 
questions that were recorded and 
transcribed.  
Method: 
Proctored administration of 
EGFRI-18 followed by a structured 
interview to assess items/s personal 
relevance to participant, as well as 
their comprehension of each item.  
Data Gathering and Analysis:  
Qualitative interviews; method 
of analysis not described.  
Lists of items that were rated by 
patients and clinicians.  
Data Gathering and Analysis:  
Qualitative interviews analyzed 
by thematic content analysis 
(symptom burden,  interference in 
physical and social function , 
emotional well-being including 
distress and self-image). Separate 
counts of frequency by clinicians 
and patients were used to generate 
priority items.  
Data Gathering and Analysis:  
Questions focused on rash and were 
based on the literature and clinical 
concerns. Questions were structured, 
but an opportunity for free response 
was allowed. Transcripts were 
reviewed and when new themes no 
longer emerged, enrollment stopped.  
An inductive qualitative approached 
was used to identify and categorize 
Data Gathering and Analysis; 
Verbatim recording of comments.  
No formal analysis process.  
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Patients and clinicians rated 62 
candidate items and could add any 
of their own items if not included, 
and ten were asked to rate the top 
20 items relevant to EGFRI 
toxicity. A second group of 
patients (n=24) completed 
preliminary questionnaires with 
38 items, as well as interviews. 
 
themes, with two investigators 
reviewing transcripts.  
 
Results/Findings: 
Patients identified physical 
symptoms as most important, 
rating burning, stinging, 
irritation, pain and dry eyes as 
their top five concerns. 
Clinicians also selected physical 
symptoms, but put a greater 
priority on items reflecting 
social well-being.  
NCI-CTC grading: 15% Grade 
1, 40% Grade 2, and 45% Grade 
3, indicating fairly significant 
symptom burdens. 
 
Results/Findings: 
The 38-item version 
of the EGFRI was reduced to an 
18-item version to measure 
HRQOL 
developed to measure HRQL 
among 
patients receiving EGFRIs. 
 
Results/Findings: 
The face and nose were described as 
the most problematic areas for rash, 
and most patients reported 
discomfort associated with it.  One 
patient reporting being hospitalized 
for a morphine drip for pain control. 
60% reported that the rash made 
them feel hopeful (in that the 
treatment was working).  
Four key themes emerged: physical 
discomfort, concerns about 
appearance, social isolation, and 
medical morbidity. Patients initially 
denied social isolation, but their 
comments proved otherwise.  
 
Results/Findings: 
Participants could not always relate 
an item to quality of life.  Family 
members often prompted 
participants about specific 
situations where QOL was 
impacted by EGFRI treatment. 
Physical symptoms were most 
associated with an impact on 
quality of life. Patients had a 
tendency to rate severity of 
symptom rather than its impact on 
QOL. Other items were suggested 
such as eye sensitivity, runny nose, 
bloody or crusty nasal cavity, skin 
sensitivities, and oral issues. 
Instrument more focused on 
cutaneous than mucosal adverse 
events.  
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Limitations—Comments 
Small sample size.  Not well 
developed in terms of 
formality of qualitative 
method. No IRB information. 
Limitations—Comments 
Extension of previous work. 
Small sample and one setting of 
care.  
Limitations—Comments 
Small sample size with majority of 
patients receiving cetuximab so may 
not apply to TKIs. 
 
Limitations—Comments 
Small sample size. May not be 
applicable across cultures.  
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